Patent Publication Number: US-2019175609-A1

Title: Therapeutic uses of a c-raf inhibitor

Description:
SEQUENCE LISTING 
     The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 7, 2017, is named PAT057346 SL.TXT and is 190,381 bytes in size. 
     FIELD OF THE INVENTION 
     The present invention relates to the use of a c-Raf (C-RAF or CRAF) inhibitor for the treatment of a cancer which is a solid tumor that harbors mitogen-activated protein kinase (MAPK) alterations, such as KRAS-mutant tumors, NRAS-mutant tumors, and certain BRAF-mutant tumors. The c-Raf inhibitor is particularly provided for use in the treatment of a cancer which is selected from KRAS-mutant NSCLC (non-small cell lung cancer), BRAF-mutant NSCLC (non-small cell lung cancer), KRAS-mutant and BRAF-mutant NSCLC (non-small cell lung cancer), KRAS-mutant ovarian cancer, BRAF-mutant ovarian cancer, KRAS-mutant and BRAF-mutant ovarian cancer, and NRAS-mutant melanoma. The present invention also provides the c-Raf inhibitor for use in the treatment of relapsed or refractory BRAF V600-mutant melanoma. 
     The present invention also relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) a c-Raf (C-RAF or CRAF) inhibitor, said combination for simultaneous, separate or sequential administration for use in the treatment of a proliferative disease, a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination; said proliferative disease being a solid tumor that harbors Mitogen-activated protein kinase (MAPK) alterations, such as KRAS-mutant tumors and NRAS-mutant tumors, and in particular, KRAS-mutant NSCLC (non-small cell lung cancer) and NRAS-mutant tumors, and in particular, NRAS-mutant melanoma. 
     BACKGROUND 
     The RAS/RAF/MEK/ERK or MAPK pathway is a key signaling cascade that drives cell proliferation, differentiation, and survival. Dysregulation of this pathway underlies many instances of tumorigenesis. Aberrant signaling or inappropriate activation of the MAPK pathway has been shown in multiple tumor types, including melanoma, lung and pancreatic cancer, and can occur through several distinct mechanisms, including activating mutations in RAS and BRAF. RAS is a superfamily of GTPases, and includes KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), which is a regulated signaling protein that can be turned on (activated) by various single-point mutations, which are known as gain of function mutations. The MAPK pathway is frequently mutated in human cancer with KRAS and BRAF mutations being among the most frequent (approximately 30%). 
     RAS mutations, particularly gain of function mutations, have been detected in 9-30% of all cancers, with KRAS mutations having the highest prevalence (86%), followed by NRAS (11%), and, infrequently, HRAS (3%) (Cox A D, Fesik S W, Kimmelman A C, et al (2014), Nat Rev Drug Discov. November; 13(11):828-51). Although selective BRAF inhibitors (BRAFi), and to a lesser extent, MEK inhibitors (MEKi) have demonstrated good activity in BRAF-mutant tumors, currently no effective therapies exist for KRAS-mutant tumors (Cantwell-Dorris E R, O&#39;Leary J J, Sheils O M (2011) Mol Cancer Ther. March; 10(3):385-94.). For example, BRAFi such as vemurafenib and encorafenib, which are efficacious in melanomas with the BRAF V600E mutation, were found to be ineffective in RAS-mutant cancers. Allosteric MEK inhibitors (MEKi) have not demonstrated robust clinical efficacy in patients with tumors harboring RAS mutations, likely due to the narrow therapeutic index and feedback-mediated pathway reactivation. Thus, (K)RAS-mutant tumors remain a high unmet medical need for which no effective treatment exists. 
     Emerging evidence on the role of c-Raf in mediating KRAS signaling and in the development of KRAS-mutant non-small cell lung cancer (NSCLC) makes it a suitable target for therapeutic intervention (Blasco R B, Francoz S, Santamaria D, et al (2011)  c - Raf but not B - Raf is essential for development of K - Ras oncogene - driven non - small cell lung carcinoma.  Cancer Cell. 2011 May 17; 19(5):652-63). c-Raf was shown to promote feedback-mediated pathway reactivation following MEKi treatment in KRAS-mutant cancers (Lito P, Saborowski A, Yue J, et al (2014)  Disruption of c - Raf - Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors . Cancer Cell 25, 697-710, Lamba et al 2014). In addition, c-Raf plays an essential role in mediating paradoxical activation following BRAFi treatment (Poulikakos P I, Zhang C, Bollag G, et al. (2010), Nature. March 18; 464(7287):427-30, Hatzivassiliou et al 2010, Heidorn et al 2010). Thus, selective pan-RAF inhibitors that potently inhibit the activity of c-Raf and BRAF could be effective in blocking BRAF-mutant tumors and RAS-mutant driven tumorigenesis and may also alleviate feedback activation. 
     The ability of T cells to mediate an immune response against an antigen requires two distinct signaling interactions (Viglietta, V. et al. (2007)  Neurotherapeutics  4:666-675; Korman, A. J. et al. (2007)  Adv. Immunol.  90:297-339). First, an antigen that has been arrayed on the surface of antigen-presenting cells (APC) is presented to an antigen-specific naive CD4 +  T cell. Such presentation delivers a signal via the T cell receptor (TCR) that directs the T cell to initiate an immune response specific to the presented antigen. Second, various co-stimulatory and inhibitory signals mediated through interactions between the APC and distinct T cell surface molecules trigger the activation and proliferation of the T cells and ultimately their inhibition. 
     The Programmed Death 1 (PD-1) protein is an inhibitory member of the extended CD28/CTLA-4 family of T cell regulators (Okazaki et al. (2002)  Curr Opin Immunol  14: 391779-82; Bennett et al. (2003)  J. Immunol.  170:711-8). Other members of the CD28 family include CD28, CTLA-4, ICOS and BTLA. It is one of the target sites in the immune checkpoint pathways that many tumors use to evade attack by the immune system. PD-1 is suggested to exist as a monomer, lacking the unpaired cysteine residue characteristic of other CD28 family members. PD-1 is expressed on activated B cells, T cells, and monocytes. 
     Given the importance of immune checkpoint pathways in regulating an immune response to tumors, the need exists for developing novel combination therapies that modulate the activity of immunoinhibitory proteins, such as PD-1, thus leading to activation of the immune system. Such agents can be used, e.g., for cancer immunotherapy and treatment of other conditions, and can be used in combination with other therapeutic agents including kinase inhibitors. 
     Lung cancer is a common type of cancer that affects men and women around the globe. NSCLC is the most common type (roughly 85%) of lung cancer with approximately 70% of these patients presenting with advanced disease (Stage IIIB or Stage IV) at the time of diagnosis. About 30% of NSCLC contain activating KRAS mutations, and these mutations are associated with resistance to EGFR TKIs (Pao W, Wang T Y, Riely G J, et al (2005) PLoS Med; 2(1): e17). 
     Immunotherapies currently in development have started to offer significant benefit to lung cancer patients, including those for whom conventional treatments are ineffective. Recently, pembrolizumab and nivolumab, two inhibitors of the PD-1/PD-L1 interaction have been approved for use in NSCLC under the trade names Keytruda® and Opdivo®, respectively. However, results indicate that many patients treated with single agent PD-1 inhibitors do not benefit adequately from treatment. 
     Melanoma is a common type of cancer that affects men and women around the globe. About 15-20% of melanoma contain activating NRAS mutations, and these mutations were identified as an independent predictor of shorter survival after a diagnosis of stage IV melanoma (Jakob J A et al (2012), Cancer, Volume 118, Issue 16, Pages 4014-4023). 
     Immunotherapies currently in development have started to offer significant benefit to melanoma cancer patients, including those for whom conventional treatments are ineffective. Recently, pembrolizumab and nivolumab, two inhibitors of the PD-1/PD-L1 interaction have been approved for use in melanoma under the trade names Keytruda® and Opdivo®, respectively. However, results indicate that many patients treated with single agent PD-1 inhibitors do not benefit adequately from treatment. 
     Direct inhibition of KRAS and NRAS has proven challenging. For example, to date, no approved targeted therapies are available for patients with KRAS-mutant NSCLC or patients with NRAS-mutant melanoma. There is thus the need for targeted therapy which is safe and/or well tolerated. A therapy which results in durable and sustained responses in such a clinical setting is also needed. 
     SUMMARY 
     The present invention provides COMPOUND A, or a pharmaceutically acceptable salt thereof, for use in the treatment of a cancer which is a solid tumor that harbors mitogen-activated protein kinase (MAPK) alterations, such as KRAS-mutant tumors and NRAS-mutant tumors. These include NRAS-mutant melanoma, KRAS-mutant NSCLC (non-small cell lung cancer), BRAF-mutant NSCLC, KRAS- and BRAF-mutant NSCLC, KRAS-mutant ovarian cancer, BRAF-mutant ovarian cancer, and KRAS- and BRAF-mutant ovarian cancer, and relapsed or refractory BRAF V600-mutant melanoma (e.g. said melanoma being relapsed after failure of BRAFi/MEKi combination therapy or refractory to BRAFi/MEKi combination therapy). 
     COMPOUND A is the compound with the following structure: 
     
       
         
         
             
             
         
       
     
     The present invention also provides a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that binds to Programmed Death 1 (PD-1), especially the exemplary antibody molecule as described below, and (b) a c-Raf inhibitor which is Compound A, or pharmaceutically acceptable salt thereof. The pharmaceutical combination may be used for the simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a solid tumor that harbors Mitogen-activated protein kinase (MAPK) alterations, such as KRAS-mutant tumors and NRAS-mutant tumors. These tumors include KRAS-mutant NSCLC (non-small cell lung cancer), NRAS-mutant melanoma, KRAS- and/or BRAF-mutated NSCLC, or KRAS- and/or BRAF-mutated ovarian cancer and BRAF-mutated melanoma resistant to BRAFi/MEKi combination treatment. 
     The present invention also relates to a pharmaceutical combination comprising 
     (A) a c-Raf inhibitor which is COMPOUND A, or pharmaceutically acceptable salt thereof and
 
(B) an isolated antibody molecule capable of binding to a human Programmed Death-1 (PD-1) comprising a heavy chain variable region (VH) comprising a HCDR1, a HCDR2 and a HCDR3 amino acid sequence of BAP049-Clone-B or BAP049-Clone-E as described in Table 1 and a light chain variable region (VL) comprising a LCDR1, a LCDR2 and a LCDR3 amino acid sequence of BAP049-Clone-B or BAP049-Clone-E as described in Table 1 below.
 
     There is also provided a pharmaceutical composition comprising such a combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination. 
     The PD-1 inhibitor is an anti-PD-1 antibody molecule as described in U.S. Ser. No. 14/604,415, entitled “Antibody Molecules to PD-1 and Uses Thereof,” and WO/2015/112900, both incorporated by reference in its entirety. In one embodiment, the anti-PD-1 antibody molecule comprises at least one antigen-binding region, e.g., a variable region or an antigen-binding fragment thereof, from an antibody described herein, including the three complementarity determining regions (CDRs) from the heavy and the three CDRs from the light chain, e.g., an antibody chosen from any of BAP049-hum01, BAP049-hum02, BAP049-hum03, BAP049-hum04, BAP049-hum05, BAP049-hum06, BAP049-hum07, BAP049-hum08, BAP049-hum09, BAP049-hum10, BAP049-hum11, BAP049-hum12, BAP049-hum13, BAP049-hum14, BAP049-hum15, BAP049-hum16, BAP049-Clone-A, BAP049-Clone-B, BAP049-Clone-C, BAP049-Clone-D, or BAP049-Clone-E; or as described in Table 1, or encoded by the nucleotide sequence in Table 1; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences. 
     For example, the anti-PD-1 antibody molecule can include VH CDR1 according to Kabat et al. or VH hypervariable loop 1 according to Chothia et al., or a combination thereof, e.g., as shown in Table 1. In one embodiment, the combination of Kabat and Chothia CDR of VH CDR1 comprises the amino acid sequence GYTFTTYWMH (SEQ ID NO: 224), or an amino acid sequence substantially identical thereto (e.g., having at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions)). The anti-PD-1 antibody molecule can further include, e.g., VH CDRs 2-3 according to Kabat et al. and VL CDRs 1-3 according to Kabat et al., e.g., as shown in Table 1. Accordingly, in some embodiments, framework regions are defined based on a combination of CDRs defined according to Kabat et al. and hypervariable loops defined according to Chothia et al. For example, the anti-PD-1 antibody molecule can include VH FR1 defined based on VH hypervariable loop 1 according to Chothia et al. and VH FR2 defined based on VH CDRs 1-2 according to Kabat et al., e.g., as shown in Table 1. The anti-PD-1 antibody molecule can further include, e.g., VH FRs 3-4 defined based on VH CDRs 2-3 according to Kabat et al. and VL FRs 1-4 defined based on VL CDRs 1-3 according to Kabat et al. 
     A preferred antibody molecule (e.g., humanized antibody molecules) that binds to Programmed Death 1 (PD-1) in the combination of the present invention is the exemplary antibody molecule which is BAP049-Clone-E and the preferred amino acid sequences are described in Table 1 herein (VH: SEQ ID NO: 38; VL: SEQ ID NO: 70). The preferred antibody molecule is also referred herein as Antibody B. 
     The present invention further provides a pharmaceutical combination comprising a c-Raf kinase inhibitor, which is COMPOUND A, or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody molecule, as described herein, for simultaneous, separate or sequential administration, for use in the treatment of a proliferative disease. 
     The present invention is particularly related to the combination of the invention for use in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway, and in particular by one or more mutations in KRAS or NRAS. 
     The present invention also provides the use of the combination of the invention for the treatment of a proliferative disease, particularly a cancer. In particular, the combination of the invention may be useful for the treatment of a cancer which is selected from KRAS-mutant NSCLC (non-small cell lung cancer), NRAS-mutant melanoma, KRAS- and/or BRAF-mutant NSCLC, KRAS- and/or BRAF-mutant ovarian cancer and BRAF-mutant melanoma resistant to BRAFi/MEKi combination treatment. 
     The present invention also provides the use of the combination of the invention for the preparation of a medicament for the treatment of a proliferative disease, particularly a cancer, particularly a solid tumor that harbors Mitogen-activated protein kinase (MAPK) alterations, e.g. KRAS-mutant NSCLC (non-small cell lung cancer), NRAS-mutant melanoma, KRAS- and/or BRAF-mutant NSCLC, KRAS- and/or BRAF-mutant ovarian cancer and BRAF-mutant melanoma resistant to BRAFi/MEKi combination treatment. 
     The present invention also provides a method of treating a proliferative disease comprising simultaneously, separately or sequentially administering to a subject in need thereof a combination of the invention in a quantity which is jointly therapeutically effective against said proliferative disease. 
     The present invention also provides a pharmaceutical composition or combined preparation comprising a quantity of the combination of the invention, which is jointly therapeutically effective against a proliferative disease, and optionally at least one pharmaceutically acceptable carrier. 
     The present invention also provides a combined preparation comprising (a) one or more dosage units of a c-Raf inhibitor, which is COMPOUND A, or a pharmaceutically acceptable salt thereof, and (b) an anti-PD-1 antibody molecule, for use in the treatment of a proliferative disease. 
     The present invention also provides a commercial package comprising as active ingredients a combination of the invention and instructions for simultaneous, separate or sequential administration of a combination of the invention to a patient in need thereof for use in the treatment of a proliferative disease, particularly a solid tumor that harbors Mitogen-activated protein kinase (MAPK) alterations, e.g. KRAS-mutant NSCLC (non-small cell lung cancer), NRAS-mutant melanoma, KRAS- and/or BRAF-mutant NSCLC, KRAS- and/or BRAF-mutant ovarian cancer and BRAF-mutant melanoma resistant to BRAFi/MEKi combination treatment. 
     The present invention also provides a commercial package comprising a c-Raf inhibitor, which is COMPOUND A, or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody molecule, and instructions for the simultaneous, separate or sequential use in the treatment of a proliferative disease. 
     In another aspect, the invention features diagnostic or therapeutic kits that include the antibody molecules described herein and instructions for use. 
     All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. 
     Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1  depicts the amino acid sequences of the light and heavy chain variable regions of murine anti-PD-1 mAb BAP049. The upper and lower sequences were from two independent analyses. The light and heavy chain CDR sequences based on Kabat numbering are underlined. The light heavy chain CDR sequences based on Chothia numbering are shown in bold italics. The unpaired Cys residue at position 102 of the light chain sequence is boxed. Sequences are disclosed as SEQ ID NOs: 8, 228, 16 and 229, respectively, in order of appearance. 
         FIG. 2A  depicts the amino acid sequences of the light and heavy chain variable regions of murine anti-PD-1 mAb BAP049 aligned with the germline sequences. The upper and lower sequences are the germline (GL) and BAP049 (Mu mAb) sequences, respectively. The light and heavy chain CDR sequences based on Kabat numbering are underlined. The light heavy chain CDR sequences based on Chothia numbering are shown in bold italics. “-” means identical amino acid residue. Sequences disclosed as SEQ ID NOs: 230, 8, 231 and 16, respectively, in order of appearance. 
         FIG. 2B  depicts the sequence of murine κ J2 gene and the corresponding mutation in murine anti-PD-1 mAb BAP049. “-” means identical nucleotide residue. Sequences disclosed as SEQ ID NOs: 233, 232, 234 and 235, respectively, in order of appearance. 
         FIGS. 3A-3B  depict the competition binding between fluorescently labeled murine anti-PD-1 mAb BAP049 (Mu mAb) and three chimeric versions of BAP049 (Chi mAb). Experiment was performed twice, and the results are shown in  FIGS. 3A and 3B , respectively. The three chimeric BAP049 antibodies (Chi mAb (Cys), Chi mAb (Tyr) and Chi mAb (Ser)) have Cys, Tyr and Ser residue at position 102 of the light chain variable region, respectively. Chi mAb (Cys), Chi mAb (Tyr) and Chi mAb (Ser) are also known as BAP049-chi, BAP049-chi-Y, and BAP049-chi-S, respectively. 
         FIG. 4  is a bar graph showing the results of FACS binding analysis for the sixteen humanized BAP049 clones (BAP049-hum01 to BAP049-hum16). The antibody concentrations are 200, 100, 50, 25 and 12.5 ng/ml from the leftmost bar to the rightmost bar for each tested mAb. 
         FIG. 5  depicts the structural analysis of the humanized BAP049 clones (a, b, c, d and e represent various types of framework region sequences). The concentrations of the mAbs in the samples are also shown. 
         FIG. 6A-6B  depicts the binding affinity and specificity of humanized BAP049 mAbs measured in a competition binding assay using a constant concentration of Alexa 488-labeled murine mAb BAP049, serial dilutions of the test antibodies, and PD-1-expressing 300.19 cells. Experiment was performed twice, and the results are shown in  FIGS. 6A and 6B , respectively. 
         FIG. 7  depicts the ranking of humanized BAP049 clones based on FACS data, competition binding and structural analysis. The concentrations of the mAbs in the samples are also shown. 
         FIGS. 8A-8B  depict blocking of ligand binding to PD-1 by selected humanized BAP049 clones. Blocking of PD-L1-Ig and PD-L2-Ig binding to PD-1 is shown in  FIG. 8A . Blocking of PD-L2-Ig binding to PD-1 is shown in  FIG. 8B . BAP049-hum01, BAP049-hum05, BAP049-hum08, BAP049-hum09, BAP049-hum10, and BAP049-hum11 were evaluated. Murine mAb BAP049 and chimeric mAb having Tyr at position 102 of the light chain variable region were also included in the analyses. 
         FIGS. 9A-9B  depict the alignment of heavy chain variable domain sequences for the sixteen humanized BAP049 clones and BAP049 chimera (BAP049-chi). In  FIG. 9A , all of the sequences are shown (SEQ ID NOs: 22, 38, 38, 38, 38, 38, 38, 38, 38, 38, 50, 50, 50, 50, 82, 82 and 86, respectively, in order of appearance). In  FIG. 9B , only amino acid sequences that are different from mouse sequence are shown (SEQ ID NOs: 22, 38, 38, 38, 38, 38, 38, 38, 38, 38, 50, 50, 50, 50, 82, 82 and 86, respectively, in order of appearance). 
         FIGS. 10A-10B  depict the alignment of light chain variable domain sequences for the sixteen humanized BAP049 clones and BAP049 chimera (BAP049-chi). In  FIG. 10A , all of the sequences are shown (SEQ ID NOs: 24, 66, 66, 66, 66, 70, 70, 70, 58, 62, 78, 74, 46, 46, 42, 54 and 54, respectively, in order of appearance). In  FIG. 10B , only amino acid sequences that are different from mouse sequence are shown (SEQ ID NOs: 24, 66, 66, 66, 66, 70, 70, 70, 58, 62, 78, 74, 46, 46, 42, 54 and 54, respectively, in order of appearance). 
         FIG. 11  is a schematic diagram that outlines the antigen processing and presentation, effector cell responses and immunosuppression pathways targeted by the combination therapies disclosed herein. 
         FIG. 12  depicts the predicted Ctrough (Cmin) concentrations across the different weights for patients while receiving the same dose of an exemplary anti-PD-1 antibody molecule. 
         FIG. 13  depicts observed versus model predicted (population or individual based) Cmin concentrations. 
         FIG. 14  depicts the accumulation, time course and within subject variability of the model used to analyze pharmacokinetics. 
         FIGS. 15A, 15B and 15C  depict the single agent activity of Compound A in various KRASmt NSCLC models. 
         FIG. 16  depicts the single agent activity of Compound A in an NRASmt melanoma model. 
     
    
    
     BRIEF DESCRIPTION OF THE TABLES 
     Table 1 is a summary of the amino acid and nucleotide sequences for the murine, chimeric and humanized anti-PD-1 antibody molecules. The antibody molecules include murine mAb BAP049, chimeric mAbs BAP049-chi and BAP049-chi-Y, and humanized mAbs BAP049-hum01 to BAP049-hum16 and BAP049-Clone-A to BAP049-Clone-E. The amino acid and nucleotide sequences of the heavy and light chain CDRs, the amino acid and nucleotide sequences of the heavy and light chain variable regions, and the amino acid and nucleotide sequences of the heavy and light chains are shown in this Table. 
     Table 2 depicts the amino acid and nucleotide sequences of the heavy and light chain framework regions for humanized mAbs BAP049-hum01 to BAP049-hum16 and BAP049-Clone-A to BAP049-Clone-E. 
     Table 3 depicts the constant region amino acid sequences of human IgG heavy chains and human kappa light chain. 
     Table 4 shows the amino acid sequences of the heavy and light chain leader sequences for humanized mAbs BAP049-Clone-A to BAP049-Clone-E. 
     Table 5 depicts exemplary PK parameters based on flat dosing schedules. 
     DETAILED DESCRIPTION 
     c-Raf Kinase Inhibitor 
     CRAF has been demonstrated to be the critical mediator of mutant KRAS-driven development in many cancers including NSCLC and plays an essential role in mediating paradoxical activation following BRAFi treatment. Compound A, a c-RAF inhibitor, may therefore be useful in treating (e.g., one or more of reducing, inhibiting, or delaying progression) a proliferative disease, particularly a solid tumor that harbors Mitogen-activated protein kinase (MAPK) alterations, e.g. NRAS-mutant melanoma, KRAS-mutant NSCLC (non-small cell lung cancer), BRAF-mutant NSCLC, KRAS- and BRAF-mutant NSCLC, KRAS-mutant ovarian cancer, BRAF-mutant ovarian cancer, and KRAS- and BRAF-mutant ovarian cancer, and relapsed or refractory BRAF V600-mutant melanoma (e.g. said melanoma being relapsed after failure of BRAFi/MEKi combination therapy or refractory to BRAFi/MEKi combination therapy). 
     As used herein, the term “Raf inhibitor” refers to an adenosine triphosphate (ATP)-competitive inhibitor of B-Raf protein kinase (also referred to herein as b-RAF, BRAF or b-Raf) and C-Raf protein kinase (also referred to herein as c-RAF, c-Raf or CRAF) that selectively targets, decreases, or inhibits at least one activity of serine/threonine-protein kinase B-Raf or C-Raf. The Raf inhibitor may inhibit both Raf monomers and Raf dimers. 
     In a preferred embodiment of the methods, treatments, combination and compositions described herein, the c-Raf inhibitor is COMPOUND A, or pharmaceutically acceptable salt thereof. 
     COMPOUND A has the following structure: 
     
       
         
         
             
             
         
       
     
     The c-Raf kinase inhibitor of the present invention, i.e. COMPOUND A, is disclosed, in WO2014/151616, which is incorporated herein by reference in its entirety, as example 1156. 
     COMPOUND A (Compound A) is also known by the name of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide. 
     COMPOUND A (also referred to herein as “Compound A”) is an adenosine triphosphate (ATP)-competitive inhibitor of BRAF (also referred to herein as b-RAF or b-Raf) and c-Raf (also referred to herein as c-RAF or CRAF) protein kinases. Throughout the present disclosure, COMPOUND A is also referred to as a c-RAF (or CRAF) inhibitor or a C-RAF/c-Raf kinase inhibitor. 
     In cell-based assays, COMPOUND A demonstrated anti-proliferative activity in cell lines that contain a variety of mutations that activate MAPK signaling. For instance, COMPOUND A inhibited the proliferation of melanoma models, including A-375 (BRAF V600E) and A-375 engineered to express BRAFi/MEKi resistance alleles, MEL-JUSO (NRAS Q61L), and IPC-298 (NRAS Q61L), as well as the non-small cell lung cancer cell line Calu-6 (KRAS Q61K) with IC 50  values ranging from 0.2-1.2 μM. 
     In vivo, treatment with COMPOUND A generated tumor regression in several KRAS-mutant models including the NSCLC-derived Calu-6 (KRAS Q61K) and NCI-H358 (KRAS G12C) as well as the ovarian Hey-A8 (KRAS G12D, BRAF G464E) xenografts and in NRAS-mutant models including the SK-MEL-30 melanoma model. In all cases, anti-tumor effects were dose-dependent and well tolerated as judged by lack of significant body weight loss. 
     Collectively, the in vitro and in vivo MAPK-pathway suppression and anti-proliferative activity observed for COMPOUND A at well-tolerated doses suggests that COMPOUND A may have anti-tumor activity in patients with tumors harboring activating lesions in the MAPK pathway. 
     Based on the mechanism of action of COMPOUND A, preclinical data and published literature on the importance of c-Raf in MAPK pathway regulation, COMPOUND A, as a single agent or in combination with an antibody molecule (e.g., a humanized antibody molecule) that binds to Programmed Death 1 (PD-1), especially the exemplary antibody molecule as described below, can be useful in the treatment of adult patients with advanced solid tumors harboring MAPK pathway alterations, and in particular, KRAS-mutant NSCLC (non-small cell lung cancer) and NRAS-mutant melanoma. 
     COMPOUND A, or a pharmaceutically acceptable salt thereof, may be administered orally. In one embodiment, COMPOUND A, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 50-1200 mg (e.g., per day). COMPOUND A, or a pharmaceutically acceptable salt thereof, can be administered at a unit dosage of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1150 mg or about 1200 mg. The unit dosage of COMPOUND A, or a pharmaceutically acceptable salt thereof, may be administered once daily, or twice daily, or three times daily, or four times daily, with the actual dosage and timing of administration determined by criteria such as the patient&#39;s age, weight, and gender; the extent and severity of the cancer to be treated; and the judgment of a treating physician. Preferably, the unit dosage of COMPOUND A is administered once daily. In another preferred embodiment, the unit dosage of COMPOUND A is administered twice daily. 
     COMPOUND A may in particular be administered at a dose of 100 mg once daily (QD), 200 mg once daily, 300 mg once daily, 400 mg once daily, 800 mg once daily or 1200 mg once daily (QD). COMPOUND A may also be administered at a dose of 200 mg twice daily or 400 mg twice daily. The dosages quoted herein may apply to the administration of COMPOUND A as monotherapy (single agent) or as part of a combination therapy, e.g as part of the combination of the present invention, as described herein. 
     When describing a dosage herein as ‘about’ a specified amount, the actual dosage can vary by up to 5-7% from the stated amount: this usage of ‘about’ recognizes that the precise amount in a given dosage form may differ slightly from an intended amount for various reasons without materially affecting the in vivo effect of the administered compound. The unit dosage of the c-Raf inhibitor may be administered once daily, or twice daily, or three times daily, or four times daily, with the actual dosage and timing of administration determined by criteria such as the patient&#39;s age, weight, and gender; the extent and severity of the cancer to be treated; and the judgment of a treating physician. 
     Since the MAPK signaling cascade has an important role in immune defense, it is expected that RAF targeted therapies with COMPOUND A may modulate an immune response to tumors. The present invention therefore also provides a medicament comprising COMPOUND A and an antibody (a) at least one antibody molecule (e.g., humanized antibody molecules) that binds to Programmed Death 1 (PD-1), especially the exemplary antibody molecule as described below, for simultaneous, sequentially, or separate administration. The combination may be useful for the treatment of a proliferative disease, particularly a solid tumor that harbors Mitogen-activated protein kinase (MAPK) alterations, e.g. KRAS-mutant NSCLC (non-small cell lung cancer), NRAS-mutant melanoma, KRAS- and/or BRAF-mutant NSCLC, KRAS- and/or BRAF-mutant ovarian cancer and BRAF-mutant melanoma resistant to BRAFi/MEKi combination treatment. 
     For example, it is expected that the combination of targeted therapy and immunotherapy in KRAS-mutated NSCLC may lead to early and robust antitumor responses from targeted therapy associated with long-term benefit of immunotherapy. It is also expected that the combination of the present invention may be beneficial (with potential synergistic activity) in NRAS mutant melanoma which is an aggressive disease which is highly susceptible to immunotherapy. 
     Antibody Molecules to PD-1 
     In one embodiment, the PD-1 inhibitor is an anti-PD-1 antibody molecule as described in U.S. Ser. No. 14/604,415, entitled “Antibody Molecules to PD-1 and Uses Thereof,” and WO/2015/112900, both incorporated by reference in its entirety. In one embodiment, the anti-PD-1 antibody molecule comprises at least one antigen-binding region, e.g., a variable region or an antigen-binding fragment thereof, from an antibody described herein, including the three complementarity determining regions (CDRs) from the heavy and the three CDRs from the light chain, e.g., an antibody chosen from any of BAP049-hum01, BAP049-hum02, BAP049-hum03, BAP049-hum04, BAP049-hum05, BAP049-hum06, BAP049-hum07, BAP049-hum08, BAP049-hum09, BAP049-hum10, BAP049-hum11, BAP049-hum12, BAP049-hum13, BAP049-hum14, BAP049-hum15, BAP049-hum16, BAP049-Clone-A, BAP049-Clone-B, BAP049-Clone-C, BAP049-Clone-D, or BAP049-Clone-E; or as described in Table 1, or encoded by the nucleotide sequence in Table 1; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences. 
     For example, the anti-PD-1 antibody molecule can include VH CDR1 according to Kabat et al. or VH hypervariable loop 1 according to Chothia et al., or a combination thereof, e.g., as shown in Table 1. In one embodiment, the combination of Kabat and Chothia CDR of VH CDR1 comprises the amino acid sequence GYTFTTYWMH (SEQ ID NO: 224), or an amino acid sequence substantially identical thereto (e.g., having at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions)). The anti-PD-1 antibody molecule can further include, e.g., VH CDRs 2-3 according to Kabat et al. and VL CDRs 1-3 according to Kabat et al., e.g., as shown in Table 1. Accordingly, in some embodiments, framework regions are defined based on a combination of CDRs defined according to Kabat et al. and hypervariable loops defined according to Chothia et al. For example, the anti-PD-1 antibody molecule can include VH FR1 defined based on VH hypervariable loop 1 according to Chothia et al. and VH FR2 defined based on VH CDRs 1-2 according to Kabat et al., e.g., as shown in Table 1. The anti-PD-1 antibody molecule can further include, e.g., VH FRs 3-4 defined based on VH CDRs 2-3 according to Kabat et al. and VL FRs 1-4 defined based on VL CDRs 1-3 according to Kabat et al. 
     A preferred antibody molecule (e.g., humanized antibody molecule) that binds to Programmed Death 1 (PD-1) in the combination of the present invention is the exemplary antibody molecule which is BAP049-Clone-E and the preferred amino acid sequences are described in Table 1 herein (VH: SEQ ID NO: 38; VL: SEQ ID NO: 70). 
     The present invention further relates to a pharmaceutical combination comprising (a) at least one antibody molecule (e.g., humanized antibody molecules) that binds to Programmed Death 1 (PD-1), especially the exemplary antibody molecule as described herein, and (b) a c-Raf inhibitor, such as Compound A, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a solid tumor that harbors Mitogen-activated protein kinase (MAPK) alterations, such as a KRAS-mutant tumor, and in particular KRAS-mutant NSCLC (non-small cell lung cancer) and NRAS-mutant tumor, and in particular NRAS-mutant melanoma. 
     In one embodiment, the invention features a method of treating (e.g., inhibiting, reducing, or ameliorating) a disorder, e.g., a hyperproliferative condition or disorder (e.g., a cancer) in a subject. The method includes administering, in combination with a c-Raf inhibitor, to the subject an anti-PD-1 antibody molecule, e.g., the preferred anti-PD-1 antibody molecule described herein, at a dose of about 300 mg to 400 mg once every three weeks or once every four weeks. In certain embodiments, the e.g., the preferred anti-PD-1 antibody molecule is administered at a dose of about 300 mg once every three weeks. In other embodiments, the e.g., the preferred anti-PD-1 antibody molecule is administered at a dose of about 400 mg once every four weeks. In some embodiments, the proliferative disorder is a KRAS-mutant tumor with a gain-of-function KRAS mutation as described herein, and in particular, KRAS-mutant NSCLC (non-small cell lung cancer). In some embodiments, the proliferative disorder is a NRAS-mutant tumor with a gain-of-function NRAS mutation as described herein, and in particular, NRAS-mutant melanoma. 
     In some embodiments, the proliferative disorder is a KRAS-mutant tumor with a gain-of-function KRAS mutation as described herein, and in particular, KRAS-mutant melanoma. In some embodiments, the proliferative disorder is a NRAS-mutant tumor with a gain-of-function NRAS mutation as described herein, and in particular, NRAS-mutant ovarian cancer. 
     In some embodiments, the proliferative disorder is a KRAS-mutant tumor with a gain-of-function KRAS mutation as described herein, and in particular, and KRAS-mutant ovarian cancer. 
     In some embodiments, the anti-PD-1 antibody molecule is administered by injection (e.g., subcutaneously or intravenously) at a dose (e.g., a flat dose) of about 200 mg to 500 mg, e.g., about 250 mg to 450 mg, about 300 mg to 400 mg, about 250 mg to 350 mg, about 350 mg to 450 mg, or about 300 mg or about 400 mg. The dosing schedule (e.g., flat dosing schedule) can vary from e.g., once a week to once every 2, 3, 4, 5, or 6 weeks. In one embodiment, the anti-PD-1 antibody molecule, e.g., the exemplary antibody molecule, is administered at a dose from about 300 mg to 400 mg once every three weeks or once every four weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose of about 300 mg once every three weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose of about 400 mg once every four weeks. In one embodiment, the anti-PD-1 antibody molecule, e.g., the exemplary antibody molecule, is administered at a dose from about 300 mg once every four weeks. In one embodiment, the anti-PD-1 antibody molecule, e.g., the exemplary antibody molecule, is administered at a dose from about 400 mg once every three weeks. 
     In another aspect, the invention features a method of reducing an activity (e.g., growth, survival, or viability, or all), of a hyperproliferative (e.g., a cancer) cell. The method includes contacting the cell with an anti-PD-1 antibody molecule, e.g., an anti-PD-1 antibody molecule described herein. The method can be performed in a subject, e.g., as part of a therapeutic protocol in combination with a c-Raf receptor tyrosine kinase inhibitor, e.g., at a dose of about 300 mg to 400 mg of an anti-PD-1 antibody molecule once every three weeks or once every four weeks. In certain embodiments, the dose is about 300 mg of an anti-PD-1 antibody molecule once every three weeks. In other embodiments, the dose is about 400 mg of an anti-PD-1 antibody molecule once every four weeks. 
     In another aspect, the invention features a composition (e.g., one or more compositions or dosage forms), that includes an anti-PD-1 antibody molecule (e.g., an anti-PD-1 antibody molecule as described herein). Formulations, e.g., dosage formulations, and kits, e.g., therapeutic kits, that include an anti-PD-1 antibody molecule (e.g., an anti-PD-1 antibody molecule as described herein), are also described herein. In certain embodiments, the composition or formulation comprises 300 mg or 400 mg of an anti-PD-1 antibody molecule (e.g., an anti-PD-1 antibody molecule as described herein). In some embodiments, the composition or formulation is administered or used once every three weeks or once every four weeks. Such composition is used in combination with a c-Raf inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration, often for treatment of NSCLC, and particularly for treating a patient having NSCLC that exhibits at least one KRAS mutation, especially a gain of function mutation such as those described herein. Such composition is used in combination with a c-Raf inhibitor, or a pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration, often for treatment of melanoma, and particularly for treating a patient having melanoma that exhibits at least one NRAS mutation, especially a mutation such as those described herein. 
     In another aspect, the invention provides an anti-PD-1 antibody for use in treating NSCLC, wherein the anti-PD-1 antibody is administered, or prepared for administration, separately, simultaneously, or sequentially with a c-Raf inhibitor. It also provides a c-Raf inhibitor for use in treating NSCLC, wherein the c-Raf inhibitor is administered, or prepared for administration, separately, simultaneously, or sequentially with an anti-PD-1 antibody. 
     In another aspect, the invention provides an anti-PD-1 antibody for use in treating melanoma, wherein the anti-PD-1 antibody is administered, or prepared for administration, separately, simultaneously, or sequentially with a c-Raf inhibitor. It also provides a c-Raf inhibitor for use in treating melanoma, wherein the c-Raf inhibitor is administered, or prepared for administration, separately, simultaneously, or sequentially with an anti-PD-1 antibody. Typically, the anti-PD-1 antibody is administered intravenously, and is thus administered separately or sequentially with the c-Raf inhibitor, which is preferably administered orally. Suitable methods, routes, dosages and frequency of administration of the c-Raf inhibitor and the anti-PD-1 antibody are described herein. 
     The combinations disclosed herein can be administered together in a single composition or administered separately in two or more different compositions, e.g., compositions or dosage forms as described herein. The administration of the therapeutic agents can be in any order. The first agent and the additional agents (e.g., second, third agents) can be administered via the same administration route or via different administration routes. 
     The pharmaceutical combinations described herein, in particular the pharmaceutical combination of the invention, may be a free combination product, i.e. a combination of two or more active ingredients, e.g. COMPOUND A and the exemplary antibody molecule described herein (Antibody B), which is administered simultaneously, separately or sequentially as two or more distinct dosage forms. 
     A free combination product can be: (a) two or more separate drug products packaged together in a single package or kit, or (b) a drug product packaged separately that according to its labelling is for use only with other individually specified drugs where each drug is required to achieve the intended use, indication, or effect. 
     The present invention also provides a combined preparation comprising (a) one or more dosage units of the c-Raf inhibitor Compound A, or a pharmaceutically acceptable salt thereof, and (b) one or more dosage units of an anti-PD-1 antibody as described herein, and at least one pharmaceutically acceptable carrier. 
     In a further embodiment, the present invention is particularly related to a method of treating a cancer harboring one or more Mitogen-activated protein kinase (MAPK) pathway alterations. In one embodiment, the present invention relates to the use of the combination of the invention for the preparation of a medicament for the treatment of a proliferative disease, particularly a cancer. In one embodiment, the combination of the invention is for use in the preparation of a medicament for the treatment of cancer. 
     In a further embodiment, the present invention relates to the use of COMPOUND A as a single agent and the use of the combination of the invention for the preparation of a medicament for the treatment of a cancer characterized by gain-of-function mutation in the MAPK pathway. 
     In a further embodiment, the present invention relates to the use of COMPOUND A as a single agent and the use of the combination of the invention for the preparation of a medicament for the treatment of a cancer characterized by gain-of-function mutation in the MAPK pathway. These tumors are further described below. 
     In a further embodiment, the present invention relates to COMPOUND A, as a single agent, for use in the treatment of a solid tumor that harbors mitogen-activated protein kinase (MAPK) alterations, such as KRAS-mutant tumors, NRAS-mutant tumors and certain BRAF-mutant tumors. In a further embodiment, the present invention relates to the pharmaceutical combination of the present invention for use in the treatment of a solid tumor that harbors mitogen-activated protein kinase (MAPK) alterations, such as KRAS-mutant tumors and NRAS-mutant tumors. These tumors are further described below. 
     Solid Tumor that Harbors Mitogen-Activated Protein Kinase (MAPK) Alterations 
     MAPK alterations are generally regarded as strong driver mutations that might be acquired in the early stages of carcinogenesis and do not change over time. 
     The present invention provides useful treatment options with patients with solid tumors harboring MAPK alteration(s). Examples of such alterations are listed in the Table below. The mutational status of tumors of such patients may be determined by using commercial kits and methods readily available in the art. 
     
       
         
           
               
             
               
                 TABLE 
               
             
            
               
                   
               
               
                 Genes of MAPK pathway. 
               
            
           
           
               
               
            
               
                 Genes 
                 Alteration(s) 
               
               
                   
               
               
                 NRAS 
                 Mutation, Amplification 
               
               
                 KRAS 
                 Mutation, Amplification 
               
               
                 NF1 
                 Mutation, Deletion 
               
               
                 BRAF V600 
                 Mutation 
               
               
                 Other BRAF (other than BRAF V600) 
                 Mutation, Amplification 
               
               
                 CRAF 
                 Mutation, Amplification 
               
               
                 MEK1 
                 Mutation, Amplification 
               
               
                 MEK2 
                 Mutation, Amplification 
               
               
                 GNAQ 
                 Mutation, Amplification 
               
               
                 GNA11 
                 Mutation, Amplification 
               
               
                   
               
            
           
         
       
     
     The present invention therefore provides treatment options for patients suffering from a solid tumor which harbors one of more MAPK alteration as described in the Table above. 
     KRAS-Mutant Tumors 
     The term “KRAS-mutant” tumor or cancer includes any tumor that exhibits a mutated KRAS protein, in particular gain-of-function KRAS-mutation; especially any G12X, G13X, Q61X or A146X KRAS-mutant, where X is any amino acid other than the one naturally occurring at that position. E.g., a G12V mutation means that a glycine is substituted with valine at codon 12. Examples of KRAS mutations in tumors include Q61K, G12V, G12C and A146T. Thus KRAS-mutant NSCLC include Q61K, G12V, G12C and A146T NSCLC. The cancer may be at an early, intermediate or late stage. 
     Non-Small Cell Lung Cancer (NSCLC) 
     NSCLC is the most common type (roughly 85%) of lung cancer with approximately 70% of these patients presenting with advanced disease (Stage IIIB or Stage IV) at the time of diagnosis. Recently, two inhibitors of the PD-1/PD-L1 interaction have been approved for use in NSCLC (pembrolizumab and nivolumab). However, results available so far indicate that many patients treated with single agent PD-1 inhibitors do not benefit adequately from treatment. KRAS-mutant NSCLC remains an elusive target for cancer therapy. About 30% of NSCLC contain activating KRAS mutations, and these mutations are associated with resistance to EGFR TKIs (Pao W, Wang T Y, Riely G J, et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med; 2(1): e17). Direct inhibition of KRAS has proven challenging. 
     BRAF mutations have been observed in up to 3% of NSCLC and have also been described as a resistance mechanism in EGFR mutation positive NSCLC (Paik P K, Arcila M E, Fara M, et al (2011). Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. May 20; 29(15):2046-51). 
     The present invention therefore provides COMPOUND A, or a pharmaceutically acceptable salt thereof, for use in the treatment of KRAS-mutant NSCLC, and/or the treatment of BRAF-mutant NSCLC. 
     The present invention also provides COMPOUND A, or a pharmaceutically acceptable salt thereof, for use in the treatment of KRAS- and BRAF-mutant NSCLC, i.e. NSCLC which is both KRAS- and BRAF-mutant. 
     The present invention also provides a pharmaceutical combination described herein,—e.g. the pharmaceutical combination comprising (a) COMPOUND A, or a pharmaceutically acceptable salt thereof, and (b) an isolated antibody molecule capable of binding to a human Programmed Death-1 (PD-1) comprising a heavy chain variable region (VH) comprising a HCDR1, a HCDR2 and a HCDR3 amino acid sequence of BAP049-Clone-B or BAP049-Clone-E as described in Table 1 and a light chain variable region (VL) comprising a LCDR1, a LCDR2 and a LCDR3 amino acid sequence of BAP049-Clone-B or BAP049-Clone-E as described in Table 1 below—for use in the treatment of KRAS-mutant NSCLC. 
     Ovarian Cancer 
     Ovarian cancer is the most lethal gynecologic cancer and is a heterogeneous disease comprised of a collection of different histologic and molecular subtypes with variable prognosis. The epithelial subtype comprises 90% of ovarian cancers. 
     The most common histologic subtype of epithelial ovarian cancer is serous carcinoma accounting for 60 to 70% of epithelial ovarian cancers. A two tiered grading system separates serous carcinoma into low-grade serous (LGS) and high-grade serous (HGS) that have different molecular characteristics, immunohistochemical profile, epidemiologic features, and clinical behavior. LGS carcinoma accounts for up to 10% of the serous epithelial ovarian cancers and ovarian carcinomas with KRAS (up to 40%) or BRAF mutations (2-6%) are predominantly LGS carcinomas. LGS carcinoma is chemoresistant, not only to first-line agents, but also in the setting of recurrent disease. 
     It is expected that COMPOUND A may be useful in the treatment of patients with KRAS- and/or BRAF-mutant ovarian cancer. 
     The present invention therefore provides COMPOUND A, or a pharmaceutically acceptable salt thereof, for use in the treatment of KRAS-mutant ovarian cancer, and/or the treatment of BRAF-mutant ovarian cancer. 
     The present invention also provides COMPOUND A, or a pharmaceutically acceptable salt thereof, for use in the treatment of KRAS- and BRAF-mutant ovarian cancer, i.e. ovarian cancer which is both KRAS-mutant and BRAF-mutant. 
     NRAS-Mutant Tumors 
     The term “NRAS-mutant” tumor or cancer includes any tumor that exhibits a mutated NRAS protein, in particular gain-of-function NRAS-mutation; especially any G12X, G13X, or Q61X NRAS-mutant, where X is any amino acid other than the one naturally occurring at that position. E.g., a G12V mutation means that a glycine is substituted with valine at codon 12. Examples of NRAS mutations in tumors include G12C, G12R, G12S, G12A, G12D, G12V, G13R, G13C, G13A, G13D, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, Q61H. Thus, NRAS-mutant melanoma comprise G12C, G12R, G12S, G12A, G12D, G12V, G13R, G13C, G13A, G13D, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, Q61H melanoma. The cancer may be at an early, intermediate or late stage. 
     Melanoma 
     The MAPK pathway plays a major role in the development and progression of melanoma). BRAF mutations occur in 40-60% and NRAS mutations in 15-20% of melanoma patients BRAF V600E and BRAF V600K-mutant patients reportedly account for 93-98% of all BRAF V600-mutant metastatic melanoma patients. These mutations constitutively activate BRAF and downstream signal transduction in the MAPK pathway, which signals for cancer cell proliferation and survival. Currently, the existing targeted therapeutic options for patients with BRAF V600-mutant melanoma comprise therapies including BRAFi (e.g. dabrafenib) and MEKi (trametinib) as a single agent or in combination. Blockade of MAPK signaling through targeted inhibition of BRAF or its downstream effector MEK has been associated with improved PFS (progression free survival) and OS (overall survival); however, patients commonly experience disease progression after a few months of treatment. Although there are multiple paths to resistance, the main mechanisms result in reactivation of the MAPK signaling pathway in the presence of an inhibitor. 
     It is thus important to identify appropriate targeted therapy for melanoma patients after relapse on BRAFi and/or MEKi treatment. BRAFi include vemurafenib, dabrafenib and encorafenib, which are efficacious in melanomas with the BRAF V600E mutation, are found to be ineffective in RAS-mutant cancers. 
     NRAS missense mutations in codons 12, 13, and 61 arise in 13-25% of all melanomas and are usually mutually exclusive to BRAF and other driver mutations. These tumors show aggressive behavior, with a high rate of liver and brain metastases at initial diagnosis, and, therefore, poor prognosis. Response to standard of care chemotherapy is very limited, and so far, there are no targeted therapies approved specifically for patients with NRAS-mutated melanoma, although a Phase 3 study demonstrated some benefit of the MEK inhibitor binimetinib as compared to standard of care chemotherapy with dacarbazine, e.g. improved overall response rate of 15 vs. 7% (Dummer R, Schadendorf D, Ascierto P A et al (2017)  Binimetinib versus dacarbazine in patients with advanced NRAS - mutant melanoma  ( NEMO ): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18: 435-45). 402 patients were randomly assigned in a 2:1 fashion. A median PFS of 2.8 (95% CI: 2.8-3.6) vs. 1.5 (1.5-1.7), HR 0.62 (0.47-0.80) in favor of binimetinib has been observed. However, discontinuation rate as a result of adverse events suspected to be related to study drug was high (20% vs. 5%), and the benefit in PFS did not transfer into improvements in overall survival (11.0 (95% CI: 8.9-13.6) vs. 10.1 (7.0-16.5) months. Treatment options for patients suffering from NRAS-mutated melanoma are therefore still needed. 
     The present invention therefore provides COMPOUND A, or a pharmaceutically acceptable salt thereof, for use in the treatment of relapsed and/or refractory BRAF V600-mutated melanoma after failure of BRAFi/MEKi, (e.g. dabrafenib and trametinib as single agents or in combination; e.g. binimetinib) therapy. 
     The present invention also provides COMPOUND A, or a pharmaceutically acceptable salt thereof, for use in the treatment of NRAS-mutated melanoma. 
     The present invention also provides a pharmaceutical combination described herein,—e.g. the pharmaceutical combination comprising (a) COMPOUND A, or a pharmaceutically acceptable salt thereof, and (b) an isolated antibody molecule capable of binding to a human Programmed Death-1 (PD-1) comprising a heavy chain variable region (VH) comprising a HCDR1, a HCDR2 and a HCDR3 amino acid sequence of BAP049-Clone-B or BAP049-Clone-E as described in Table 1 and a light chain variable region (VL) comprising a LCDR1, a LCDR2 and a LCDR3 amino acid sequence of BAP049-Clone-B or BAP049-Clone-E as described in Table 1 below—for use in the treatment of NRAS-mutated melanoma. The pharmaceutical combinations described herein may be useful in patients suffering from NRAS-mutated melanoma who may have received prior immunotherapies or may be immunotherapy naïve. 
     Uses of the Combination Therapies 
     The combinations disclosed herein can result in one or more of: an increase in antigen presentation, an increase in effector cell function (e.g., one or more of T cell proliferation, IFN-γ secretion or cytolytic function), inhibition of regulatory T cell function, an effect on the activity of multiple cell types, such as regulatory T cell, effector T cells and NK cells), an increase in tumor infiltrating lymphocytes, an increase in T-cell receptor mediated proliferation, and a decrease in immune evasion by cancerous cells. In one embodiment, the use of a PD-1 inhibitor in the combination inhibits, reduces or neutralizes one or more activities of PD-1, resulting in blockade or reduction of an immune checkpoint. Thus, such combinations can be used to treat or prevent disorders where enhancing an immune response in a subject is desired. 
     Accordingly, in another aspect, a method of modulating an immune response in a subject is provided. The method comprises administering to the subject a combination disclosed herein (e.g., a combination comprising a therapeutically effective amount of an anti-PD-1 antibody molecule and a therapeutically effective amount of COMPOUND A, or a pharmaceutically acceptable salt thereof), such that the immune response in the subject is modulated. In one embodiment, the antibody molecule enhances, stimulates or increases the immune response in the subject. The subject can be a mammal, e.g., a primate, preferably a higher primate, e.g., a human (e.g., a patient having, or at risk of having, a disorder described herein). In one embodiment, the subject is in need of enhancing an immune response. In one embodiment, the subject has, or is at risk of, having a disorder described herein, e.g., a cancer or an infectious disorder as described herein. In certain embodiments, the subject is, or is at risk of being, immunocompromised. For example, the subject is undergoing or has undergone a chemotherapeutic treatment and/or radiation therapy. Alternatively, or in combination, the subject is, or is at risk of being, immunocompromised as a result of an infection. 
     In one aspect, a method of treating (e.g., one or more of reducing, inhibiting, or delaying progression) proliferative disease which is a solid tumor that harbors Mitogen-activated protein kinase (MAPK) alterations, such as KRAS-mutant tumors, and in particular, KRAS-mutant NSCLC (non-small cell lung cancer) in a subject is provided. In another aspect, a method of treating (e.g., one or more of reducing, inhibiting, or delaying progression) proliferative disease which is a solid tumor that harbors Mitogen-activated protein kinase (MAPK) alterations, such as NRAS-mutant tumors, and in particular, NRAS-mutant melanoma in a subject is provided. The method comprises administering to the subject a combination disclosed herein (e.g., a combination comprising a therapeutically effective amount of an anti-PD-1 antibody molecule and a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof). 
     The combinations as described herein can be administered to the subject systemically (e.g., orally, parenterally, subcutaneously, intravenously, rectally, intramuscularly, intraperitoneally, intranasally, transdermally, or by inhalation or intracavitary installation), topically, or by application to mucous membranes, such as the nose, throat and bronchial tubes. 
     Dosages and therapeutic regimens of the therapeutic agents disclosed herein can be determined by a skilled artisan. In certain embodiments, the anti-PD-1 antibody molecule is administered by injection (e.g., subcutaneously or intravenously) at a dose of about 1 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg. The dosing schedule can vary from e.g., once a week to once every 2, 3, or 4 weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 10 to 20 mg/kg every other week. 
     In some embodiments, the anti-PD-1 antibody molecule is administered by injection (e.g., subcutaneously or intravenously) at a dose (e.g., a flat dose) of about 200 mg to 500 mg, e.g., about 250 mg to 450 mg, about 300 mg to 400 mg, about 250 mg to 350 mg, about 350 mg to 450 mg, or about 300 mg or about 400 mg. The dosing schedule (e.g., flat dosing schedule) can vary from e.g., once a week to once every 2, 3, 4, 5, or 6 weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 300 mg to 400 mg once every three weeks or once every four weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 300 mg once every three weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 400 mg once every four weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 300 mg once every four weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 400 mg once every three weeks. 
     The total daily dose of COMPOUND A may be administered in a single dose (i.e. once daily) or twice daily. For example, COMPOUND A may be administered at a dose of 1200 mg once daily, or 400 mg twice daily. 
     The c-Raf inhibitor which is COMPOUND A may be administered at a dose of about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200 mg once a day and the preferred anti-PD-1 antibody molecule is administered at a dose of about 400 mg once every three weeks. 
     The c-Raf inhibitor which is COMPOUND A may be the c-Raf inhibitor is administered at a dose of about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200 mg once a day and the anti-PD-1 antibody molecule is administered at a dose of about 400 mg once every four weeks. 
     COMPOUND A may in particular be administered at a once daily (QD) dose of 100, 200, 400, 800 or 1200 mg; or 200 mg twice daily; or 400 mg twice daily. The dosages quoted herein may apply to the administration of COMPOUND A as monotherapy or as part of a combination therapy, e.g., as part of the combination of the present invention, as described herein. 
     In a preferred embodiment, the exemplary anti-PD-1 molecule may be administered at a dose of 400 mg once every four weeks and COMPOUND A may be administered at a total dose of at a once daily (QD) dose of 100, 200, 400, 800 or 1200 mg; or 200 mg twice daily; or 400 mg twice daily. 
     Further Combination Therapies 
     The methods and combinations described herein can be used in combination with other agents or therapeutic modalities. In one embodiment, the methods described herein include administering to the subject a combination comprising an anti-PD-1 antibody molecule as described herein, in combination with an agent or therapeutic procedure or modality, in an amount effective to treat or prevent a disorder. The anti-PD-1 antibody molecule and the agent or therapeutic procedure or modality can be administered simultaneously or sequentially in any order. Any combination and sequence of the anti-PD-1 antibody molecules and other therapeutic agents, procedures or modalities (e.g., as described herein) can be used. The antibody molecule and/or other therapeutic agents, procedures or modalities can be administered during periods of active disorder, or during a period of remission or less active disease. The antibody molecule can be administered before the other treatment, concurrently with the treatment, post-treatment, or during remission of the disorder. 
     In certain embodiments, the methods and compositions described herein are administered in combination with one or more of other antibody molecules, chemotherapy, other anti-cancer therapy (e.g., targeted anti-cancer therapies, gene therapy, viral therapy, RNA therapy bone marrow transplantation, nanotherapy, or oncolytic drugs), cytotoxic agents, immune-based therapies (e.g., cytokines or cell-based immune therapies), surgical procedures (e.g., lumpectomy or mastectomy) or radiation procedures, or a combination of any of the foregoing. The additional therapy may be in the form of adjuvant or neoadjuvant therapy. In some embodiments, the additional therapy is an enzymatic inhibitor (e.g., a small molecule enzymatic inhibitor) or a metastatic inhibitor. Exemplary cytotoxic agents that can be administered in combination with include antimicrotubule agents, topoisomerase inhibitors, anti-metabolites, mitotic inhibitors, alkylating agents, anthracyclines, vinca alkaloids, intercalating agents, agents capable of interfering with a signal transduction pathway, agents that promote apoptosis, proteosome inhibitors, and radiation (e.g., local or whole body irradiation (e.g., gamma irradiation). In other embodiments, the additional therapy is surgery or radiation, or a combination thereof. In other embodiments, the additional therapy is a therapy targeting one or more of PI3K/AKT/mTOR pathway, an HSP90 inhibitor, or a tubulin inhibitor. 
     Alternatively, or in combination with the aforesaid combinations, the methods and compositions described herein can be administered in combination with one or more of: an immunomodulator (e.g., an activator of a costimulatory molecule or an inhibitor of an inhibitory molecule, e.g., an immune checkpoint molecule); a vaccine, e.g., a therapeutic cancer vaccine; or other forms of cellular immunotherapy. 
     In one embodiment, the combination disclosed herein, e.g., a combination comprising an anti-PD-1 antibody molecule, is used in combination with chemotherapy to treat a lung cancer, e.g., non-small cell lung cancer. In one embodiment, the anti-PD-1 antibody molecule is used with standard lung, e.g., NSCLC, chemotherapy, e.g., platinum doublet therapy, to treat lung cancer. The cancer may be at an early, intermediate or late stage. 
     In one embodiment, the combination disclosed herein, e.g., a combination comprising an anti-PD-1 antibody molecule, is used in combination with chemotherapy to treat skin cancer, e.g., melanoma. In one embodiment, the anti-PD-1 antibody molecule is used with standard skin, e.g., melanoma, chemotherapy, e.g., platinum doublet therapy, to treat skin cancer. The cancer may be at an early, intermediate or late stage. 
     Any combination and sequence of the anti-PD-1 antibody molecules and other therapeutic agents, procedures or modalities (e.g., as described herein) can be used. The antibody molecule and/or other therapeutic agents, procedures or modalities can be administered during periods of active disorder, or during a period of remission or less active disease. The antibody molecule can be administered before the other treatment, concurrently with the treatment, post-treatment, or during remission of the disorder. 
     Disclosed herein, at least in part, are antibody molecules (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1) with high affinity and specificity. Nucleic acid molecules encoding the antibody molecules, expression vectors, host cells and methods for making the antibody molecules are also provided. Pharmaceutical compositions and dose formulations comprising the antibody molecules are also provided. The anti-PD-1 antibody molecules disclosed herein can be used (alone or in combination with other agents or therapeutic modalities) to treat, prevent and/or diagnose disorders, such as cancerous disorders (e.g., solid and soft-tissue tumors). Thus, compositions and methods for detecting PD-1, as well as methods for treating various disorders including cancer using the anti-PD-1 antibody molecules are disclosed herein. In certain embodiments, the anti-PD-1 antibody molecule is administered or used at a flat or fixed dose. 
     Additional terms are defined below and throughout the application. 
     As used herein, the articles “a” and “an” refer to one or to more than one (e.g., to at least one) of the grammatical object of the article. 
     The term “or” is used herein to mean, and is used interchangeably with, the term “and/or”, unless context clearly indicates otherwise. 
     “About” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given value or range of values. 
     By “a combination” or “in combination with,” it is not intended to imply that the therapy or the therapeutic agents must be administered at the same time and/or formulated for delivery together, although these methods of delivery are within the scope described herein. The therapeutic agents in the combination can be administered concurrently with, prior to, or subsequent to, one or more other additional therapies or therapeutic agents. The therapeutic agents or therapeutic protocol can be administered in any order. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. In will further be appreciated that the additional therapeutic agent utilized in this combination may be administered together in a single composition or administered separately in different compositions. In general, it is expected that additional therapeutic agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually. 
     In embodiments, the additional therapeutic agent is administered at a therapeutic or lower-than therapeutic dose. In certain embodiments, the concentration of the second therapeutic agent that is required to achieve inhibition, e.g., growth inhibition is lower when the second therapeutic agent is administered in combination with the first therapeutic agent, e.g., the anti-PD-1 antibody molecule, than when the second therapeutic agent is administered individually. In certain embodiments, the concentration of the first therapeutic agent that is required to achieve inhibition, e.g., growth inhibition is lower when the first therapeutic agent is administered in combination with the second therapeutic agent than when the first therapeutic agent is administered individually. In certain embodiments, in a combination therapy, the concentration of the second therapeutic agent that is required to achieve inhibition, e.g., growth inhibition is lower than the therapeutic dose of the second therapeutic agent as a monotherapy, e.g., 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, or 80-90% lower. In certain embodiments, in a combination therapy, the concentration of the first therapeutic agent that is required to achieve inhibition, e.g. growth inhibition, is lower than the therapeutic dose of the first therapeutic agent as a monotherapy, e.g., 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, or 80-90% lower. 
     The term “inhibition,” “inhibitor,” or “antagonist” includes a reduction in a certain parameter, e.g., an activity, of a given molecule, e.g., an immune checkpoint inhibitor. For example, inhibition of an activity, e.g., a PD-1 or PD-L1 activity, of at least 5%, 10%, 20%, 30%, 40% or more is included by this term. Thus, inhibition need not be 100%. 
     The term “activation,” “activator,” or “agonist” includes an increase in a certain parameter, e.g., an activity, of a given molecule, e.g., a costimulatory molecule. For example, increase of an activity, e.g., a costimulatory activity, of at least 5%, 10%, 25%, 50%, 75% or more is included by this term. 
     The term “cancer” refers to a disease characterized by the rapid and uncontrolled growth of aberrant cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. As used herein, the term “cancer” or “tumor” includes premalignant, as well as malignant cancers and tumors. 
     As used herein, the terms “treat”, “treatment” and “treating” refer to the reduction or amelioration of the progression, severity and/or duration of a disorder, e.g., a proliferative disorder, or the amelioration of one or more symptoms (preferably, one or more discernible symptoms) of the disorder resulting from the administration of one or more therapies. In specific embodiments, the terms “treat,” “treatment” and “treating” refer to the amelioration of at least one measurable physical parameter of a proliferative disorder, such as growth of a tumor, not necessarily discernible by the patient. In other embodiments the terms “treat”, “treatment” and “treating” refer to the inhibition of the progression of a proliferative disorder, either physically by, e.g., stabilization of a discernible symptom, physiologically by, e.g., stabilization of a physical parameter, or both. In other embodiments the terms “treat”, “treatment” and “treating” refer to the reduction or stabilization of tumor size or cancerous cell count. 
     The term “isolated,” as used herein, refers to material that is removed from its original or native environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated by human intervention from some or all of the co-existing materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of the environment in which it is found in nature. 
     Various aspects of the invention are described in further detail below. Additional definitions are set out throughout the specification. 
     Antibody Molecules 
     In one embodiment, the antibody molecule binds to a mammalian, e.g., human, PD-1. For example, the antibody molecule binds specifically to an epitope, e.g., linear or conformational epitope, (e.g., an epitope as described herein) on PD-1. 
     As used herein, the term “antibody molecule” refers to a protein, e.g., an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable domain sequence. The term “antibody molecule” includes, for example, a monoclonal antibody (including a full length antibody which has an immunoglobulin Fc region). In an embodiment, an antibody molecule comprises a full length antibody, or a full length immunoglobulin chain. In an embodiment, an antibody molecule comprises an antigen binding or functional fragment of a full length antibody, or a full length immunoglobulin chain. In an embodiment, an antibody molecule is a multispecific antibody molecule, e.g., it comprises a plurality of immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope. In an embodiment, a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope. 
     In an embodiment, an antibody molecule is a monospecific antibody molecule and binds a single epitope. E.g., a monospecific antibody molecule having a plurality of immunoglobulin variable domain sequences, each of which binds the same epitope. 
     In an embodiment an antibody molecule is a multispecific antibody molecule, e.g., it comprises a plurality of immunoglobulin variable domains sequences, wherein a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope. In an embodiment the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein). In an embodiment the first and second epitopes overlap. In an embodiment the first and second epitopes do not overlap. In an embodiment the first and second epitopes are on different antigens, e.g., the different proteins (or different subunits of a multimeric protein). In an embodiment a multispecific antibody molecule comprises a third, fourth or fifth immunoglobulin variable domain. In an embodiment, a multispecific antibody molecule is a bispecific antibody molecule, a trispecific antibody molecule, or tetraspecific antibody molecule, 
     In an embodiment a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope. In an embodiment the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein). In an embodiment the first and second epitopes overlap. In an embodiment the first and second epitopes do not overlap. In an embodiment the first and second epitopes are on different antigens, e.g., the different proteins (or different subunits of a multimeric protein). In an embodiment a bispecific antibody molecule comprises a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a first epitope and a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody having binding specificity for a first epitope and a half antibody having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody, or fragment thereof, having binding specificity for a first epitope and a half antibody, or fragment thereof, having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a scFv, or fragment thereof, have binding specificity for a first epitope and a scFv, or fragment thereof, have binding specificity for a second epitope. In an embodiment the first epitope is located on PD-1 and the second epitope is located on a TIM-3, LAG-3, CEACAM (e.g., CEACAM-1 and/or CEACAM-5), PD-L1, or PD-L2. 
     In an embodiment, an antibody molecule comprises a diabody, and a single-chain molecule, as well as an antigen-binding fragment of an antibody (e.g., Fab, F(ab′) 2 , and Fv). For example, an antibody molecule can include a heavy (H) chain variable domain sequence (abbreviated herein as VH), and a light (L) chain variable domain sequence (abbreviated herein as VL). In an embodiment an antibody molecule comprises or consists of a heavy chain and a light chain (referred to herein as a half antibody). In another example, an antibody molecule includes two heavy (H) chain variable domain sequences and two light (L) chain variable domain sequence, thereby forming two antigen binding sites, such as Fab, Fab′, F(ab′) 2 , Fc, Fd, Fd′, Fv, single chain antibodies (scFv for example), single variable domain antibodies, diabodies (Dab) (bivalent and bispecific), and chimeric (e.g., humanized) antibodies, which may be produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies. These functional antibody fragments retain the ability to selectively bind with their respective antigen or receptor. Antibodies and antibody fragments can be from any class of antibodies including, but not limited to, IgG, IgA, IgM, IgD, and IgE, and from any subclass (e.g., IgG1, IgG2, IgG3, and IgG4) of antibodies. The preparation of antibody molecules can be monoclonal or polyclonal. An antibody molecule can also be a human, humanized, CDR-grafted, or in vitro generated antibody. The antibody can have a heavy chain constant region chosen from, e.g., IgG1, IgG2, IgG3, or IgG4. The antibody can also have a light chain chosen from, e.g., kappa or lambda. The term “immunoglobulin” (Ig) is used interchangeably with the term “antibody” herein. 
     Examples of antigen-binding fragments of an antibody molecule include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a diabody (dAb) fragment, which consists of a VH domain; (vi) a camelid or camelized variable domain; (vii) a single chain Fv (scFv), see e.g., Bird et al. (1988)  Science  242:423-426; and Huston et al. (1988)  Proc. Natl. Acad. Sci. USA  85:5879-5883); (viii) a single domain antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. 
     The term “antibody” includes intact molecules as well as functional fragments thereof. Constant regions of the antibodies can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function). 
     The VH and VL regions can be subdivided into regions of hypervariability, termed “complementarity determining regions” (CDR), interspersed with regions that are more conserved, termed “framework regions” (FR or FW). 
     The extent of the framework region and CDRs has been precisely defined by a number of methods (see, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Chothia, C. et al. (1987)  J Mol. Biol.  196:901-917; and the AbM definition used by Oxford Molecular&#39;s AbM antibody modeling software. See, generally, e.g.,  Protein Sequence and Structure Analysis of Antibody Variable Domains . In: Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg). 
     The terms “complementarity determining region,” and “CDR,” as used herein refer to the sequences of amino acids within antibody variable regions which confer antigen specificity and binding affinity. In general, there are three CDRs in each heavy chain variable region (HCDR1, HCDR2, HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, LCDR3). 
     The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (“Kabat” numbering scheme), Al-Lazikani et al., (1997)  JMB  273, 927-948 (“Chothia” numbering scheme). As used herein, the CDRs defined according the “Chothia” number scheme are also sometimes referred to as “hypervariable loops.” 
     For example, under Kabat, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3); and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under Chothia the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3); and the amino acid residues in VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3). By combining the CDR definitions of both Kabat and Chothia, the CDRs consist of amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3) in human VH and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) in human VL. 
     Generally, unless specifically indicated, the anti-PD-1 antibody molecules can include any combination of one or more Kabat CDRs and/or Chothia hypervariable loops, e.g., described in Table 1. In one embodiment, the following definitions are used for the anti-PD-1 antibody molecules described in Table 1: HCDR1 according to the combined CDR definitions of both Kabat and Chothia, and HCCDRs 2-3 and LCCDRs 1-3 according the CDR definition of Kabat. Under all definitions, each VH and VL typically includes three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. 
     As used herein, an “immunoglobulin variable domain sequence” refers to an amino acid sequence which can form the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally-occurring variable domain. For example, the sequence may or may not include one, two, or more N- or C-terminal amino acids, or may include other alterations that are compatible with formation of the protein structure. 
     The term “antigen-binding site” refers to the part of an antibody molecule that comprises determinants that form an interface that binds to the PD-1 polypeptide, or an epitope thereof. With respect to proteins (or protein mimetics), the antigen-binding site typically includes one or more loops (of at least four amino acids or amino acid mimics) that form an interface that binds to the PD-1 polypeptide. Typically, the antigen-binding site of an antibody molecule includes at least one or two CDRs and/or hypervariable loops, or more typically at least three, four, five or six CDRs and/or hypervariable loops. 
     The terms “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. A monoclonal antibody can be made by hybridoma technology or by methods that do not use hybridoma technology (e.g., recombinant methods). 
     A humanized or CDR-grafted antibody will have at least one or two but generally all three recipient CDRs (of heavy and or light immuoglobulin chains) replaced with a donor CDR. The antibody may be replaced with at least a portion of a non-human CDR or only some of the CDRs may be replaced with non-human CDRs. It is only necessary to replace the number of CDRs required for binding of the humanized antibody to PD-1. Preferably, the donor will be a rodent antibody, e.g., a rat or mouse antibody, and the recipient will be a human framework or a human consensus framework. Typically, the immunoglobulin providing the CDRs is called the “donor” and the immunoglobulin providing the framework is called the “acceptor”. In one embodiment, the donor immunoglobulin is a non-human (e.g., rodent). The acceptor framework is a naturally-occurring (e.g., a human) framework or a consensus framework, or a sequence about 85% or higher, preferably 90%, 95%, 99% or higher identical thereto. 
     Exemplary PD-1 Inhibitors 
     PD-1 is a CD28/CTLA-4 family member expressed, e.g., on activated CD4 +  and CD8 +  T cells, T regs , and B cells. It negatively regulates effector T cell signaling and function. PD-1 is induced on tumor-infiltrating T cells, and can result in functional exhaustion or dysfunction (Keir et al. (2008)  Annu. Rev. Immunol.  26:677-704; Pardoll et al. (2012)  Nat Rev Cancer  12(4):252-64). PD-1 delivers a coinhibitory signal upon binding to either of its two ligands, Programmed Death-Ligand 1 (PD-L1) or Programmed Death-Ligand 2 (PD-L2). PD-L1 is expressed on a number of cell types, including T cells, natural killer (NK) cells, macrophages, dendritic cells (DCs), B cells, epithelial cells, vascular endothelial cells, as well as many types of tumors. High expression of PD-L1 on murine and human tumors has been linked to poor clinical outcomes in a variety of cancers (Keir et al. (2008)  Annu. Rev. Immunol.  26:677-704; Pardoll et al. (2012)  Nat Rev Cancer  12(4):252-64). PD-L2 is expressed on dendritic cells, macrophages, and some tumors. Blockade of the PD-1 pathway has been pre-clinically and clinically validated for cancer immunotherapy. Both preclinical and clinical studies have demonstrated that anti-PD-1 blockade can restore activity of effector T cells and results in robust anti-tumor response. For example, blockade of PD-1 pathway can restore exhausted/dysfunctional effector T cell function (e.g., proliferation, IFN-γ secretion, or cytolytic function) and/or inhibit T reg  cell function (Keir et al. (2008)  Annu. Rev. Immunol.  26:677-704; Pardoll et al. (2012)  Nat Rev Cancer  12(4):252-64). Blockade of the PD-1 pathway can be effected with an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide of PD-1, PD-L1 and/or PD-L2. 
     As used herein, the term “Programmed Death 1” or “PD-1” include isoforms, mammalian, e.g., human PD-1, species homologs of human PD-1, and analogs comprising at least one common epitope with PD-1. The amino acid sequence of PD-1, e.g., human PD-1, is known in the art, e.g., Shinohara T et al. (1994)  Genomics  23(3):704-6; Finger L R, et al.  Gene  (1997) 197(1-2):177-87. 
     The anti-PD-1 antibody molecules described herein can be used alone or in combination with one or more additional agents described herein in accordance with a method described herein. In certain embodiments, the combinations described herein include a PD-1 inhibitor, e.g., an anti-PD-1 antibody molecule (e.g., humanized antibody molecules) as described herein. 
     In one embodiment, the anti-PD-1 antibody molecule includes: 
     (a) a heavy chain variable region (VH) comprising a HCDR1 amino acid sequence of SEQ ID NO: 4, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a LCDR1 amino acid sequence of SEQ ID NO: 13, a LCDR2 amino acid sequence of SEQ ID NO: 14, and a LCDR3 amino acid sequence of SEQ ID NO: 33; 
     (b) a VH comprising a HCDR1 amino acid sequence chosen from SEQ ID NO: 1; a HCDR2 amino acid sequence of SEQ ID NO: 2; and a HCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 10, a LCDR2 amino acid sequence of SEQ ID NO: 11, and a LCDR3 amino acid sequence of SEQ ID NO: 32; 
     (c) a VH comprising a HCDR1 amino acid sequence of SEQ ID NO: 4, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 13, a LCDR2 amino acid sequence of SEQ ID NO: 14, and a LCDR3 amino acid sequence of SEQ ID NO: 33; or 
     (d) a VH comprising a HCDR1 amino acid sequence of SEQ ID NO: 1; a HCDR2 amino acid sequence of SEQ ID NO: 2; and a HCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 10, a LCDR2 amino acid sequence of SEQ ID NO: 11, and a LCDR3 amino acid sequence of SEQ ID NO: 32. 
     2. The pharmaceutical combination of claim  1 , wherein the anti-PD-1 antibody molecule comprises: 
     (a) a heavy chain variable region (VH) comprising a HCDR1 amino acid sequence of SEQ ID NO: 4, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a LCDR1 amino acid sequence of SEQ ID NO: 13, a LCDR2 amino acid sequence of SEQ ID NO: 14, and a LCDR3 amino acid sequence of SEQ ID NO: 33; 
     (b) a VH comprising a HCDR1 amino acid sequence of SEQ ID NO: 1; a HCDR2 amino acid sequence of SEQ ID NO: 2; and a HCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 10, a LCDR2 amino acid sequence of SEQ ID NO: 11, and a LCDR3 amino acid sequence of SEQ ID NO: 32; 
     (c) a VH comprising a HCDR1 amino acid sequence of SEQ ID NO: 224, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 13, a LCDR2 amino acid sequence of SEQ ID NO: 14, and a LCDR3 amino acid sequence of SEQ ID NO: 33; or 
     (d) a VH comprising a HCDR1 amino acid sequence of SEQ ID NO: 224; a HCDR2 amino acid sequence of SEQ ID NO: 2; and a HCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 10, a LCDR2 amino acid sequence of SEQ ID NO: 11, and a LCDR3 amino acid sequence of SEQ ID NO: 32. 
     In certain embodiments, the anti-PD-1 antibody molecule comprises: 
     (i) a heavy chain variable region (VH) comprising a HCDR1 amino acid sequence chosen from SEQ ID NO: 1, SEQ ID NO: 4 or SEQ ID NO: 224; a HCDR2 amino acid sequence of SEQ ID NO: 2; and a HCDR3 amino acid sequence of SEQ ID NO: 3; and 
     (ii) a light chain variable region (VL) comprising a LCDR1 amino acid sequence of SEQ ID NO: 10, a LCDR2 amino acid sequence of SEQ ID NO: 11, and a LCDR3 amino acid sequence of SEQ ID NO: 32. 
     In other embodiments, the anti-PD-1 antibody molecule comprises: 
     (i) a heavy chain variable region (VH) comprising a HCDR1 amino acid sequence chosen from SEQ ID NO: 1, SEQ ID NO: 4 or SEQ ID NO: 224; a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 3; and 
     (ii) a light chain variable region (VL) comprising a LCDR1 amino acid sequence of SEQ ID NO: 13, a LCDR2 amino acid sequence of SEQ ID NO: 14, and a LCDR3 amino acid sequence of SEQ ID NO: 33. 
     In embodiments of the aforesaid antibody molecules, the HCDR1 comprises the amino acid sequence of SEQ ID NO: 1. In other embodiments, the HCDR1 comprises the amino acid sequence of SEQ ID NO: 4. In yet other embodiments, the HCDR1 amino acid sequence of SEQ ID NO: 224. 
     In embodiments, the aforesaid antibody molecules have a heavy chain variable region comprising at least one framework (FW) region comprising the amino acid sequence of any of SEQ ID NOs: 147, 151, 153, 157, 160, 162, 166, or 169, or an amino acid sequence at least 90% identical thereto, or having no more than two amino acid substitutions, insertions or deletions compared to the amino acid sequence of any of SEQ ID NOs: 147, 151, 153, 157, 160, 162, 166, or 169. 
     In other embodiments, the aforesaid antibody molecules have a heavy chain variable region comprising at least one framework region comprising the amino acid sequence of any of SEQ ID NOs: 147, 151, 153, 157, 160, 162, 166, or 169. 
     In yet other embodiments, the aforesaid antibody molecules have a heavy chain variable region comprising at least two, three, or four framework regions comprising the amino acid sequences of any of SEQ ID NOs: 147, 151, 153, 157, 160, 162, 166, or 169. 
     In other embodiments, the aforesaid antibody molecules comprise a VHFW1 amino acid sequence of SEQ ID NO: 147 or 151, a VHFW2 amino acid sequence of SEQ ID NO: 153, 157, or 160, and a VHFW3 amino acid sequence of SEQ ID NO: 162 or 166, and, optionally, further comprising a VHFW4 amino acid sequence of SEQ ID NO: 169. 
     In other embodiments, the aforesaid antibody molecules have a light chain variable region comprising at least one framework region comprising the amino acid sequence of any of SEQ ID NOs: 174, 177, 181, 183, 185, 187, 191, 194, 196, 200, 202, 205, or 208, or an amino acid sequence at least 90% identical thereto, or having no more than two amino acid substitutions, insertions or deletions compared to the amino acid sequence of any of 174, 177, 181, 183, 185, 187, 191, 194, 196, 200, 202, 205, or 208. 
     In other embodiments, the aforesaid antibody molecules have a light chain variable region comprising at least one framework region comprising the amino acid sequence of any of SEQ ID NOs: 174, 177, 181, 183, 185, 187, 191, 194, 196, 200, 202, 205, or 208. 
     In other embodiments, the aforesaid antibody molecules have a light chain variable region comprising at least two, three, or four framework regions comprising the amino acid sequences of any of SEQ ID NOs: 174, 177, 181, 183, 185, 187, 191, 194, 196, 200, 202, 205, or 208. 
     In other embodiments, the aforesaid antibody molecules comprise a VLFW1 amino acid sequence of SEQ ID NO: 174, 177, 181, 183, or 185, a VLFW2 amino acid sequence of SEQ ID NO: 187, 191, or 194, and a VLFW3 amino acid sequence of SEQ ID NO: 196, 200, 202, or 205, and, optionally, further comprising a VLFW4 amino acid sequence of SEQ ID NO: 208. 
     In other embodiments, the aforesaid antibodies comprise a heavy chain variable domain comprising an amino acid sequence at least 85% identical to any of SEQ ID NOs: 38, 50, 82, or 86. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38, 50, 82, or 86. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain variable domain comprising an amino acid sequence at least 85% identical to any of SEQ ID NOs: 42, 46, 54, 58, 62, 66, 70, 74, or 78. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 42, 46, 54, 58, 62, 66, 70, 74, or 78. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 40. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 91. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 50. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 102. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 82. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 84. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 86. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 88. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 42. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain comprising the amino acid sequence of SEQ ID NO: 44. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 46. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain comprising the amino acid sequence of SEQ ID NO: 48. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 54. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain comprising the amino acid sequence of SEQ ID NO: 56. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 58. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain comprising the amino acid sequence of SEQ ID NO: 60. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62. 
     In other embodiments, the aforesaid antibodies comprise a light chain comprising the amino acid sequence of SEQ ID NO: 64. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 66. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain comprising the amino acid sequence of SEQ ID NO: 68. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 70. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain comprising the amino acid sequence of SEQ ID NO: 72. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 74. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain comprising the amino acid sequence of SEQ ID NO: 76. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 78. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain comprising the amino acid sequence of SEQ ID NO: 80. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 42. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 66. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 70. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 50 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 70. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 46. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 50 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 46. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 50 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 54. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 54. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 58. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 50 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 66. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 74. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 78. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 82 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 70. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 82 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 66. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 86 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 66. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain comprising the amino acid sequence of SEQ ID NO: 44. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain comprising the amino acid sequence of SEQ ID NO: 56. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain comprising the amino acid sequence of SEQ ID NO: 68. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain comprising the amino acid sequence of SEQ ID NO: 72. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 72. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 40 and a light chain comprising the amino acid sequence of SEQ ID NO: 44. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 40 and a light chain comprising the amino acid sequence of SEQ ID NO: 48. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 52 and a light chain comprising the amino acid sequence of SEQ ID NO: 48. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 52 and a light chain comprising the amino acid sequence of SEQ ID NO: 56. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 40 and a light chain comprising the amino acid sequence of SEQ ID NO: 56. 
     In other embodiments, the aforesaid antibodies comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 40 and a light chain comprising the amino acid sequence of SEQ ID NO: 60. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 40 and a light chain comprising the amino acid sequence of SEQ ID NO: 64. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 52 and a light chain comprising the amino acid sequence of SEQ ID NO: 68. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 40 and a light chain comprising the amino acid sequence of SEQ ID NO: 68. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 52 and a light chain comprising the amino acid sequence of SEQ ID NO: 72. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 40 and a light chain comprising the amino acid sequence of SEQ ID NO: 72. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 40 and a light chain comprising the amino acid sequence of SEQ ID NO: 76. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 40 and a light chain comprising the amino acid sequence of SEQ ID NO: 80. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 84 and a light chain comprising the amino acid sequence of SEQ ID NO: 72. 
     In other embodiments, the aforesaid antibodies comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 84 and a light chain comprising the amino acid sequence of SEQ ID NO: 68. 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 and a light chain comprising the amino acid sequence of SEQ ID NO: 68. 
     In other embodiments, the aforesaid antibody molecules are chosen from a Fab, F(ab′)2, Fv, or a single chain Fv fragment (scFv). 
     In other embodiments, the aforesaid antibody molecules comprise a heavy chain constant region selected from IgG1, IgG2, IgG3, and IgG4. 
     In other embodiments, the aforesaid antibody molecules comprise a light chain constant region chosen from the light chain constant regions of kappa or lambda. 
     In other embodiments, the aforesaid antibody molecules comprise a human IgG4 heavy chain constant region with a mutation at position 228 according to EU numbering or position 108 of SEQ ID NO: 212 or 214 and a kappa light chain constant region. 
     In other embodiments, the aforesaid antibody molecules comprise a human IgG4 heavy chain constant region with a Serine to Proline mutation at position 228 according to EU numbering or position 108 of SEQ ID NO: 212 or 214 and a kappa light chain constant region. 
     In other embodiments, the aforesaid antibody molecules comprise a human IgG1 heavy chain constant region with an Asparagine to Alanine mutation at position 297 according to EU numbering or position 180 of SEQ ID NO: 216 and a kappa light chain constant region. 
     In other embodiments, the aforesaid antibody molecules comprise a human IgG1 heavy chain constant region with an Aspartate to Alanine mutation at position 265 according to EU numbering or position 148 of SEQ ID NO: 217, and Proline to Alanine mutation at position 329 according to EU numbering or position 212 of SEQ ID NO: 217 and a kappa light chain constant region. 
     In other embodiments, the aforesaid antibody molecules comprise a human IgG1 heavy chain constant region with a Leucine to Alanine mutation at position 234 according to EU numbering or position 117 of SEQ ID NO: 218, and Leucine to Alanine mutation at position 235 according to EU numbering or position 118 of SEQ ID NO: 218 and a kappa light chain constant region. 
     In other embodiments, the aforesaid antibody molecules are capable of binding to human PD-1 with a dissociation constant (K D ) of less than about 0.2 nM. 
     In some embodiments, the aforesaid antibody molecules bind to human PD-1 with a K D  of less than about 0.2 nM, 0.15 nM, 0.1 nM, 0.05 nM, or 0.02 nM, e.g., about 0.13 nM to 0.03 nM, e.g., about 0.077 nM to 0.088 nM, e.g., about 0.083 nM, e.g., as measured by a Biacore method. 
     In other embodiments, the aforesaid antibody molecules bind to cynomolgus PD-1 with a K D  of less than about 0.2 nM, 0.15 nM, 0.1 nM, 0.05 nM, or 0.02 nM, e.g., about 0.11 nM to 0.08 nM, e.g., about 0.093 nM, e.g., as measured by a Biacore method. 
     In certain embodiments, the aforesaid antibody molecules bind to both human PD-1 and cynomolgus PD-1 with similar K D , e.g., in the nM range, e.g., as measured by a Biacore method. In some embodiments, the aforesaid antibody molecules bind to a human PD-1-Ig fusion protein with a K D  of less than about 0.1 nM, 0.075 nM, 0.05 nM, 0.025 nM, or 0.01 nM, e.g., about 0.04 nM, e.g., as measured by ELISA. 
     In some embodiments, the aforesaid antibody molecules bind to Jurkat cells that express human PD-1 (e.g., human PD-1-transfected Jurkat cells) with a K D  of less than about 0.1 nM, 0.075 nM, 0.05 nM, 0.025 nM, or 0.01 nM, e.g., about 0.06 nM, e.g., as measured by FACS analysis. 
     In some embodiments, the aforesaid antibody molecules bind to cynomolgus T cells with a K D  of less than about 1 nM, 0.75 nM, 0.5 nM, 0.25 nM, or 0.1 nM, e.g., about 0.4 nM, e.g., as measured by FACS analysis. 
     In some embodiments, the aforesaid antibody molecules bind to cells that express cynomolgus PD-1 (e.g., cells transfected with cynomolgus PD-1) with a K D  of less than about 1 nM, 0.75 nM, 0.5 nM, 0.25 nM, or 0.01 nM, e.g., about 0.6 nM, e.g., as measured by FACS analysis. 
     In certain embodiments, the aforesaid antibody molecules are not cross-reactive with mouse or rat PD-1. In other embodiments, the aforesaid antibodies are cross-reactive with rhesus PD-1. For example, the cross-reactivity can be measured by a Biacore method or a binding assay using cells that expresses PD-1 (e.g., human PD-1-expressing 300.19 cells). In other embodiments, the aforesaid antibody molecules bind an extracellular Ig-like domain of PD-1. 
     In other embodiments, the aforesaid antibody molecules are capable of reducing binding of PD-1 to PD-L1, PD-L2, or both, or a cell that expresses PD-L1, PD-L2, or both. In some embodiments, the aforesaid antibody molecules reduce (e.g., block) PD-L1 binding to a cell that expresses PD-1 (e.g., human PD-1-expressing 300.19 cells) with an IC50 of less than about 1.5 nM, 1 nM, 0.8 nM, 0.6 nM, 0.4 nM, 0.2 nM, or 0.1 nM, e.g., between about 0.79 nM and about 1.09 nM, e.g., about 0.94 nM, or about 0.78 nM or less, e.g., about 0.3 nM. In some embodiments, the aforesaid antibodies reduce (e.g., block) PD-L2 binding to a cell that expresses PD-1 (e.g., human PD-1-expressing 300.19 cells) with an IC50 of less than about 2 nM, 1.5 nM, 1 nM, 0.5 nM, or 0.2 nM, e.g., between about 1.05 nM and about 1.55 nM, or about 1.3 nM or less, e.g., about 0.9 nM. 
     In other embodiments, the aforesaid antibody molecules are capable of enhancing an antigen-specific T cell response. 
     In embodiments, the antibody molecule is a monospecific antibody molecule or a bispecific antibody molecule. In embodiments, the antibody molecule has a first binding specificity for PD-1 and a second binding specifity for TIM-3, LAG-3, CEACAM (e.g., CEACAM-1, CEACAM-3, and/or CEACAM-5), PD-L1 or PD-L2. In embodiments, the antibody molecule comprises an antigen binding fragment of an antibody, e.g., a half antibody or antigen binding fragment of a half antibody. 
     In some embodiments, the aforesaid antibody molecules increase the expression of IL-2 from cells activated by Staphylococcal enterotoxin B (SEB) (e.g., at 25 μg/mL) by at least about 2, 3, 4, 5-fold, e.g., about 2 to 3-fold, e.g., about 2 to 2.6-fold, e.g., about 2.3-fold, compared to the expression of IL-2 when an isotype control (e.g., IgG4) is used, e.g., as measured in a SEB T cell activation assay or a human whole blood ex vivo assay. 
     In some embodiments, the aforesaid antibody molecules increase the expression of IFN-γ from T cells stimulated by anti-CD3 (e.g., at 0.1 pg/mL) by at least about 2, 3, 4, 5-fold, e.g., about 1.2 to 3.4-fold, e.g., about 2.3-fold, compared to the expression of IFN-γ when an isotype control (e.g., IgG4) is used, e.g., as measured in an IFN-γ activity assay. In some embodiments, the aforesaid antibody molecules increase the expression of IFN-γ from T cells activated by SEB (e.g., at 3 pg/mL) by at least about 2, 3, 4, 5-fold, e.g., about 0.5 to 4.5-fold, e.g., about 2.5-fold, compared to the expression of IFN-γ when an isotype control (e.g., IgG4) is used, e.g., as measured in an IFN-γ activity assay. 
     In some embodiments, the aforesaid antibody molecules increase the expression of IFN-γ from T cells activated with an CMV peptide by at least about 2, 3, 4, 5-fold, e.g., about 2 to 3.6-fold, e.g., about 2.8-fold, compared to the expression of IFN-γ when an isotype control (e.g., IgG4) is used, e.g., as measured in an IFN-γ activity assay. 
     In some embodiments, the aforesaid antibody molecules increase the proliferation of CD8 +  T cells activated with an CMV peptide by at least about 1, 2, 3, 4, 5-fold, e.g., about 1.5-fold, compared to the proliferation of CD8 +  T cells when an isotype control (e.g., IgG4) is used, e.g., as measured by the percentage of CD8+ T cells that passed through at least n (e.g., n=2 or 4) cell divisions. 
     In certain embodiments, the aforesaid antibody molecules has a Cmax between about 100 μg/mL and about 500 μg/mL, between about 150 μg/mL and about 450 μg/mL, between about 250 μg/mL and about 350 μg/mL, or between about 200 μg/mL and about 400 μg/mL, e.g., about 292.5 μg/mL, e.g., as measured in monkey. 
     In certain embodiments, the aforesaid antibody molecules has a T 112  between about 250 hours and about 650 hours, between about 300 hours and about 600 hours, between about 350 hours and about 550 hours, or between about 400 hours and about 500 hours, e.g., about 465.5 hours, e.g., as measured in monkey. 
     In some embodiments, the aforesaid antibody molecules bind to PD-1 with a Kd slower than 5×10 −4 , 1×10 −4 , 5×10 −5 , or 1×10 −5  s −1 , e.g., about 2.13×10 −4  s −1 , e.g., as measured by a Biacore method. In some embodiments, the aforesaid antibody molecules bind to PD-1 with a Ka faster than 1×10 4 , 5×10 4 , 1×10 5 , or 5×10 5  M −1 s −1 , e.g., about 2.78×10 5  M −1 s −1 , e.g., as measured by a Biacore method. 
     In some embodiments, the aforesaid anti-PD-1 antibody molecules bind to one or more residues within the C strand, CC′ loop, C′ strand and FG loop of PD-1. The domain structure of PD-1 is described, e.g., in Cheng et al., “Structure and Interactions of the Human Programmed Cell Death 1 Receptor”  J. Biol. Chem.  2013, 288:11771-11785. As described in Cheng et. al., the C strand comprises residues F43-M50, the CC′ loop comprises S51-N54, the C′ strand comprises residues Q55-F62, and the FG loop comprises residues L108-I114 (amino acid numbering according to Chang et al. supra). Accordingly, in some embodiments, an anti-PD-1 antibody as described herein binds to at least one residue in one or more of the ranges F43-M50, S51-N54, Q55-F62, and L108-I114 of PD-1. In some embodiments, an anti-PD-1 antibody as described herein binds to at least one residue in two, three, or all four of the ranges F43-M50, S51-N54, Q55-F62, and L108-I114 of PD-1. In some embodiments, the anti-PD-1 antibody binds to a residue in PD-1 that is also part of a binding site for one or both of PD-L1 and PD-L2. 
     In another aspect, the invention provides an isolated nucleic acid molecule encoding any of the aforesaid antibody molecules, vectors and host cells thereof. 
     An isolated nucleic acid encoding the antibody heavy chain variable region or light chain variable region, or both, of any the aforesaid antibody molecules is also provided. 
     In one embodiment, the isolated nucleic acid encodes heavy chain CDRs 1-3, wherein said nucleic acid comprises a nucleotide sequence of SEQ ID NO: 108-112, 223, 122-126, 133-137, or 144-146. 
     In another embodiment, the isolated nucleic acid encodes light chain CDRs 1-3, wherein said nucleic acid comprises a nucleotide sequence of SEQ ID NO: 113-120, 127-132, or 138-143. 
     In other embodiments, the aforesaid nucleic acid further comprises a nucleotide sequence encoding a heavy chain variable domain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 39, 51, 83, 87, 90, 95, or 101. 
     In other embodiments, the aforesaid nucleic acid further comprises a nucleotide sequence encoding a heavy chain variable domain, wherein said nucleotide sequence comprises any of SEQ ID NO: 39, 51, 83, 87, 90, 95, or 101. 
     In other embodiments, the aforesaid nucleic acid further comprises a nucleotide sequence encoding a heavy chain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 41, 53, 85, 89, 92, 96, or 103. 
     In other embodiments, the aforesaid nucleic acid further comprises a nucleotide sequence encoding a heavy chain, wherein said nucleotide sequence comprises any of SEQ ID NO: 41, 53, 85, 89, 92, 96, or 103. 
     In other embodiments, the aforesaid nucleic acid further comprises a nucleotide sequence encoding a light chain variable domain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 45, 49, 57, 61, 65, 69, 73, 77, 81, 94, 98, 100, 105, or 107. 
     In other embodiments, the aforesaid nucleic acid further comprises a nucleotide sequence encoding a light chain variable domain, wherein said nucleotide sequence comprises any of SEQ ID NO: 45, 49, 57, 61, 65, 69, 73, 77, 81, 94, 98, 100, 105, or 107. 
     In other embodiments, the aforesaid nucleic acid further comprises a nucleotide sequence encoding a light chain, wherein said nucleotide sequence is at least 85% identical to any of SEQ ID NO: 45, 49, 57, 61, 65, 69, 73, 77, 81, 94, 98, 100, 105 or 107. 
     In other embodiments, the aforesaid nucleic acid further comprises a nucleotide sequence encoding a light chain, wherein said nucleotide sequence comprises any of SEQ ID NO: 45, 49, 57, 61, 65, 69, 73, 77, 81, 94, 98, 100, 105 or 107. 
     In certain embodiments, one or more expression vectors and host cells comprising the aforesaid nucleic acids are provided. 
     A method of producing an antibody molecule or fragment thereof, comprising culturing the host cell as described herein under conditions suitable for gene expression is also provided. 
     In one aspect, the invention features a method of providing an antibody molecule described herein. The method includes: providing a PD-1 antigen (e.g., an antigen comprising at least a portion of a PD-1 epitope); obtaining an antibody molecule that specifically binds to the PD-1 polypeptide; and evaluating if the antibody molecule specifically binds to the PD-1 polypeptide, or evaluating efficacy of the antibody molecule in modulating, e.g., inhibiting, the activity of the PD-1. The method can further include administering the antibody molecule to a subject, e.g., a human or non-human animal. 
     In another aspect, the invention provides, compositions, e.g., pharmaceutical compositions, which include a pharmaceutically acceptable carrier, excipient or stabilizer, and at least one of the therapeutic agents, e.g., anti-PD-1 antibody molecules described herein. In one embodiment, the composition, e.g., the pharmaceutical composition, includes a combination of the antibody molecule and one or more agents, e.g., a therapeutic agent or other antibody molecule, as described herein. In one embodiment, the antibody molecule is conjugated to a label or a therapeutic agent. 
     Pharmaceutical Compositions and Kits 
     In another aspect, the present invention provides compositions, e.g., pharmaceutically acceptable compositions, which include an antibody molecule described herein, formulated together with a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, isotonic and absorption delaying agents, and the like that are physiologically compatible. The carrier can be suitable for intravenous, intramuscular, subcutaneous, parenteral, rectal, spinal or epidermal administration (e.g. by injection or infusion). 
     The compositions of this invention may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Typical preferred compositions are in the form of injectable or infusible solutions. The preferred mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). In a preferred embodiment, the antibody is administered by intravenous infusion or injection. In another preferred embodiment, the antibody is administered by intramuscular or subcutaneous injection. 
     The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. 
     Therapeutic compositions typically should be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high antibody concentration. Sterile injectable solutions can be prepared by incorporating the active compound (i.e., antibody or antibody portion) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin. 
     The antibody molecules can be administered by a variety of methods known in the art, although for many therapeutic applications, the preferred route/mode of administration is intravenous injection or infusion. For example, the antibody molecules can be administered by intravenous infusion at a rate of more than 20 mg/min, e.g., 20-40 mg/min, and typically greater than or equal to 40 mg/min to reach a dose of about 35 to 440 mg/m 2 , typically about 70 to 310 mg/m 2 , and more typically, about 110 to 130 mg/m 2 . In embodiments, the antibody molecules can be administered by intravenous infusion at a rate of less than 10 mg/min; preferably less than or equal to 5 mg/min to reach a dose of about 1 to 100 mg/m 2 , preferably about 5 to 50 mg/m 2 , about 7 to 25 mg/m 2  and more preferably, about 10 mg/m 2 . As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g.,  Sustained and Controlled Release Drug Delivery Systems , J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978. 
     In certain embodiments, an antibody molecule can be orally administered, for example, with an inert diluent or an assimilable edible carrier. The compound (and other ingredients, if desired) may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject&#39;s diet. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. To administer a compound of the invention by other than parenteral administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation. Therapeutic compositions can also be administered with medical devices known in the art. 
     Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals. 
     An exemplary, non-limiting range for a therapeutically or prophylactically effective amount of an antibody molecule is 0.1-30 mg/kg, more preferably 1-25 mg/kg. Dosages and therapeutic regimens of the anti-PD-1 antibody molecule can be determined by a skilled artisan. In certain embodiments, the anti-PD-1 antibody molecule is administered by injection (e.g., subcutaneously or intravenously) at a dose of about 1 to 40 mg/kg, e.g., 1 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, 1 to 10 mg/kg, 5 to 15 mg/kg, 10 to 20 mg/kg, 15 to 25 mg/kg, or about 3 mg/kg. The dosing schedule can vary from e.g., once a week to once every 2, 3, or 4 weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 10 to 20 mg/kg every other week. 
     As another example, non-limiting range for a therapeutically or prophylactically effective amount of an antibody molecule is 200-500 mg, more preferably 300-400 mg/kg. Dosages and therapeutic regimens of the anti-PD-1 antibody molecule can be determined by a skilled artisan. In certain embodiments, the anti-PD-1 antibody molecule is administered by injection (e.g., subcutaneously or intravenously) at a dose (e.g., a flat dose) of about 200 mg to 500 mg, e.g., about 250 mg to 450 mg, about 300 mg to 400 mg, about 250 mg to 350 mg, about 350 mg to 450 mg, or about 300 mg or about 400 mg. The dosing schedule (e.g., flat dosing schedule) can vary from e.g., once a week to once every 2, 3, 4, 5, or 6 weeks. In one embodiment the anti-PD-1 antibody molecule is administered at a dose from about 300 mg to 400 mg once every three or once every four weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 300 mg once every three weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 400 mg once every four weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 300 mg once every four weeks. In one embodiment, the anti-PD-1 antibody molecule is administered at a dose from about 400 mg once every three weeks. While not wishing to be bound by theory, in some embodiments, flat or fixed dosing can be beneficial to patients, for example, to save drug supply and to reduce pharmacy errors. 
     In some embodiments, the clearance (CL) of the anti-PD-1 antibody molecule is from about 6 to 16 mL/h, e.g., about 7 to 15 mL/h, about 8 to 14 mL/h, about 9 to 12 mL/h, or about 10 to 11 mL/h, e.g., about 8.9 mL/h, 10.9 mL/h, or 13.2 mL/h. 
     In some embodiments, the exponent of weight on CL of the anti-PD-1 antibody molecule is from about 0.4 to 0.7, about 0.5 to 0.6, or 0.7 or less, e.g., 0.6 or less, or about 0.54. 
     In some embodiments, the volume of distribution at steady state (Vss) of the anti-PD-1 antibody molecule is from about 5 to 10 V, e.g., about 6 to 9 V, about 7 to 8 V, or about 6.5 to 7.5 V, e.g., about 7.2 V. 
     In some embodiments, the half-life of the anti-PD-1 antibody molecule is from about 10 to 30 days, e.g., about 15 to 25 days, about 17 to 22 days, about 19 to 24 days, or about 18 to 22 days, e.g., about 20 days. 
     In some embodiments, the Cmin (e.g., for a 80 kg patient) of the anti-PD-1 antibody molecule is at least about 0.4 μg/mL, e.g., at least about 3.6 μg/mL, e.g., from about 20 to 50 μg/mL, e.g., about 22 to 42 μg/mL, about 26 to 47 μg/mL, about 22 to 26 μg/mL, about 42 to 47 μg/mL, about 25 to 35 μg/mL, about 32 to 38 μg/mL, e.g., about 31 μg/mL or about 35 μg/mL. In one embodiment, the Cmin is determined in a patient receiving the anti-PD-1 antibody molecule at a dose of about 400 mg once every four weeks. In another embodiment, the Cmin is determined in a patient receiving the anti-PD-1 antibody molecule at a dose of about 300 mg once every three weeks. In certain embodiments, the Cmin is at least about 50-fold higher, e.g., at least about 60-fold, 65-fold, 70-fold, 75-fold, 80-fold, 85-fold, 90-fold, 95-fold, or 100-fold, e.g., at least about 77-fold, higher than the EC50 of the anti-PD-1 antibody molecule, e.g., as determined based on IL-2 change in an SEB ex-vivo assay. In other embodiments, the Cmin is at least 5-fold higher, e.g., at least 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold, e.g., at least about 8.6-fold, higher than the EC90 of the anti-PD-1 antibody molecule, e.g., as determined based on IL-2 change in an SEB ex-vivo assay. 
     The antibody molecule can be administered by intravenous infusion at a rate of more than 20 mg/min, e.g., 20-40 mg/min, and typically greater than or equal to 40 mg/min to reach a dose of about 35 to 440 mg/m 2 , typically about 70 to 310 mg/m 2 , and more typically, about 110 to 130 mg/m 2 . In embodiments, the infusion rate of about 110 to 130 mg/m 2  achieves a level of about 3 mg/kg. In other embodiments, the antibody molecule can be administered by intravenous infusion at a rate of less than 10 mg/min, e.g., less than or equal to 5 mg/min to reach a dose of about 1 to 100 mg/m 2 , e.g., about 5 to 50 mg/m 2 , about 7 to 25 mg/m 2 , or, about 10 mg/m 2 . In some embodiments, the antibody is infused over a period of about 30 min. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. 
     The pharmaceutical compositions of the invention may include a “therapeutically effective amount” or a “prophylactically effective amount” of an antibody or antibody portion of the invention. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the modified antibody or antibody fragment may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody or antibody portion to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the modified antibody or antibody fragment is outweighed by the therapeutically beneficial effects. A “therapeutically effective dosage” preferably inhibits a measurable parameter, e.g., tumor growth rate by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects. The ability of a compound to inhibit a measurable parameter, e.g., cancer, can be evaluated in an animal model system predictive of efficacy in human tumors. Alternatively, this property of a composition can be evaluated by examining the ability of the compound to inhibit, such inhibition in vitro by assays known to the skilled practitioner. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount. 
     Also within the scope of the invention is a kit comprising an antibody molecule described herein. The kit can include one or more other elements including: instructions for use; other reagents, e.g., a label, a therapeutic agent, or an agent useful for chelating, or otherwise coupling, an antibody to a label or therapeutic agent, or a radioprotective composition; devices or other materials for preparing the antibody for administration; pharmaceutically acceptable carriers; and devices or other materials for administration to a subject. 
     Uses of the Combination Therapies 
     The combinations, e.g., the anti-PD-1 antibody molecules disclosed herein, have in vitro and in vivo diagnostic, as well as therapeutic and prophylactic utilities. For example, these molecules can be administered to cells in culture, in vitro or ex vivo, or to a human subject, to treat, prevent, and/or diagnose a variety of disorders, such as cancers and infectious disorders. 
     Accordingly, in one aspect, the invention provides a method of modifying an immune response in a subject comprising administering to the subject the combination described herein, such that the immune response in the subject is modified. In one embodiment, the immune response is enhanced, stimulated or up-regulated. 
     As used herein, the term “subject” is a human patient having a disorder or condition characterized by abnormal PD-1 functioning. 
     
       
         
           
               
             
               
                 TABLE 1 
               
               
                   
               
               
                 Amino acid and nucleotide sequences for murine chimeric and humanized antibody 
               
               
                 molecules. The antibody molecules include murine mAb BAP049 chimeric mAbs BAP049- 
               
               
                 chi and BAP049-chi-Y and humanized mAbs BAP049-hum01 to BAP049-hum16 and 
               
               
                 BAP049-Clone-A to BAP049-Clone-E. The amino acid and nucleotide sequences of the 
               
               
                 heavy and light chain CDRs the heavy and light chain variable regions and the heavy and 
               
               
                 light chains are shown. 
               
               
                   
               
             
            
               
                 BAP049 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 6 
                 VH 
                 QVQLQQPGSELVRPGASVKLSCKASGYTFTTYW 
               
               
                   
                   
                 MHWVRQRPGQGLEWIGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RTSLTVDTSSTTAYMHLASLTSEDSAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTLVTVSA 
               
               
                 SEQ ID NO: 7 
                 DNA VH 
                 CAGGTCCAGCTGCAGCAACCTGGGTCTGAGCTG 
               
               
                   
                   
                 GTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGC 
               
               
                   
                   
                 AAGGCGTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGAGGCAGAGGCCTGGACAAGGC 
               
               
                   
                   
                 CTTGAGTGGATTGGAAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAAAAC 
               
               
                   
                   
                 AGGACCTCACTGACTGTAGACACATCCTCCACC 
               
               
                   
                   
                 ACAGCCTACATGCACCTCGCCAGCCTGACATCT 
               
               
                   
                   
                 GAGGACTCTGCGGTCTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAAGGG 
               
               
                   
                   
                 ACTCTGGTCACTGTCTCTGCA 
               
               
                 SEQ ID NO: 8 
                 VH 
                 QVQLQQSGSELVRPGASVKLSCKASGYTFTTYW 
               
               
                   
                   
                 MHWVRQRPGQGLEWIGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RTSLTVDTSSTTAYMHLASLTSEDSAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTLVTVSA 
               
               
                 SEQ ID NO: 9 
                 DNA VH 
                 CAGGTCCAGCTGCAGCAGTCTGGGTCTGAGCTG 
               
               
                   
                   
                 GTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGC 
               
               
                   
                   
                 AAGGCGTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGAGGCAGAGGCCTGGACAAGGC 
               
               
                   
                   
                 CTTGAGTGGATTGGAAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAAAAC 
               
               
                   
                   
                 AGGACCTCACTGACTGTAGACACATCCTCCACC 
               
               
                   
                   
                 ACAGCCTACATGCACCTCGCCAGCCTGACATCT 
               
               
                   
                   
                 GAGGACTCTGCGGTCTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAAGGG 
               
               
                   
                   
                 ACTCTGGTCACTGTCTCTGCA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 12 (Kabat) 
                 LCDR3 
                 QNDYSYPCT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 15 (Chothia) 
                 LCDR3 
                 DYSYPC 
               
               
                 SEQ ID NO: 16 
                 VL 
                 DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQPPKLLIFWASTRESGVPD 
               
               
                   
                   
                 RFTGSGSVTDFTLTISSVQAEDLAVYYCQNDYS 
               
               
                   
                   
                 YPCTFGGGTKLEIK 
               
               
                 SEQ ID NO: 17 
                 DNA VL 
                 GACATTGTGATGACCCAGTCTCCATCCTCCCTG 
               
               
                   
                   
                 ACTGTGACAGCAGGAGAGAAGGTCACTATGAGC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCAGGGCAGCCTCCTAAACTGTTGATCTTC 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCTGAT 
               
               
                   
                   
                 CGCTTCACAGGCAGTGGATCTGTAACAGATTTC 
               
               
                   
                   
                 ACTCTCACCATCAGCAGTGTGCAGGCTGAAGAC 
               
               
                   
                   
                 CTGGCAGTTTATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTGCACGTTCGGAGGGGGGACCAAGCTG 
               
               
                   
                   
                 GAAATAAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-chi HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 18 
                 VH 
                 QVQLQQPGSELVRPGASVKLSCKASGYTFTTYW 
               
               
                   
                   
                 MHWVRQRPGQGLEWIGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RTSLTVDTSSTTAYMHLASLTSEDSAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 19 
                 DNA VH 
                 CAGGTCCAGCTGCAGCAGCCTGGGTCTGAGCTG 
               
               
                   
                   
                 GTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGC 
               
               
                   
                   
                 AAGGCGTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGAGGCAGAGGCCTGGACAAGGC 
               
               
                   
                   
                 CTTGAGTGGATTGGAAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAAAAC 
               
               
                   
                   
                 AGGACCTCACTGACTGTAGACACATCCTCCACC 
               
               
                   
                   
                 ACAGCCTACATGCACCTCGCCAGCCTGACATCT 
               
               
                   
                   
                 GAGGACTCTGCGGTCTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                   
                   
                 QVQLQQPGSELVRPGASVKLSCKASGYTFTTYW 
               
               
                 SEQ ID NO: 20 
                 HC 
                 MHWVRQRPGQGLEWIGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RTSLTVDTSSTTAYMHLASLTSEDSAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 21 
                 DNA HC 
                 CAGGTCCAGCTGCAGCAGCCTGGGTCTGAGCTG 
               
               
                   
                   
                 GTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGC 
               
               
                   
                   
                 AAGGCGTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGAGGCAGAGGCCTGGACAAGGC 
               
               
                   
                   
                 CTTGAGTGGATTGGAAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAAAAC 
               
               
                   
                   
                 AGGACCTCACTGACTGTAGACACATCCTCCACC 
               
               
                   
                   
                 ACAGCCTACATGCACCTCGCCAGCCTGACATCT 
               
               
                   
                   
                 GAGGACTCTGCGGTCTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                 SEQ ID NO: 22 
                 VH 
                 QVQLQQSGSELVRPGASVKLSCKASGYTFTTYW 
               
               
                   
                   
                 MHWVRQRPGQGLEWIGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RTSLTVDTSSTTAYMHLASLTSEDSAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 23 
                 DNA VH 
                 CAGGTCCAGCTGCAGCAGTCTGGGTCTGAGCTG 
               
               
                   
                   
                 GTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGC 
               
               
                   
                   
                 AAGGCGTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGAGGCAGAGGCCTGGACAAGGC 
               
               
                   
                   
                 CTTGAGTGGATTGGAAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAAAAC 
               
               
                   
                   
                 AGGACCTCACTGACTGTAGACACATCCTCCACC 
               
               
                   
                   
                 ACAGCCTACATGCACCTCGCCAGCCTGACATCT 
               
               
                   
                   
                 GAGGACTCTGCGGTCTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 30 
                 HC 
                 QVQLQQSGSELVRPGASVKLSCKASGYTFTTYW 
               
               
                   
                   
                 MHWVRQRPGQGLEWIGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RTSLTVDTSSTTAYMHLASLTSEDSAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 31 
                 DNA HC 
                 CAGGTCCAGCTGCAGCAGTCTGGGTCTGAGCTG 
               
               
                   
                   
                 GTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGC 
               
               
                   
                   
                 AAGGCGTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGAGGCAGAGGCCTGGACAAGGC 
               
               
                   
                   
                 CTTGAGTGGATTGGAAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAAAAC 
               
               
                   
                   
                 AGGACCTCACTGACTGTAGACACATCCTCCACC 
               
               
                   
                   
                 ACAGCCTACATGCACCTCGCCAGCCTGACATCT 
               
               
                   
                   
                 GAGGACTCTGCGGTCTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-chi LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 12 (Kabat) 
                 LCDR3 
                 QNDYSYPCT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 15 (Chothia) 
                 LCDR3 
                 DYSYPC 
               
               
                 SEQ ID NO: 24 
                 VL 
                 DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQPPKLLIFWASTRESGVPD 
               
               
                   
                   
                 RFTGSGSVTDFTLTISSVQAEDLAVYYCQNDYS 
               
               
                   
                   
                 YPCTFGQGTKVEIK 
               
               
                 SEQ ID NO: 25 
                 DNA VL 
                 GACATTGTGATGACCCAGTCTCCATCCTCCCTG 
               
               
                   
                   
                 ACTGTGACAGCAGGAGAGAAGGTCACTATGAGC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCAGGGCAGCCTCCTAAACTGTTGATCTTC 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCTGAT 
               
               
                   
                   
                 CGCTTCACAGGCAGTGGATCTGTAACAGATTTC 
               
               
                   
                   
                 ACTCTCACCATCAGCAGTGTGCAGGCTGAAGAC 
               
               
                   
                   
                 CTGGCAGTTTATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTGCACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 26 
                 LC 
                 DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQPPKLLIFWASTRESGVPD 
               
               
                   
                   
                 RFTGSGSVTDFTLTISSVQAEDLAVYYCQNDYS 
               
               
                   
                   
                 YPCTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 27 
                 DNA LC 
                 GACATTGTGATGACCCAGTCTCCATCCTCCCTG 
               
               
                   
                   
                 ACTGTGACAGCAGGAGAGAAGGTCACTATGAGC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCAGGGCAGCCTCCTAAACTGTTGATCTTC 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCTGAT 
               
               
                   
                   
                 CGCTTCACAGGCAGTGGATCTGTAACAGATTTC 
               
               
                   
                   
                 ACTCTCACCATCAGCAGTGTGCAGGCTGAAGAC 
               
               
                   
                   
                 CTGGCAGTTTATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTGCACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTAEAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-chi-Y HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 18 
                 VH 
                 QVQLQQPGSELVRPGASVKLSCKASGYTFTTYW 
               
               
                   
                   
                 MHWVRQRPGQGLEWIGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RTSLTVDTSSTTAYMHLASLTSEDSAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 19 
                 DNA VH 
                 CAGGTCCAGCTGCAGCAGCCTGGGTCTGAGCTG 
               
               
                   
                   
                 GTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGC 
               
               
                   
                   
                 AAGGCGTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGAGGCAGAGGCCTGGACAAGGC 
               
               
                   
                   
                 CTTGAGTGGATTGGAAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAAAAC 
               
               
                   
                   
                 AGGACCTCACTGACTGTAGACACATCCTCCACC 
               
               
                   
                   
                 ACAGCCTACATGCACCTCGCCAGCCTGACATCT 
               
               
                   
                   
                 GAGGACTCTGCGGTCTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 20 
                 HC 
                 QVQLQQPGSELVRPGASVKLSCKASGYTFTTYW 
               
               
                   
                   
                 MHWVRQRPGQGLEWIGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RTSLTVDTSSTTAYMHLASLTSEDSAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 21 
                 DNA HC 
                 CAGGTCCAGCTGCAGCAGCCTGGGTCTGAGCTG 
               
               
                   
                   
                 GTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGC 
               
               
                   
                   
                 AAGGCGTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGAGGCAGAGGCCTGGACAAGGC 
               
               
                   
                   
                 CTTGAGTGGATTGGAAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAAAAC 
               
               
                   
                   
                 AGGACCTCACTGACTGTAGACACATCCTCCACC 
               
               
                   
                   
                 ACAGCCTACATGCACCTCGCCAGCCTGACATCT 
               
               
                   
                   
                 GAGGACTCTGCGGTCTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                 SEQ ID NO: 22 
                 VH 
                 QVQLQQSGSELVRPGASVKLSCKASGYTFTTYW 
               
               
                   
                   
                 MHWVRQRPGQGLEWIGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RTSLTVDTSSTTAYMHLASLTSEDSAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 23 
                 DNA VH 
                 CAGGTCCAGCTGCAGCAGTCTGGGTCTGAGCTG 
               
               
                   
                   
                 GTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGC 
               
               
                   
                   
                 AAGGCGTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGAGGCAGAGGCCTGGACAAGGC 
               
               
                   
                   
                 CTTGAGTGGATTGGAAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAAAAC 
               
               
                   
                   
                 AGGACCTCACTGACTGTAGACACATCCTCCACC 
               
               
                   
                   
                 ACAGCCTACATGCACCTCGCCAGCCTGACATCT 
               
               
                   
                   
                 GAGGACTCTGCGGTCTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 30 
                 HC 
                 QVQLQQSGSELVRPGASVKLSCKASGYTFTTYW 
               
               
                   
                   
                 MHWVRQRPGQGLEWIGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RTSLTVDTSSTTAYMHLASLTSEDSAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 31 
                 DNA HC 
                 CAGGTCCAGCTGCAGCAGTCTGGGTCTGAGCTG 
               
               
                   
                   
                 GTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGC 
               
               
                   
                   
                 AAGGCGTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGAGGCAGAGGCCTGGACAAGGC 
               
               
                   
                   
                 CTTGAGTGGATTGGAAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAAAAC 
               
               
                   
                   
                 AGGACCTCACTGACTGTAGACACATCCTCCACC 
               
               
                   
                   
                 ACAGCCTACATGCACCTCGCCAGCCTGACATCT 
               
               
                   
                   
                 GAGGACTCTGCGGTCTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-chi-Y LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 34 
                 VL 
                 DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQPPKLLIFWASTRESGVPD 
               
               
                   
                   
                 RFTGSGSVTDFTLTISSVQAEDLAVYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 35 
                 DNA VL 
                 GACATTGTGATGACCCAGTCTCCATCCTCCCTG 
               
               
                   
                   
                 ACTGTGACAGCAGGAGAGAAGGTCACTATGAGC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCAGGGCAGCCTCCTAAACTGTTGATCTTC 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCTGAT 
               
               
                   
                   
                 CGCTTCACAGGCAGTGGATCTGTAACAGATTTC 
               
               
                   
                   
                 ACTCTCACCATCAGCAGTGTGCAGGCTGAAGAC 
               
               
                   
                   
                 CTGGCAGTTTATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 36 
                 LC 
                 DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQPPKLLIFWASTRESGVPD 
               
               
                   
                   
                 RFTGSGSVTDFTLTISSVQAEDLAVYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 37 
                 DNA LC 
                 GACATTGTGATGACCCAGTCTCCATCCTCCCTG 
               
               
                   
                   
                 ACTGTGACAGCAGGAGAGAAGGTCACTATGAGC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCAGGGCAGCCTCCTAAACTGTTGATCTTC 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCTGAT 
               
               
                   
                   
                 CGCTTCACAGGCAGTGGATCTGTAACAGATTTC 
               
               
                   
                   
                 ACTCTCACCATCAGCAGTGTGCAGGCTGAAGAC 
               
               
                   
                   
                 CTGGCAGTTTATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum01 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 39 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 40 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 41 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum01 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 42 
                 VL 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTEFTLTISSLQPDDFATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 43 
                 DNA VL 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCATCA 
               
               
                   
                   
                 AGGTTCAGCGGCAGTGGATCTGGGACAGAATTC 
               
               
                   
                   
                 ACTCTCACCATCAGCAGCCTGCAGCCTGATGAT 
               
               
                   
                   
                 TTTGCAACTTATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 44 
                 LC 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTEFTLTISSLQPDDFATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 45 
                 DNA LC 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCATCA 
               
               
                   
                   
                 AGGTTCAGCGGCAGTGGATCTGGGACAGAATTC 
               
               
                   
                   
                 ACTCTCACCATCAGCAGCCTGCAGCCTGATGAT 
               
               
                   
                   
                 TTTGCAACTTATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum02 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 39 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 40 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 41 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum02 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 46 
                 VL 
                 DIQMTQSPSSLSASVGDRVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGIPP 
               
               
                   
                   
                 RFSGSGYGTDFTLTINNIESEDAAYYFCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 47 
                 DNA VL 
                 GACATCCAGATGACCCAGTCTCCATCCTCCCTG 
               
               
                   
                   
                 TCTGCATCTGTAGGAGACAGAGTCACCATCACT 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGATCCCACCT 
               
               
                   
                   
                 CGATTCAGTGGCAGCGGGTATGGAACAGATTTT 
               
               
                   
                   
                 ACCCTCACAATTAATAACATAGAATCTGAGGAT 
               
               
                   
                   
                 GCTGCATATTACTTCTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 48 
                 LC 
                 DIQMTQSPSSLSASVGDRVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGIPP 
               
               
                   
                   
                 RFSGSGYGTDFTLTINNIESEDAAYYFCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 49 
                 DNA LC 
                 GACATCCAGATGACCCAGTCTCCATCCTCCCTG 
               
               
                   
                   
                 TCTGCATCTGTAGGAGACAGAGTCACCATCACT 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGATCCCACCT 
               
               
                   
                   
                 CGATTCAGTGGCAGCGGGTATGGAACAGATTTT 
               
               
                   
                   
                 ACCCTCACAATTAATAACATAGAATCTGAGGAT 
               
               
                   
                   
                 GCTGCATATTACTTCTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum03 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 50 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 51 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 52 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 53 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum03 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 46 
                 VL 
                 DIQMTQSPSSLSASVGDRVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGIPP 
               
               
                   
                   
                 RFSGSGYGTDFTLTINNIESEDAAYYFCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 47 
                 DNA VL 
                 GACATCCAGATGACCCAGTCTCCATCCTCCCTG 
               
               
                   
                   
                 TCTGCATCTGTAGGAGACAGAGTCACCATCACT 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGATCCCACCT 
               
               
                   
                   
                 CGATTCAGTGGCAGCGGGTATGGAACAGATTTT 
               
               
                   
                   
                 ACCCTCACAATTAATAACATAGAATCTGAGGAT 
               
               
                   
                   
                 GCTGCATATTACTTCTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 48 
                 LC 
                 DIQMTQSPSSLSASVGDRVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGIPP 
               
               
                   
                   
                 RFSGSGYGTDFTLTINNIESEDAAYYFCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 49 
                 DNA LC 
                 GACATCCAGATGACCCAGTCTCCATCCTCCCTG 
               
               
                   
                   
                 TCTGCATCTGTAGGAGACAGAGTCACCATCACT 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGATCCCACCT 
               
               
                   
                   
                 CGATTCAGTGGCAGCGGGTATGGAACAGATTTT 
               
               
                   
                   
                 ACCCTCACAATTAATAACATAGAATCTGAGGAT 
               
               
                   
                   
                 GCTGCATATTACTTCTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum04 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 50 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 51 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 52 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 53 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum04 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 54 
                 VL 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGKAPKLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLQPEDIATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 55 
                 DNA VL 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAACCAGGGAAAGCTCCTAAGCTCCTGATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCATCA 
               
               
                   
                   
                 AGGTTCAGTGGAAGTGGATCTGGGACAGATTTT 
               
               
                   
                   
                 ACTTTCACCATCAGCAGCCTGCAGCCTGAAGAT 
               
               
                   
                   
                 ATTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 56 
                 LC 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGKAPKLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLQPEDIATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 57 
                 DNA LC 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAACCAGGGAAAGCTCCTAAGCTCCTGATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCATCA 
               
               
                   
                   
                 AGGTTCAGTGGAAGTGGATCTGGGACAGATTTT 
               
               
                   
                   
                 ACTTTCACCATCAGCAGCCTGCAGCCTGAAGAT 
               
               
                   
                   
                 ATTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum05 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 39 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 40 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 41 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum05 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 54 
                 VL 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGKAPKLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLQPEDIATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 55 
                 DNA VL 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAACCAGGGAAAGCTCCTAAGCTCCTGATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCATCA 
               
               
                   
                   
                 AGGTTCAGTGGAAGTGGATCTGGGACAGATTTT 
               
               
                   
                   
                 ACTTTCACCATCAGCAGCCTGCAGCCTGAAGAT 
               
               
                   
                   
                 ATTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 56 
                 LC 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGKAPKLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLQPEDIATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 57 
                 DNA LC 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAACCAGGGAAAGCTCCTAAGCTCCTGATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCATCA 
               
               
                   
                   
                 AGGTTCAGTGGAAGTGGATCTGGGACAGATTTT 
               
               
                   
                   
                 ACTTTCACCATCAGCAGCCTGCAGCCTGAAGAT 
               
               
                   
                   
                 ATTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum06 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 39 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 40 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 41 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum06 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 58 
                 VL 
                 DIVMTQTPLSLPVTPGEPASISCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 59 
                 DNA VL 
                 GATATTGTGATGACCCAGACTCCACTCTCCCTG 
               
               
                   
                   
                 CCCGTCACCCCTGGAGAGCCGGCCTCCATCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 60 
                 LC 
                 DIVMTQTPLSLPVTPGEPASISCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 61 
                 DNA LC 
                 GATATTGTGATGACCCAGACTCCACTCTCCCTG 
               
               
                   
                   
                 CCCGTCACCCCTGGAGAGCCGGCCTCCATCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum07 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 39 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 40 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 41 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum07 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 62 
                 VL 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGKAPKLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 63 
                 DNA VL 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAACCAGGGAAAGCTCCTAAGCTCCTGATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 64 
                 LC 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGKAPKLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 65 
                 DNA LC 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAACCAGGGAAAGCTCCTAAGCTCCTGATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum08 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 50 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 51 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 52 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 53 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum08 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 66 
                 VL 
                 EIVLTQSPDFQSVTPKEKVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 67 
                 DNA VL 
                 GAAATTGTGCTGACTCAGTCTCCAGACTTTCAG 
               
               
                   
                   
                 TCTGTGACTCCAAAGGAGAAAGTCACCATCACC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 68 
                 LC 
                 EIVLTQSPDFQSVTPKEKVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 69 
                 DNA LC 
                 GAAATTGTGCTGACTCAGTCTCCAGACTTTCAG 
               
               
                   
                   
                 TCTGTGACTCCAAAGGAGAAAGTCACCATCACC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum09 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 39 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 40 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 41 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum09 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 66 
                 VL 
                 EIVLTQSPDFQSVTPKEKVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 67 
                 DNA VL 
                 GAAATTGTGCTGACTCAGTCTCCAGACTTTCAG 
               
               
                   
                   
                 TCTGTGACTCCAAAGGAGAAAGTCACCATCACC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 68 
                 LC 
                 EIVLTQSPDFQSVTPKEKVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 69 
                 DNA LC 
                 GAAATTGTGCTGACTCAGTCTCCAGACTTTCAG 
               
               
                   
                   
                 TCTGTGACTCCAAAGGAGAAAGTCACCATCACC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum10 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 50 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 51 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 52 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 53 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum10 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 70 
                 VL 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 71 
                 DNA VL 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 72 
                 LC 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 73 
                 DNA LC 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum11 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 39 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 40 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 41 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum11 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 70 
                 VL 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 71 
                 DNA VL 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 72 
                 LC 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 73 
                 DNA LC 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum12 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 39 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 40 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 41 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum12 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 74 
                 VL 
                 DIQMTQSPSSLSASVGDRVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYLQKPGQSPQLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 75 
                 DNA VL 
                 GACATCCAGATGACCCAGTCTCCATCCTCCCTG 
               
               
                   
                   
                 TCTGCATCTGTAGGAGACAGAGTCACCATCACT 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCTGCAG 
               
               
                   
                   
                 AAGCCAGGGCAGTCTCCACAGCTCCTGATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 76 
                 LC 
                 DIQMTQSPSSLSASVGDRVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYLQKPGQSPQLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 77 
                 DNA LC 
                 GACATCCAGATGACCCAGTCTCCATCCTCCCTG 
               
               
                   
                   
                 TCTGCATCTGTAGGAGACAGAGTCACCATCACT 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCTGCAG 
               
               
                   
                   
                 AAGCCAGGGCAGTCTCCACAGCTCCTGATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum13 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 39 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 40 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 41 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCACTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTCACGATTACCGCGGACAAATCCACGAGC 
               
               
                   
                   
                 ACAGCCTACATGGAGCTGAGCAGCCTGAGATCT 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum13 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 78 
                 VL 
                 DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGKAPKLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 79 
                 DNA VL 
                 GATGTTGTGATGACTCAGTCTCCACTCTCCCTG 
               
               
                   
                   
                 CCCGTCACCCTTGGACAGCCGGCCTCCATCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTAACCTGGTATCAGCAG 
               
               
                   
                   
                 AAACCAGGGAAAGCTCCTAAGCTCCTGATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 80 
                 LC 
                 DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGKAPKLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 81 
                 DNA LC 
                 GATGTTGTGATGACTCAGTCTCCACTCTCCCTG 
               
               
                   
                   
                 CCCGTCACCCTTGGACAGCCGGCCTCCATCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTAACCTGGTATCAGCAG 
               
               
                   
                   
                 AAACCAGGGAAAGCTCCTAAGCTCCTGATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum14 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 82 
                 VH 
                 QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 83 
                 DNA VH 
                 CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTG 
               
               
                   
                   
                 AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC 
               
               
                   
                   
                 AAGGCTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCT TAC TGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 84 
                 HC 
                 QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 85 
                 DNA HC 
                 CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTG 
               
               
                   
                   
                 AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC 
               
               
                   
                   
                 AAGGCTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTACTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum14 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 70 
                 VL 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 71 
                 DNA VL 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 72 
                 LC 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 73 
                 DNA LC 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTG 
               
               
                   
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum15 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 82 
                 VH 
                 QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 83 
                 DNA VH 
                 CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTG 
               
               
                   
                   
                 AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC 
               
               
                   
                   
                 AAGGCTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTACTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 84 
                 HC 
                 QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 85 
                 DNA HC 
                 CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTG 
               
               
                   
                   
                 AAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGC 
               
               
                   
                   
                 AAGGCTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGATCAGGCAGTCCCCATCGAGAGGC 
               
               
                   
                   
                 CTTGAGTGGCTGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTACTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum15 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 66 
                 VL 
                 EIVLTQSPDFQSVTPKEKVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 67 
                 DNA VL 
                 GAAATTGTGCTGACTCAGTCTCCAGACTTTCAG 
               
               
                   
                   
                 TCTGTGACTCCAAAGGAGAAAGTCACCATCACC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 68 
                 LC 
                 EIVLTQSPDFQSVTPKEKVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 69 
                 DNA LC 
                 GAAATTGTGCTGACTCAGTCTCCAGACTTTCAG 
               
               
                   
                   
                 TCTGTGACTCCAAAGGAGAAAGTCACCATCACC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum16 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 86 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQAPGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 87 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCCCTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 88 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQAPGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLGK 
               
               
                 SEQ ID NO: 89 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTG 
               
               
                   
                   
                 AAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGT 
               
               
                   
                   
                 AAGGGTTCTGGCTACACATTCACCACTTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCCCCTGGACAAGGG 
               
               
                   
                   
                 CTTGAGTGGATGGGTAATATTTATCCTGGTACT 
               
               
                   
                   
                 GGTGGTTCTAACTTCGATGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
                   
                 ACGCTGTATCTTCAAATGAACAGCCTGAGAGCC 
               
               
                   
                   
                 GAGGACACGGCCGTGTATTACTGTACAAGATGG 
               
               
                   
                   
                 ACTACTGGGACGGGAGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACCGTGACCGTGTCCTCCGCTTCCACCAAG 
               
               
                   
                   
                 GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCC 
               
               
                   
                   
                 AGGAGCACCTCCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTG 
               
               
                   
                   
                 ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCGGCTGTCCTACAGTCC 
               
               
                   
                   
                 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC 
               
               
                   
                   
                 ACCTGCAACGTAGATCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGAGTTGAGTCCAAATATGGT 
               
               
                   
                   
                 CCCCCATGCCCACCGTGCCCAGCACCTGAGTTC 
               
               
                   
                   
                 CTGGGGGGACCATCAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                 AAACCCAAGGACACTCTCATGATCTCCCGGACC 
               
               
                   
                   
                 CCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC 
               
               
                   
                   
                 CAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTGGAGGTGCATAATGCCAAGACA 
               
               
                   
                   
                 AAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC 
               
               
                   
                   
                 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAG 
               
               
                   
                   
                 GTGTCCAACAAAGGCCTCCCGTCCTCCATCGAG 
               
               
                   
                   
                 AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA 
               
               
                   
                   
                 GAGCCACAGGTGTACACCCTGCCCCCATCCCAG 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTCAGCCTGACC 
               
               
                   
                   
                 TGCCTGGTCAAAGGCTTCTACCCCAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG 
               
               
                   
                   
                 AACAACTACAAGACCACGCCTCCCGTGCTGGAC 
               
               
                   
                   
                 TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTA 
               
               
                   
                   
                 ACCGTGGACAAGAGCAGGTGGCAGGAGGGGAAT 
               
               
                   
                   
                 GTCTTCTCATGCTCCGTGATGCATGAGGCTCTG 
               
               
                   
                   
                 CACAACCACTACACACAGAAGAGCCTCTCCCTG 
               
               
                   
                   
                 TCTCTGGGTAAA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum16 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 66 
                 VL 
                 EIVLTQSPDFQSVTPKEKVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 67 
                 DNA VL 
                 GAAATTGTGCTGACTCAGTCTCCAGACTTTCAG 
               
               
                   
                   
                 TCTGTGACTCCAAAGGAGAAAGTCACCATCACC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAA 
               
               
                 SEQ ID NO: 68 
                 LC 
                 EIVLTQSPDFQSVTPKEKVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 69 
                 DNA LC 
                 GAAATTGTGCTGACTCAGTCTCCAGACTTTCAG 
               
               
                   
                   
                 TCTGTGACTCCAAAGGAGAAAGTCACCATCACC 
               
               
                   
                   
                 TGCAAGTCCAGTCAGAGTCTGTTAGACAGTGGA 
               
               
                   
                   
                 AATCAAAAGAACTTCTTGACCTGGTACCAGCAG 
               
               
                   
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
                   
                 TGGGCATCCACTAGGGAATCTGGGGTCCCCTCG 
               
               
                   
                   
                 AGGTTCAGTGGCAGTGGATCTGGGACAGATTTC 
               
               
                   
                   
                 ACCTTTACCATCAGTAGCCTGGAAGCTGAAGAT 
               
               
                   
                   
                 GCTGCAACATATTACTGTCAGAATGATTATAGT 
               
               
                   
                   
                 TATCCGTACACGTTCGGCCAAGGGACCAAGGTG 
               
               
                   
                   
                 GAAATCAAACGTACGGTGGCTGCACCATCTGTC 
               
               
                   
                   
                 TTCATCTTCCCGCCATCTGATGAGCAGTTGAAA 
               
               
                   
                   
                 TCTGGAACTGCCTCTGTTGTGTGCCTGCTGAAT 
               
               
                   
                   
                 AACTTCTATCCCAGAGAGGCCAAAGTACAGTGG 
               
               
                   
                   
                 AAGGTGGATAACGCCCTCCAATCGGGTAACTCC 
               
               
                   
                   
                 CAGGAGAGTGTCACAGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 AGCACCTACAGCCTCAGCAGCACCCTGACGCTG 
               
               
                   
                   
                 AGCAAAGCAGACTACGAGAAACACAAAGTCTAC 
               
               
                   
                   
                 GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCG 
               
               
                   
                   
                 CCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-A HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 90 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGCGCCGAAGTG 
               
               
                   
                   
                 AAGAAGCCTGGCGAGTCCCTGCGGATCTCCTGC 
               
               
                   
                   
                 AAGGGCTCTGGCTACACCTTCACCACCTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCTACCGGCCAGGGC 
               
               
                   
                   
                 CTGGAATGGATGGGCAACATCTATCCTGGCACC 
               
               
                   
                   
                 GGCGGCTCCAACTTCGACGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTGACCATCACCGCCGACAAGTCCACCTCC 
               
               
                   
                   
                 ACCGCCTACATGGAACTGTCCTCCCTGAGATCC 
               
               
                   
                   
                 GAGGACACCGCCGTGTACTACTGCACCCGGTGG 
               
               
                   
                   
                 ACAACCGGCACAGGCGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACAGTGACCGTGTCCTCT 
               
               
                 SEQ ID NO: 91 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLG 
               
               
                 SEQ ID NO: 92 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGCGCCGAAGTG 
               
               
                   
                   
                 AAGAAGCCTGGCGAGTCCCTGCGGATCTCCTGC 
               
               
                   
                   
                 AAGGGCTCTGGCTACACCTTCACCACCTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCTACCGGCCAGGGC 
               
               
                   
                   
                 CTGGAATGGATGGGCAACATCTATCCTGGCACC 
               
               
                   
                   
                 GGCGGCTCCAACTTCGACGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTGACCATCACCGCCGACAAGTCCACCTCC 
               
               
                   
                   
                 ACCGCCTACATGGAACTGTCCTCCCTGAGATCC 
               
               
                   
                   
                 GAGGACACCGCCGTGTACTACTGCACCCGGTGG 
               
               
                   
                   
                 ACAACCGGCACAGGCGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACAGTGACCGTGTCCTCTGCTTCTACCAAG 
               
               
                   
                   
                 GGGCCCAGCGTGTTCCCCCTGGCCCCCTGCTCC 
               
               
                   
                   
                 AGAAGCACCAGCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTGAAGGACTACTTCCCCGAGCCCGTG 
               
               
                   
                   
                 ACCGTGTCCTGGAACAGCGGAGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC 
               
               
                   
                   
                 AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCAGCAGCAGCCTGGGCACCAAGACCTAC 
               
               
                   
                   
                 ACCTGTAACGTGGACCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGGGTGGAGAGCAAGTACGGC 
               
               
                   
                   
                 CCACCCTGCCCCCCCTGCCCAGCCCCCGAGTTC 
               
               
                   
                   
                 CTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCC 
               
               
                   
                   
                 AAGCCCAAGGACACCCTGATGATCAGCAGAACC 
               
               
                   
                   
                 CCCGAGGTGACCTGTGTGGTGGTGGACGTGTCC 
               
               
                   
                   
                 CAGGAGGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGACGGCGTGGAGGTGCACAACGCCAAGACC 
               
               
                   
                   
                 AAGCCCAGAGAGGAGCAGTTTAACAGCACCTAC 
               
               
                   
                   
                 CGGGTGGTGTCCGTGCTGACCGTGCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAAGAGTACAAGTGTAAG 
               
               
                   
                   
                 GTCTCCAACAAGGGCCTGCCAAGCAGCATCGAA 
               
               
                   
                   
                 AAGACCATCAGCAAGGCCAAGGGCCAGCCTAGA 
               
               
                   
                   
                 GAGCCCCAGGTCTACACCCTGCCACCCAGCCAA 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTGTCCCTGACC 
               
               
                   
                   
                 TGTCTGGTGAAGGGCTTCTACCCAAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAG 
               
               
                   
                   
                 AACAACTACAAGACCACCCCCCCAGTGCTGGAC 
               
               
                   
                   
                 AGCGACGGCAGCTTCTTCCTGTACAGCAGGCTG 
               
               
                   
                   
                 ACCGTGGACAAGTCCAGATGGCAGGAGGGCAAC 
               
               
                   
                   
                 GTCTTTAGCTGCTCCGTGATGCACGAGGCCCTG 
               
               
                   
                   
                 CACAACCACTACACCCAGAAGAGCCTGAGCCTG 
               
               
                   
                   
                 TCCCTGGGC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-A LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 42 
                 VL 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTEFTLTISSLQPDDFATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 93 
                 DNA VL 
                 GAGATCGTGCTGACCCAGTCCCCTGCCACCCTG 
               
               
                   
                   
                 TCACTGTCTCCAGGCGAGAGAGCTACCCTGTCC 
               
               
                   
                   
                 TGCAAGTCCTCCCAGTCCCTGCTGGACTCCGGC 
               
               
                   
                   
                 AACCAGAAGAACTTCCTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAGCCCGGCCAGGCCCCCAGACTGCTGATCTAC 
               
               
                   
                   
                 TGGGCCTCCACCCGGGAATCTGGCGTGCCCTCT 
               
               
                   
                   
                 AGATTCTCCGGCTCCGGCTCTGGCACCGAGTTT 
               
               
                   
                   
                 ACCCTGACCATCTCCAGCCTGCAGCCCGACGAC 
               
               
                   
                   
                 TTCGCCACCTACTACTGCCAGAACGACTACTCC 
               
               
                   
                   
                 TACCCCTACACCTTCGGCCAGGGCACCAAGGTG 
               
               
                   
                   
                 GAAATCAAG 
               
               
                 SEQ ID NO: 44 
                 LC 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTEFTLTISSLQPDDFATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 94 
                 DNA LC 
                 GAGATCGTGCTGACCCAGTCCCCTGCCACCCTG 
               
               
                   
                   
                 TCACTGTCTCCAGGCGAGAGAGCTACCCTGTCC 
               
               
                   
                   
                 TGCAAGTCCTCCCAGTCCCTGCTGGACTCCGGC 
               
               
                   
                   
                 AACCAGAAGAACTTCCTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAGCCCGGCCAGGCCCCCAGACTGCTGATCTAC 
               
               
                   
                   
                 TGGGCCTCCACCCGGGAATCTGGCGTGCCCTCT 
               
               
                   
                   
                 AGATTCTCCGGCTCCGGCTCTGGCACCGAGTTT 
               
               
                   
                   
                 ACCCTGACCATCTCCAGCCTGCAGCCCGACGAC 
               
               
                   
                   
                 TTCGCCACCTACTACTGCCAGAACGACTACTCC 
               
               
                   
                   
                 TACCCCTACACCTTCGGCCAGGGCACCAAGGTG 
               
               
                   
                   
                 GAAATCAAGCGTACGGTGGCCGCTCCCAGCGTG 
               
               
                   
                   
                 TTCATCTTCCCCCCAAGCGACGAGCAGCTGAAG 
               
               
                   
                   
                 AGCGGCACCGCCAGCGTGGTGTGTCTGCTGAAC 
               
               
                   
                   
                 AACTTCTACCCCAGGGAGGCCAAGGTGCAGTGG 
               
               
                   
                   
                 AAGGTGGACAACGCCCTGCAGAGCGGCAACAGC 
               
               
                   
                   
                 CAGGAGAGCGTCACCGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 TCCACCTACAGCCTGAGCAGCACCCTGACCCTG 
               
               
                   
                   
                 AGCAAGGCCGACTACGAGAAGCACAAGGTGTAC 
               
               
                   
                   
                 GCCTGTGAGGTGACCCACCAGGGCCTGTCCAGC 
               
               
                   
                   
                 CCCGTGACCAAGAGCTTCAACAGGGGCGAGTGC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-B HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 95 
                 DNA VH 
                 GAGGTGCAGCTGGTGCAGTCAGGCGCCGAAGTG 
               
               
                   
                   
                 AAGAAGCCCGGCGAGTCACTGAGAATTAGCTGT 
               
               
                   
                   
                 AAAGGTTCAGGCTACACCTTCACTACCTACTGG 
               
               
                   
                   
                 ATGCACTGGGTCCGCCAGGCTACCGGTCAAGGC 
               
               
                   
                   
                 CTCGAGTGGATGGGTAATATCTACCCCGGCACC 
               
               
                   
                   
                 GGCGGCTCTAACTTCGACGAGAAGTTTAAGAAT 
               
               
                   
                   
                 AGAGTGACTATCACCGCCGATAAGTCTACTAGC 
               
               
                   
                   
                 ACCGCCTATATGGAACTGTCTAGCCTGAGATCA 
               
               
                   
                   
                 GAGGACACCGCCGTCTACTACTGCACTAGGTGG 
               
               
                   
                   
                 ACTACCGGCACAGGCGCCTACTGGGGTCAAGGC 
               
               
                   
                   
                 ACTACCGTGACCGTGTCTAGC 
               
               
                 SEQ ID NO: 91 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLG 
               
               
                 SEQ ID NO: 96 
                 DNA HC 
                 GAGGTGCAGCTGGTGCAGTCAGGCGCCGAAGTG 
               
               
                   
                   
                 AAGAAGCCCGGCGAGTCACTGAGAATTAGCTGT 
               
               
                   
                   
                 AAAGGTTCAGGCTACACCTTCACTACCTACTGG 
               
               
                   
                   
                 ATGCACTGGGTCCGCCAGGCTACCGGTCAAGGC 
               
               
                   
                   
                 CTCGAGTGGATGGGTAATATCTACCCCGGCACC 
               
               
                   
                   
                 GGCGGCTCTAACTTCGACGAGAAGTTTAAGAAT 
               
               
                   
                   
                 AGAGTGACTATCACCGCCGATAAGTCTACTAGC 
               
               
                   
                   
                 ACCGCCTATATGGAACTGTCTAGCCTGAGATCA 
               
               
                   
                   
                 GAGGACACCGCCGTCTACTACTGCACTAGGTGG 
               
               
                   
                   
                 ACTACCGGCACAGGCGCCTACTGGGGTCAAGGC 
               
               
                   
                   
                 ACTACCGTGACCGTGTCTAGCGCTAGCACTAAG 
               
               
                   
                   
                 GGCCCGTCCGTGTTCCCCCTGGCACCTTGTAGC 
               
               
                   
                   
                 CGGAGCACTAGCGAATCCACCGCTGCCCTCGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGATTACTTCCCGGAGCCCGTG 
               
               
                   
                   
                 ACCGTGTCCTGGAACAGCGGAGCCCTGACCTCC 
               
               
                   
                   
                 GGAGTGCACACCTTCCCCGCTGTGCTGCAGAGC 
               
               
                   
                   
                 TCCGGGCTGTACTCGCTGTCGTCGGTGGTCACG 
               
               
                   
                   
                 GTGCCTTCATCTAGCCTGGGTACCAAGACCTAC 
               
               
                   
                   
                 ACTTGCAACGTGGACCACAAGCCTTCCAACACT 
               
               
                   
                   
                 AAGGTGGACAAGCGCGTCGAATCGAAGTACGGC 
               
               
                   
                   
                 CCACCGTGCCCGCCTTGTCCCGCGCCGGAGTTC 
               
               
                   
                   
                 CTCGGCGGTCCCTCGGTCTTTCTGTTCCCACCG 
               
               
                   
                   
                 AAGCCCAAGGACACTTTGATGATTTCCCGCACC 
               
               
                   
                   
                 CCTGAAGTGACATGCGTGGTCGTGGACGTGTCA 
               
               
                   
                   
                 CAGGAAGATCCGGAGGTGCAGTTCAATTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTCGAGGTGCACAACGCCAAAACC 
               
               
                   
                   
                 AAGCCGAGGGAGGAGCAGTTCAACTCCACTTAC 
               
               
                   
                   
                 CGCGTCGTGTCCGTGCTGACGGTGCTGCATCAG 
               
               
                   
                   
                 GACTGGCTGAACGGGAAGGAGTACAAGTGCAAA 
               
               
                   
                   
                 GTGTCCAACAAGGGACTTCCTAGCTCAATCGAA 
               
               
                   
                   
                 AAGACCATCTCGAAAGCCAAGGGACAGCCCCGG 
               
               
                   
                   
                 GAACCCCAAGTGTATACCCTGCCACCGAGCCAG 
               
               
                   
                   
                 GAAGAAATGACTAAGAACCAAGTCTCATTGACT 
               
               
                   
                   
                 TGCCTTGTGAAGGGCTTCTACCCATCGGATATC 
               
               
                   
                   
                 GCCGTGGAATGGGAGTCCAACGGCCAGCCGGAA 
               
               
                   
                   
                 AACAACTACAAGACCACCCCTCCGGTGCTGGAC 
               
               
                   
                   
                 TCAGACGGATCCTTCTTCCTCTACTCGCGGCTG 
               
               
                   
                   
                 ACCGTGGATAAGAGCAGATGGCAGGAGGGAAAT 
               
               
                   
                   
                 GTGTTCAGCTGTTCTGTGATGCATGAAGCCCTG 
               
               
                   
                   
                 CACAACCACTACACTCAGAAGTCCCTGTCCCTC 
               
               
                   
                   
                 TCCCTGGGA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-B LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 54 
                 VL 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGKAPKLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLQPEDIATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 97 
                 DNA VL 
                 GAGATCGTCCTGACTCAGTCACCCGCTACCCTG 
               
               
                   
                   
                 AGCCTGAGCCCTGGCGAGCGGGCTACACTGAGC 
               
               
                   
                   
                 TGTAAATCTAGTCAGTCACTGCTGGATAGCGGT 
               
               
                   
                   
                 AATCAGAAGAACTTCCTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAGCCCGGTAAAGCCCCTAAGCTGCTGATCTAC 
               
               
                   
                   
                 TGGGCCTCTACTAGAGAATCAGGCGTGCCCTCT 
               
               
                   
                   
                 AGGTTTAGCGGTAGCGGTAGTGGCACCGACTTC 
               
               
                   
                   
                 ACCTTCACTATCTCTAGCCTGCAGCCCGAGGAT 
               
               
                   
                   
                 ATCGCTACCTACTACTGTCAGAACGACTATAGC 
               
               
                   
                   
                 TACCCCTACACCTTCGGTCAAGGCACTAAGGTC 
               
               
                   
                   
                 GAGATTAAG 
               
               
                 SEQ ID NO: 56 
                 LC 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGKAPKLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLQPEDIATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 98 
                 DNA LC 
                 GAGATCGTCCTGACTCAGTCACCCGCTACCCTG 
               
               
                   
                   
                 AGCCTGAGCCCTGGCGAGCGGGCTACACTGAGC 
               
               
                   
                   
                 TGTAAATCTAGTCAGTCACTGCTGGATAGCGGT 
               
               
                   
                   
                 AATCAGAAGAACTTCCTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAGCCCGGTAAAGCCCCTAAGCTGCTGATCTAC 
               
               
                   
                   
                 TGGGCCTCTACTAGAGAATCAGGCGTGCCCTCT 
               
               
                   
                   
                 AGGTTTAGCGGTAGCGGTAGTGGCACCGACTTC 
               
               
                   
                   
                 ACCTTCACTATCTCTAGCCTGCAGCCCGAGGAT 
               
               
                   
                   
                 ATCGCTACCTACTACTGTCAGAACGACTATAGC 
               
               
                   
                   
                 TACCCCTACACCTTCGGTCAAGGCACTAAGGTC 
               
               
                   
                   
                 GAGATTAAGCGTACGGTGGCCGCTCCCAGCGTG 
               
               
                   
                   
                 TTCATCTTCCCCCCCAGCGACGAGCAGCTGAAG 
               
               
                   
                   
                 AGCGGCACCGCCAGCGTGGTGTGCCTGCTGAAC 
               
               
                   
                   
                 AACTTCTACCCCCGGGAGGCCAAGGTGCAGTGG 
               
               
                   
                   
                 AAGGTGGACAACGCCCTGCAGAGCGGCAACAGC 
               
               
                   
                   
                 CAGGAGAGCGTCACCGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 TCCACCTACAGCCTGAGCAGCACCCTGACCCTG 
               
               
                   
                   
                 AGCAAGGCCGACTACGAGAAGCATAAGGTGTAC 
               
               
                   
                   
                 GCCTGCGAGGTGACCCACCAGGGCCTGTCCAGC 
               
               
                   
                   
                 CCCGTGACCAAGAGCTTCAACAGGGGCGAGTGC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-C HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 90 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGCGCCGAAGTG 
               
               
                   
                   
                 AAGAAGCCTGGCGAGTCCCTGCGGATCTCCTGC 
               
               
                   
                   
                 AAGGGCTCTGGCTACACCTTCACCACCTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCTACCGGCCAGGGC 
               
               
                   
                   
                 CTGGAATGGATGGGCAACATCTATCCTGGCACC 
               
               
                   
                   
                 GGCGGCTCCAACTTCGACGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTGACCATCACCGCCGACAAGTCCACCTCC 
               
               
                   
                   
                 ACCGCCTACATGGAACTGTCCTCCCTGAGATCC 
               
               
                   
                   
                 GAGGACACCGCCGTGTACTACTGCACCCGGTGG 
               
               
                   
                   
                 ACAACCGGCACAGGCGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACAGTGACCGTGTCCTCT 
               
               
                 SEQ ID NO: 91 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLG 
               
               
                 SEQ ID NO: 92 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGCGCCGAAGTG 
               
               
                   
                   
                 AAGAAGCCTGGCGAGTCCCTGCGGATCTCCTGC 
               
               
                   
                   
                 AAGGGCTCTGGCTACACCTTCACCACCTACTGG 
               
               
                   
                   
                 ATGCACTGGGTGCGACAGGCTACCGGCCAGGGC 
               
               
                   
                   
                 CTGGAATGGATGGGCAACATCTATCCTGGCACC 
               
               
                   
                   
                 GGCGGCTCCAACTTCGACGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGAGTGACCATCACCGCCGACAAGTCCACCTCC 
               
               
                   
                   
                 ACCGCCTACATGGAACTGTCCTCCCTGAGATCC 
               
               
                   
                   
                 GAGGACACCGCCGTGTACTACTGCACCCGGTGG 
               
               
                   
                   
                 ACAACCGGCACAGGCGCTTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACCACAGTGACCGTGTCCTCTGCTTCTACCAAG 
               
               
                   
                   
                 GGGCCCAGCGTGTTCCCCCTGGCCCCCTGCTCC 
               
               
                   
                   
                 AGAAGCACCAGCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTGAAGGACTACTTCCCCGAGCCCGTG 
               
               
                   
                   
                 ACCGTGTCCTGGAACAGCGGAGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC 
               
               
                   
                   
                 AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCAGCAGCAGCCTGGGCACCAAGACCTAC 
               
               
                   
                   
                 ACCTGTAACGTGGACCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGGGTGGAGAGCAAGTACGGC 
               
               
                   
                   
                 CCACCCTGCCCCCCCTGCCCAGCCCCCGAGTTC 
               
               
                   
                   
                 CTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCC 
               
               
                   
                   
                 AAGCCCAAGGACACCCTGATGATCAGCAGAACC 
               
               
                   
                   
                 CCCGAGGTGACCTGTGTGGTGGTGGACGTGTCC 
               
               
                   
                   
                 CAGGAGGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGACGGCGTGGAGGTGCACAACGCCAAGACC 
               
               
                   
                   
                 AAGCCCAGAGAGGAGCAGTTTAACAGCACCTAC 
               
               
                   
                   
                 CGGGTGGTGTCCGTGCTGACCGTGCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAAGAGTAEAAGTGTAAG 
               
               
                   
                   
                 GTCTCCAACAAGGGCCTGCCAAGCAGCATCGAA 
               
               
                   
                   
                 AAGACCATCAGCAAGGCCAAGGGCCAGCCTAGA 
               
               
                   
                   
                 GAGCCCCAGGTCTACACCCTGCCACCCAGCCAA 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTGTCCCTGACC 
               
               
                   
                   
                 TGTCTGGTGAAGGGCTTCTACCCAAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAG 
               
               
                   
                   
                 AACAACTACAAGACCACCCCCCCAGTGCTGGAC 
               
               
                   
                   
                 AGCGACGGCAGCTTCTTCCTGTACAGCAGGCTG 
               
               
                   
                   
                 ACCGTGGACAAGTCCAGATGGCAGGAGGGCAAC 
               
               
                   
                   
                 GTCTTTAGCTGCTCCGTGATGCACGAGGCCCTG 
               
               
                   
                   
                 CACAACCACTACACCCAGAAGAGCCTGAGCCTG 
               
               
                   
                   
                 TCCCTGGGC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-C LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 66 
                 VL 
                 EIVLTQSPDFQSVTPKEKVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 99 
                 DNA VL 
                 GAGATCGTGCTGACCCAGTCCCCCGACTTCCAG 
               
               
                   
                   
                 TCCGTGACCCCCAAAGAAAAAGTGACCATCACA 
               
               
                   
                   
                 TGCAAGTCCTCCCAGTCCCTGCTGGACTCCGGC 
               
               
                   
                   
                 AACCAGAAGAACTTCCTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAGCCCGGCCAGGCCCCCAGACTGCTGATCTAC 
               
               
                   
                   
                 TGGGCCTCCACCCGGGAATCTGGCGTGCCCTCT 
               
               
                   
                   
                 AGATTCTCCGGCTCCGGCTCTGGCACCGACTTT 
               
               
                   
                   
                 ACCTTCACCATCTCCAGCCTGGAAGCCGAGGAC 
               
               
                   
                   
                 GCCGCCACCTACTACTGCCAGAACGACTACTCC 
               
               
                   
                   
                 TACCCCTACACCTTCGGCCAGGGCACCAAGGTG 
               
               
                   
                   
                 GAAATCAAG 
               
               
                 SEQ ID NO: 68 
                 LC 
                 EIVLTQSPDFQSVTPKEKVTITCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 100 
                 DNA LC 
                 GAGATCGTGCTGACCCAGTCCCCCGACTTCCAG 
               
               
                   
                   
                 TCCGTGACCCCCAAAGAAAAAGTGACCATCACA 
               
               
                   
                   
                 TGCAAGTCCTCCCAGTCCCTGCTGGACTCCGGC 
               
               
                   
                   
                 AACCAGAAGAACTTCCTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAGCCCGGCCAGGCCCCCAGACTGCTGATCTAC 
               
               
                   
                   
                 TGGGCCTCCACCCGGGAATCTGGCGTGCCCTCT 
               
               
                   
                   
                 AGATTCTCCGGCTCCGGCTCTGGCACCGACTTT 
               
               
                   
                   
                 ACCTTCACCATCTCCAGCCTGGAAGCCGAGGAC 
               
               
                   
                   
                 GCCGCCACCTACTACTGCCAGAACGACTACTCC 
               
               
                   
                   
                 TACCCCTACACCTTCGGCCAGGGCACCAAGGTG 
               
               
                   
                   
                 GAAATCAAGCGTACGGTGGCCGCTCCCAGCGTG 
               
               
                   
                   
                 TTCATCTTCCCCCCAAGCGACGAGCAGCTGAAG 
               
               
                   
                   
                 AGCGGCACCGCCAGCGTGGTGTGTCTGCTGAAC 
               
               
                   
                   
                 AACTTCTACCCCAGGGAGGCCAAGGTGCAGTGG 
               
               
                   
                   
                 AAGGTGGACAACGCCCTGCAGAGCGGCAACAGC 
               
               
                   
                   
                 CAGGAGAGCGTCACCGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 TCCACCTACAGCCTGAGCAGCACCCTGACCCTG 
               
               
                   
                   
                 AGCAAGGCCGACTACGAGAAGCACAAGGTGTAC 
               
               
                   
                   
                 GCCTGTGAGGTGACCCACCAGGGCCTGTCCAGC 
               
               
                   
                   
                 CCCGTGACCAAGAGCTTCAACAGGGGCGAGTGC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-D HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 50 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 101 
                 DNA VH 
                 GAAGTGCAGCTGGTGCAGTCTGGCGCCGAAGTG 
               
               
                   
                   
                 AAGAAGCCTGGCGAGTCCCTGCGGATCTCCTGC 
               
               
                   
                   
                 AAGGGCTCTGGCTACACCTTCACCACCTACTGG 
               
               
                   
                   
                 ATGCACTGGATCCGGCAGTCCCCCTCTAGGGGC 
               
               
                   
                   
                 CTGGAATGGCTGGGCAACATCTACCCTGGCACC 
               
               
                   
                   
                 GGCGGCTCCAACTTCGACGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGGTTCACCATCTCCCGGGACAACTCCAAGAAC 
               
               
                   
                   
                 ACCCTGTACCTGCAGATGAACTCCCTGCGGGCC 
               
               
                   
                   
                 GAGGACACCGCCGTGTACTACTGTACCAGATGG 
               
               
                   
                   
                 ACCACCGGAACCGGCGCCTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACAACAGTGACCGTGTCCTCC 
               
               
                 SEQ ID NO: 102 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWIRQSPSRGLEWLGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLG 
               
               
                 SEQ ID NO: 103 
                 DNA HC 
                 GAAGTGCAGCTGGTGCAGTCTGGCGCCGAAGTG 
               
               
                   
                   
                 AAGAAGCCTGGCGAGTCCCTGCGGATCTCCTGC 
               
               
                   
                   
                 AAGGGCTCTGGCTACACCTTCACCACCTACTGG 
               
               
                   
                   
                 ATGCACTGGATCCGGCAGTCCCCCTCTAGGGGC 
               
               
                   
                   
                 CTGGAATGGCTGGGCAACATCTACCCTGGCACC 
               
               
                   
                   
                 GGCGGCTCCAACTTCGACGAGAAGTTCAAGAAC 
               
               
                   
                   
                 AGGTTCACCATCTCCCGGGACAACTCCAAGAAC 
               
               
                   
                   
                 ACCCTGTACCTGCAGATGAACTCCCTGCGGGCC 
               
               
                   
                   
                 GAGGACACCGCCGTGTACTACTGTACCAGATGG 
               
               
                   
                   
                 ACCACCGGAACCGGCGCCTATTGGGGCCAGGGC 
               
               
                   
                   
                 ACAACAGTGACCGTGTCCTCCGCTTCTACCAAG 
               
               
                   
                   
                 GGGCCCAGCGTGTTCCCCCTGGCCCCCTGCTCC 
               
               
                   
                   
                 AGAAGCACCAGCGAGAGCACAGCCGCCCTGGGC 
               
               
                   
                   
                 TGCCTGGTGAAGGACTACTTCCCCGAGCCCGTG 
               
               
                   
                   
                 ACCGTGTCCTGGAACAGCGGAGCCCTGACCAGC 
               
               
                   
                   
                 GGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC 
               
               
                   
                   
                 AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACC 
               
               
                   
                   
                 GTGCCCAGCAGCAGCCTGGGCACCAAGACCTAC 
               
               
                   
                   
                 ACCTGTAACGTGGACCACAAGCCCAGCAACACC 
               
               
                   
                   
                 AAGGTGGACAAGAGGGTGGAGAGCAAGTACGGC 
               
               
                   
                   
                 CCACCCTGCCCCCCCTGCCCAGCCCCCGAGTTC 
               
               
                   
                   
                 CTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCC 
               
               
                   
                   
                 AAGCCCAAGGACACCCTGATGATCAGCAGAACC 
               
               
                   
                   
                 CCCGAGGTGACCTGTGTGGTGGTGGACGTGTCC 
               
               
                   
                   
                 CAGGAGGACCCCGAGGTCCAGTTCAACTGGTAC 
               
               
                   
                   
                 GTGGACGGCGTGGAGGTGCACAACGCCAAGACC 
               
               
                   
                   
                 AAGCCCAGAGAGGAGCAGTTTAACAGCACCTAC 
               
               
                   
                   
                 CGGGTGGTGTCCGTGCTGACCGTGCTGCACCAG 
               
               
                   
                   
                 GACTGGCTGAACGGCAAAGAGTACAAGTGTAAG 
               
               
                   
                   
                 GTCTCCAACAAGGGCCTGCCAAGCAGCATCGAA 
               
               
                   
                   
                 AAGACCATCAGCAAGGCCAAGGGCCAGCCTAGA 
               
               
                   
                   
                 GAGCCCCAGGTCTACACCCTGCCACCCAGCCAA 
               
               
                   
                   
                 GAGGAGATGACCAAGAACCAGGTGTCCCTGACC 
               
               
                   
                   
                 TGTCTGGTGAAGGGCTTCTACCCAAGCGACATC 
               
               
                   
                   
                 GCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAG 
               
               
                   
                   
                 AACAACTACAAGACCACCCCCCCAGTGCTGGAC 
               
               
                   
                   
                 AGCGACGGCAGCTTCTTCCTGTACAGCAGGCTG 
               
               
                   
                   
                 ACCGTGGACAAGTCCAGATGGCAGGAGGGCAAC 
               
               
                   
                   
                 GTCTTTAGCTGCTCCGTGATGCACGAGGCCCTG 
               
               
                   
                   
                 CACAACCACTACACCCAGAAGAGCCTGAGCCTG 
               
               
                   
                   
                 TCCCTGGGC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-D LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 70 
                 VL 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 104 
                 DNA VL 
                 GAGATCGTGCTGACCCAGTCCCCTGCCACCCTG 
               
               
                   
                   
                 TCACTGTCTCCAGGCGAGAGAGCTACCCTGTCC 
               
               
                   
                   
                 TGCAAGTCCTCCCAGTCCCTGCTGGACTCCGGC 
               
               
                   
                   
                 AACCAGAAGAACTTCCTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAGCCCGGCCAGGCCCCCAGACTGCTGATCTAC 
               
               
                   
                   
                 TGGGCCTCCACCCGGGAATCTGGCGTGCCCTCT 
               
               
                   
                   
                 AGATTCTCCGGCTCCGGCTCTGGCACCGACTTT 
               
               
                   
                   
                 ACCTTCACCATCTCCAGCCTGGAAGCCGAGGAC 
               
               
                   
                   
                 GCCGCCACCTACTACTGCCAGAACGACTACTCC 
               
               
                   
                   
                 TACCCCTACACCTTCGGCCAGGGCACCAAGGTG 
               
               
                   
                   
                 GAAATCAAG 
               
               
                 SEQ ID NO: 72 
                 LC 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 105 
                 DNA LC 
                 GAGATCGTGCTGACCCAGTCCCCTGCCACCCTG 
               
               
                   
                   
                 TCACTGTCTCCAGGCGAGAGAGCTACCCTGTCC 
               
               
                   
                   
                 TGCAAGTCCTCCCAGTCCCTGCTGGACTCCGGC 
               
               
                   
                   
                 AACCAGAAGAACTTCCTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAGCCCGGCCAGGCCCCCAGACTGCTGATCTAC 
               
               
                   
                   
                 TGGGCCTCCACCCGGGAATCTGGCGTGCCCTCT 
               
               
                   
                   
                 AGATTCTCCGGCTCCGGCTCTGGCACCGACTTT 
               
               
                   
                   
                 ACCTTCACCATCTCCAGCCTGGAAGCCGAGGAC 
               
               
                   
                   
                 GCCGCCACCTACTACTGCCAGAACGACTACTCC 
               
               
                   
                   
                 TACCCCTACACCTTCGGCCAGGGCACCAAGGTG 
               
               
                   
                   
                 GAAATCAAGCGTACGGTGGCCGCTCCCAGCGTG 
               
               
                   
                   
                 TTCATCTTCCCCCCAAGCGACGAGCAGCTGAAG 
               
               
                   
                   
                 AGCGGCACCGCCAGCGTGGTGTGTCTGCTGAAC 
               
               
                   
                   
                 AACTTCTACCCCAGGGAGGCCAAGGTGCAGTGG 
               
               
                   
                   
                 AAGGTGGACAACGCCCTGCAGAGCGGCAACAGC 
               
               
                   
                   
                 CAGGAGAGCGTCACCGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 TCCACCTACAGCCTGAGCAGCACCCTGACCCTG 
               
               
                   
                   
                 AGCAAGGCCGACTACGAGAAGCACAAGGTGTAC 
               
               
                   
                   
                 GCCTGTGAGGTGACCCACCAGGGCCTGTCCAGC 
               
               
                   
                   
                 CCCGTGACCAAGAGCTTCAACAGGGGCGAGTGC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-E HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 1 (Kabat) 
                 HCDR1 
                 TYWMH 
               
               
                 SEQ ID NO: 2 (Kabat) 
                 HCDR2 
                 NIYPGTGGSNFDEKFKN 
               
               
                 SEQ ID NO: 3 (Kabat) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 4 (Chothia) 
                 HCDR1 
                 GYTFTTY 
               
               
                 SEQ ID NO: 5 (Chothia) 
                 HCDR2 
                 YPGTGG 
               
               
                 SEQ ID NO: 3 (Chothia) 
                 HCDR3 
                 WTTGTGAY 
               
               
                 SEQ ID NO: 38 
                 VH 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSS 
               
               
                 SEQ ID NO: 95 
                 DNA VH 
                 GAGGTGCAGCTGGTGCAGTCAGGCGCCGAAGTG 
               
               
                   
                   
                 AAGAAGCCCGGCGAGTCACTGAGAATTAGCTGT 
               
               
                   
                   
                 AAAGGTTCAGGCTACACCTTCACTACCTACTGG 
               
               
                   
                   
                 ATGCACTGGGTCCGCCAGGCTACCGGTCAAGGC 
               
               
                   
                   
                 CTCGAGTGGATGGGTAATATCTACCCCGGCACC 
               
               
                   
                   
                 GGCGGCTCTAACTTCGACGAGAAGTTTAAGAAT 
               
               
                   
                   
                 AGAGTGACTATCACCGCCGATAAGTCTACTAGC 
               
               
                   
                   
                 ACCGCCTATATGGAACTGTCTAGCCTGAGATCA 
               
               
                   
                   
                 GAGGACACCGCCGTCTACTACTGCACTAGGTGG 
               
               
                   
                   
                 ACTACCGGCACAGGCGCCTACTGGGGTCAAGGC 
               
               
                   
                   
                 ACTACCGTGACCGTGTCTAGC 
               
               
                 SEQ ID NO: 91 
                 HC 
                 EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYW 
               
               
                   
                   
                 MHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKN 
               
               
                   
                   
                 RVTITADKSTSTAYMELSSLRSEDTAVYYCTRW 
               
               
                   
                   
                 TTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCS 
               
               
                   
                   
                 RSTSESTAALGCLVKDYFPEPVTVSWNSGALTS 
               
               
                   
                   
                 GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTY 
               
               
                   
                   
                 TCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS 
               
               
                   
                   
                 QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY 
               
               
                   
                   
                 RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE 
               
               
                   
                   
                 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 
               
               
                   
                   
                 SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL 
               
               
                   
                   
                 HNHYTQKSLSLSLG 
               
               
                 SEQ ID NO: 96 
                 DNA HC 
                 GAGGTGCAGCTGGTGCAGTCAGGCGCCGAAGTG 
               
               
                   
                   
                 AAGAAGCCCGGCGAGTCACTGAGAATTAGCTGT 
               
               
                   
                   
                 AAAGGTTCAGGCTACACCTTCACTACCTACTGG 
               
               
                   
                   
                 ATGCACTGGGTCCGCCAGGCTACCGGTCAAGGC 
               
               
                   
                   
                 CTCGAGTGGATGGGTAATATCTACCCCGGCACC 
               
               
                   
                   
                 GGCGGCTCTAACTTCGACGAGAAGTTTAAGAAT 
               
               
                   
                   
                 AGAGTGACTATCACCGCCGATAAGTCTACTAGC 
               
               
                   
                   
                 ACCGCCTATATGGAACTGTCTAGCCTGAGATCA 
               
               
                   
                   
                 GAGGACACCGCCGTCTACTACTGCACTAGGTGG 
               
               
                   
                   
                 ACTACCGGCACAGGCGCCTACTGGGGTCAAGGC 
               
               
                   
                   
                 ACTACCGTGACCGTGTCTAGCGCTAGCACTAAG 
               
               
                   
                   
                 GGCCCGTCCGTGTTCCCCCTGGCACCTTGTAGC 
               
               
                   
                   
                 CGGAGCACTAGCGAATCCACCGCTGCCCTCGGC 
               
               
                   
                   
                 TGCCTGGTCAAGGATTACTTCCCGGAGCCCGTG 
               
               
                   
                   
                 ACCGTGTCCTGGAACAGCGGAGCCCTGACCTCC 
               
               
                   
                   
                 GGAGTGCACACCTTCCCCGCTGTGCTGCAGAGC 
               
               
                   
                   
                 TCCGGGCTGTACTCGCTGTCGTCGGTGGTCACG 
               
               
                   
                   
                 GTGCCTTCATCTAGCCTGGGTACCAAGACCTAC 
               
               
                   
                   
                 ACTTGCAACGTGGACCACAAGCCTTCCAACACT 
               
               
                   
                   
                 AAGGTGGACAAGCGCGTCGAATCGAAGTACGGC 
               
               
                   
                   
                 CCACCGTGCCCGCCTTGTCCCGCGCCGGAGTTC 
               
               
                   
                   
                 CTCGGCGGTCCCTCGGTCTTTCTGTTCCCACCG 
               
               
                   
                   
                 AAGCCCAAGGACACTTTGATGATTTCCCGCACC 
               
               
                   
                   
                 CCTGAAGTGACATGCGTGGTCGTGGACGTGTCA 
               
               
                   
                   
                 CAGGAAGATCCGGAGGTGCAGTTCAATTGGTAC 
               
               
                   
                   
                 GTGGATGGCGTCGAGGTGCACAACGCCAAAACC 
               
               
                   
                   
                 AAGCCGAGGGAGGAGCAGTTCAACTCCACTTAC 
               
               
                   
                   
                 CGCGTCGTGTCCGTGCTGACGGTGCTGCATCAG 
               
               
                   
                   
                 GACTGGCTGAACGGGAAGGAGTACAAGTGCAAA 
               
               
                   
                   
                 GTGTCCAACAAGGGACTTCCTAGCTCAATCGAA 
               
               
                   
                   
                 AAGACCATCTCGAAAGCCAAGGGACAGCCCCGG 
               
               
                   
                   
                 GAACCCCAAGTGTATACCCTGCCACCGAGCCAG 
               
               
                   
                   
                 GAAGAAATGACTAAGAACCAAGTCTCATTGACT 
               
               
                   
                   
                 TGCCTTGTGAAGGGCTTCTACCCATCGGATATC 
               
               
                   
                   
                 GCCGTGGAATGGGAGTCCAACGGCCAGCCGGAA 
               
               
                   
                   
                 AACAACTACAAGACCACCCCTCCGGTGCTGGAC 
               
               
                   
                   
                 TCAGACGGATCCTTCTTCCTCTACTCGCGGCTG 
               
               
                   
                   
                 ACCGTGGATAAGAGCAGATGGCAGGAGGGAAAT 
               
               
                   
                   
                 GTGTTCAGCTGTTCTGTGATGCATGAAGCCCTG 
               
               
                   
                   
                 CACAACCACTACACTCAGAAGTCCCTGTCCCTC 
               
               
                   
                   
                 TCCCTGGGA 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-E LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 10 (Kabat) 
                 LCDR1 
                 KSSQSLLDSGNQKNFLT 
               
               
                 SEQ ID NO: 11 (Kabat) 
                 LCDR2 
                 WASTRES 
               
               
                 SEQ ID NO: 32 (Kabat) 
                 LCDR3 
                 QNDYSYPYT 
               
               
                 SEQ ID NO: 13 (Chothia) 
                 LCDR1 
                 SQSLLDSGNQKNF 
               
               
                 SEQ ID NO: 14 (Chothia) 
                 LCDR2 
                 WAS 
               
               
                 SEQ ID NO: 33 (Chothia) 
                 LCDR3 
                 DYSYPY 
               
               
                 SEQ ID NO: 70 
                 VL 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIK 
               
               
                 SEQ ID NO: 106 
                 DNA VL 
                 GAGATCGTCCTGACTCAGTCACCCGCTACCCTG 
               
               
                   
                   
                 AGCCTGAGCCCTGGCGAGCGGGCTACACTGAGC 
               
               
                   
                   
                 TGTAAATCTAGTCAGTCACTGCTGGATAGCGGT 
               
               
                   
                   
                 AATCAGAAGAACTTCCTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAGCCCGGTCAAGCCCCTAGACTGCTGATCTAC 
               
               
                   
                   
                 TGGGCCTCTACTAGAGAATCAGGCGTGCCCTCT 
               
               
                   
                   
                 AGGTTTAGCGGTAGCGGTAGTGGCACCGACTTC 
               
               
                   
                   
                 ACCTTCACTATCTCTAGCCTGGAAGCCGAGGAC 
               
               
                   
                   
                 GCCGCTACCTACTACTGTCAGAACGACTATAGC 
               
               
                   
                   
                 TACCCCTACACCTTCGGTCAAGGCACTAAGGTC 
               
               
                   
                   
                 GAGATTAAG 
               
               
                 SEQ ID NO: 72 
                 LC 
                 EIVLTQSPATLSLSPGERATLSCKSSQSLLDSG 
               
               
                   
                   
                 NQKNFLTWYQQKPGQAPRLLIYWASTRESGVPS 
               
               
                   
                   
                 RFSGSGSGTDFTFTISSLEAEDAATYYCQNDYS 
               
               
                   
                   
                 YPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK 
               
               
                   
                   
                 SGTASVVCLLNNFYPREAKVQWKVDNALQSGNS 
               
               
                   
                   
                 QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY 
               
               
                   
                   
                 ACEVTHQGLSSPVTKSFNRGEC 
               
               
                 SEQ ID NO: 107 
                 DNA LC 
                 GAGATCGTCCTGACTCAGTCACCCGCTACCCTG 
               
               
                   
                   
                 AGCCTGAGCCCTGGCGAGCGGGCTACACTGAGC 
               
               
                   
                   
                 TGTAAATCTAGTCAGTCACTGCTGGATAGCGGT 
               
               
                   
                   
                 AATCAGAAGAACTTCCTGACCTGGTATCAGCAG 
               
               
                   
                   
                 AAGCCCGGTCAAGCCCCTAGACTGCTGATCTAC 
               
               
                   
                   
                 TGGGCCTCTACTAGAGAATCAGGCGTGCCCTCT 
               
               
                   
                   
                 AGGTTTAGCGGTAGCGGTAGTGGCACCGACTTC 
               
               
                   
                   
                 ACCTTCACTATCTCTAGCCTGGAAGCCGAGGAC 
               
               
                   
                   
                 GCCGCTACCTACTACTGTCAGAACGACTATAGC 
               
               
                   
                   
                 TACCCCTACACCTTCGGTCAAGGCACTAAGGTC 
               
               
                   
                   
                 GAGATTAAGCGTACGGTGGCCGCTCCCAGCGTG 
               
               
                   
                   
                 TTCATCTTCCCCCCCAGCGACGAGCAGCTGAAG 
               
               
                   
                   
                 AGCGGCACCGCCAGCGTGGTGTGCCTGCTGAAC 
               
               
                   
                   
                 AACTTCTACCCCCGGGAGGCCAAGGTGCAGTGG 
               
               
                   
                   
                 AAGGTGGACAACGCCCTGCAGAGCGGCAACAGC 
               
               
                   
                   
                 CAGGAGAGCGTCACCGAGCAGGACAGCAAGGAC 
               
               
                   
                   
                 TCCACCTACAGCCTGAGCAGCACCCTGACCCTG 
               
               
                   
                   
                 AGCAAGGCCGACTACGAGAAGCATAAGGTGTAC 
               
               
                   
                   
                 GCCTGCGAGGTGACCCACCAGGGCCTGTCCAGC 
               
               
                   
                   
                 CCCGTGACCAAGAGCTTCAACAGGGGCGAGTGC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 115 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTGCACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 118 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTGC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-chi HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-chi LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 115 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTGCACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 118 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTGC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-chi Y HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-chi Y LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum01 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum01 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum02 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum02 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum03 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum03 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum04 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum04 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum05 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                   
                   
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum05 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum06 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum06 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum07 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum07 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum08 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum08 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum09 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum09 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum10 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum10 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum11 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum11 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum12 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum12 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum13 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum13 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 121 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTAACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum14 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 223 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAC 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 223 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum14 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum15 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 223 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAC 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 223 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum15 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum16 HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 108 (Kabat) 
                 HCDR1 
                 ACTTACTGGATGCAC 
               
               
                 SEQ ID NO: 109 (Kabat) 
                 HCDR2 
                 AATATTTATCCTGGTACTGGTGGTTCTAACTTC 
               
               
                   
                   
                 GATGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 110 (Kabat) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                 SEQ ID NO: 111 (Chothia) 
                 HCDR1 
                 GGCTACACATTCACCACTTAC 
               
               
                 SEQ ID NO: 112 (Chothia) 
                 HCDR2 
                 TATCCTGGTACTGGTGGT 
               
               
                 SEQ ID NO: 110 (Chothia) 
                 HCDR3 
                 TGGACTACTGGGACGGGAGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-hum16 LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 113 (Kabat) 
                 LCDR1 
                 AAGTCCAGTCAGAGTCTGTTAGACAGTGGAAAT 
               
               
                   
                   
                 CAAAAGAACTTCTTGACC 
               
               
                 SEQ ID NO: 114 (Kabat) 
                 LCDR2 
                 TGGGCATCCACTAGGGAATCT 
               
               
                 SEQ ID NO: 119 (Kabat) 
                 LCDR3 
                 CAGAATGATTATAGTTATCCGTACACG 
               
               
                 SEQ ID NO: 116 (Chothia) 
                 LCDR1 
                 AGTCAGAGTCTGTTAGACAGTGGAAATCAAAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 117 (Chothia) 
                 LCDR2 
                 TGGGCATCC 
               
               
                 SEQ ID NO: 120 (Chothia) 
                 LCDR3 
                 GATTATAGTTATCCGTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-A HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 122 (Kabat) 
                 HCDR1 
                 ACCTACTGGATGCAC 
               
               
                 SEQ ID NO: 123 (Kabat) 
                 HCDR2 
                 AACATCTATCCTGGCACCGGCGGCTCCAACTTC 
               
               
                   
                   
                 GACGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 124 (Kabat) 
                 HCDR3 
                 TGGACAACCGGCACAGGCGCTTAT 
               
               
                 SEQ ID NO: 125 (Chothia) 
                 HCDR1 
                 GGCTACACCTTCACCACCTAC 
               
               
                 SEQ ID NO: 126 (Chothia) 
                 HCDR2 
                 TATCCTGGCACCGGCGGC 
               
               
                 SEQ ID NO: 124 (Chothia) 
                 HCDR3 
                 TGGACAACCGGCACAGGCGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-A LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 127 (Kabat) 
                 LCDR1 
                 AAGTCCTCCCAGTCCCTGCTGGACTCCGGCAAC 
               
               
                   
                   
                 CAGAAGAACTTCCTGACC 
               
               
                 SEQ ID NO: 128 (Kabat) 
                 LCDR2 
                 TGGGCCTCCACCCGGGAATCT 
               
               
                 SEQ ID NO: 129 (Kabat) 
                 LCDR3 
                 CAGAACGACTACTCCTACCCCTACACC 
               
               
                 SEQ ID NO: 130 (Chothia) 
                 LCDR1 
                 TCCCAGTCCCTGCTGGACTCCGGCAACCAGAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 131 (Chothia) 
                 LCDR2 
                 TGGGCCTCC 
               
               
                 SEQ ID NO: 132 (Chothia) 
                 LCDR3 
                 GACTACTCCTACCCCTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-B HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 133 (Kabat) 
                 HCDR1 
                 ACCTACTGGATGCAC 
               
               
                 SEQ ID NO: 134 (Kabat) 
                 HCDR2 
                 AATATCTACCCCGGCACCGGCGGCTCTAACTTC 
               
               
                   
                   
                 GACGAGAAGTTTAAGAAT 
               
               
                 SEQ ID NO: 135 (Kabat) 
                 HCDR3 
                 TGGACTACCGGCACAGGCGCCTAC 
               
               
                 SEQ ID NO: 136 (Chothia) 
                 HCDR1 
                 GGCTACACCTTCACTACCTAC 
               
               
                 SEQ ID NO: 137 (Chothia) 
                 HCDR2 
                 TACCCCGGCACCGGCGGC 
               
               
                 SEQ ID NO: 135 (Chothia) 
                 HCDR3 
                 TGGACTACCGGCACAGGCGCCTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-B LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 138 (Kabat) 
                 LCDR1 
                 AAATCTAGTCAGTCACTGCTGGATAGCGGTAAT 
               
               
                   
                   
                 CAGAAGAACTTCCTGACC 
               
               
                 SEQ ID NO: 139 (Kabat) 
                 LCDR2 
                 TGGGCCTCTACTAGAGAATCA 
               
               
                 SEQ ID NO: 140 (Kabat) 
                 LCDR3 
                 CAGAACGACTATAGCTACCCCTACACC 
               
               
                 SEQ ID NO: 141 (Chothia) 
                 LCDR1 
                 AGTCAGTCACTGCTGGATAGCGGTAATCAGAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 142 (Chothia) 
                 LCDR2 
                 TGGGCCTCT 
               
               
                 SEQ ID NO: 143 (Chothia) 
                 LCDR3 
                 GACTATAGCTACCCCTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-C HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 122 (Kabat) 
                 HCDR1 
                 ACCTACTGGATGCAC 
               
               
                 SEQ ID NO: 123 (Kabat) 
                 HCDR2 
                 AACATCTATCCTGGCACCGGCGGCTCCAACTTC 
               
               
                   
                   
                 GACGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 124 (Kabat) 
                 HCDR3 
                 TGGACAACCGGCACAGGCGCTTAT 
               
               
                 SEQ ID NO: 125 (Chothia) 
                 HCDR1 
                 GGCTACACCTTCACCACCTAC 
               
               
                 SEQ ID NO: 126 (Chothia) 
                 HCDR2 
                 TATCCTGGCACCGGCGGC 
               
               
                 SEQ ID NO: 124 (Chothia) 
                 HCDR3 
                 TGGACAACCGGCACAGGCGCTTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-C LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 127 (Kabat) 
                 LCDR1 
                 AAGTCCTCCCAGTCCCTGCTGGACTCCGGCAAC 
               
               
                   
                   
                 CAGAAGAACTTCCTGACC 
               
               
                 SEQ ID NO: 128 (Kabat) 
                 LCDR2 
                 TGGGCCTCCACCCGGGAATCT 
               
               
                 SEQ ID NO: 129 (Kabat) 
                 LCDR3 
                 CAGAACGACTACTCCTACCCCTACACC 
               
               
                 SEQ ID NO: 130 (Chothia) 
                 LCDR1 
                 TCCCAGTCCCTGCTGGACTCCGGCAACCAGAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 131 (Chothia) 
                 LCDR2 
                 TGGGCCTCC 
               
               
                 SEQ ID NO: 132 (Chothia) 
                 LCDR3 
                 GACTACTCCTACCCCTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-D HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 122 (Kabat) 
                 HCDR1 
                 ACCTACTGGATGCAC 
               
               
                 SEQ ID NO: 144 (Kabat) 
                 HCDR2 
                 AACATCTACCCTGGCACCGGCGGCTCCAACTTC 
               
               
                   
                   
                 GACGAGAAGTTCAAGAAC 
               
               
                 SEQ ID NO: 145 (Kabat) 
                 HCDR3 
                 TGGACCACCGGAACCGGCGCCTAT 
               
               
                 SEQ ID NO: 125 (Chothia) 
                 HCDR1 
                 GGCTACACCTTCACCACCTAC 
               
               
                 SEQ ID NO: 146 (Chothia) 
                 HCDR2 
                 TACCCTGGCACCGGCGGC 
               
               
                 SEQ ID NO: 145 (Chothia) 
                 HCDR3 
                 TGGACCACCGGAACCGGCGCCTAT 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-D LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 127 (Kabat) 
                 LCDR1 
                 AAGTCCTCCCAGTCCCTGCTGGACTCCGGCAAC 
               
               
                   
                   
                 CAGAAGAACTTCCTGACC 
               
               
                 SEQ ID NO: 128 (Kabat) 
                 LCDR2 
                 TGGGCCTCCACCCGGGAATCT 
               
               
                 SEQ ID NO: 129 (Kabat) 
                 LCDR3 
                 CAGAACGACTACTCCTACCCCTACACC 
               
               
                 SEQ ID NO: 130 (Chothia) 
                 LCDR1 
                 TCCCAGTCCCTGCTGGACTCCGGCAACCAGAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 131 (Chothia) 
                 LCDR2 
                 TGGGCCTCC 
               
               
                 SEQ ID NO: 132 (Chothia) 
                 LCDR3 
                 GACTACTCCTACCCCTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-E HC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 133 (Kabat) 
                 HCDR1 
                 ACCTACTGGATGCAC 
               
               
                 SEQ ID NO: 134 (Kabat) 
                 HCDR2 
                 AATATCTACCCCGGCACCGGCGGCTCTAACTTC 
               
               
                   
                   
                 GACGAGAAGTTTAAGAAT 
               
               
                 SEQ ID NO: 135 (Kabat) 
                 HCDR3 
                 TGGACTACCGGCACAGGCGCCTAC 
               
               
                 SEQ ID NO: 136 (Chothia) 
                 HCDR1 
                 GGCTACACCTTCACTACCTAC 
               
               
                 SEQ ID NO: 137 (Chothia) 
                 HCDR2 
                 TACCCCGGCACCGGCGGC 
               
               
                 SEQ ID NO: 135 (Chothia) 
                 HCDR3 
                 TGGACTACCGGCACAGGCGCCTAC 
               
               
                   
               
            
           
           
               
            
               
                 BAP049-Clone-E LC 
               
            
           
           
               
               
               
            
               
                 SEQ ID NO: 138 (Kabat) 
                 LCDR1 
                 AAATCTAGTCAGTCACTGCTGGATAGCGGTAAT 
               
               
                   
                   
                 CAGAAGAACTTCCTGACC 
               
               
                 SEQ ID NO: 139 (Kabat) 
                 LCDR2 
                 TGGGCCTCTACTAGAGAATCA 
               
               
                 SEQ ID NO: 140 (Kabat) 
                 LCDR3 
                 CAGAACGACTATAGCTACCCCTACACC 
               
               
                 SEQ ID NO: 141 (Chothia) 
                 LCDR1 
                 AGTCAGTCACTGCTGGATAGCGGTAATCAGAAG 
               
               
                   
                   
                 AACTTC 
               
               
                 SEQ ID NO: 142 (Chothia) 
                 LCDR2 
                 TGGGCCTCT 
               
               
                 SEQ ID NO: 143 (Chothia) 
                 LCDR3 
                 GACTATAGCTACCCCTAC 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Amino acid and nucleotide sequences of the heavy and light chain framework 
               
               
                 regions for humanized mAbs BAP049-hum01 to BAP049-hum16 and BAP049-Clone-A to 
               
               
                 BALP049-Clone-E 
               
            
           
           
               
               
               
            
               
                   
                 Amino Acid Sequence 
                 Nucleotide Sequence 
               
               
                   
               
               
                 VHFW1 
                 EVQLVQSGAEVKKPGESLRISCKGS 
                 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAA 
               
               
                 (type a) 
                 (SEQ ID NO: 147) 
                 GCCCGGGGAGTCTCTGAGGATCTCCTGTAAGGGTTCT 
               
               
                   
                   
                 (SEQ ID NO: 148) 
               
               
                   
                   
                 GAAGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAA 
               
               
                   
                   
                 GCCTGGCGAGTCCCTGCGGATCTCCTGCAAGGGCTCT 
               
               
                   
                   
                 (SEQ ID NO: 149) 
               
               
                   
                   
                 GAGGTGCAGCTGGTGCAGTCAGGCGCCGAAGTGAAGAA 
               
               
                   
                   
                 GCCCGGCGAGTCACTGAGAATTAGCTGTAAAGGTTCA 
               
               
                   
                   
                 (SEQ ID NO: 150) 
               
               
                   
               
               
                 VHFW1 
                 QVQLVQSGAEVKKPGASVKVSCKAS 
                 CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAA 
               
               
                 (type b) 
                 (SEQ ID NO: 151) 
                 GCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCT 
               
               
                   
                   
                 (SEQ ID NO: 152) 
               
               
                   
               
               
                 VHFW2 
                 WVRQATGQGLEWMG 
                 TGGGTGCGACAGGCCACTGGACAAGGGCTTGAGTGGAT 
               
               
                 (type a) 
                 (SEQ ID NO: 153) 
                 GGGT (SEQ ID NO: 154) 
               
               
                   
                   
                 TGGGTGCGACAGGCTACCGGCCAGGGCCTGGAATGGAT 
               
               
                   
                   
                 GGGC (SEQ ID NO: 155) 
               
               
                   
                   
                 TGGGTCCGCCAGGCTACCGGTCAAGGCCTCGAGTGGAT 
               
               
                   
                   
                 GGGT (SEQ ID NO: 156) 
               
               
                   
               
               
                 VHFW2 
                 WIRQSPSRGLEWLG 
                 TGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCT 
               
               
                 (type b) 
                 (SEQ ID NO: 157) 
                 GGGT (SEQ ID NO: 158) 
               
               
                   
                   
                 TGGATCCGGCAGTCCCCCTCTAGGGGCCTGGAATGGCT 
               
               
                   
                   
                 GGGC (SEQ ID NO: 159) 
               
               
                   
               
               
                 VHFW2 
                 WVRQAPGQGLEWMG 
                 TGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGAT 
               
               
                 (type c) 
                 (SEQ ID NO: 160) 
                 GGGT (SEQ ID NO: 161) 
               
               
                   
               
               
                 VHFW3 
                 RVTITADKSTSTAYMELSSLRSEDTAVY 
                 AGAGTCACGATTACCGCGGACAAATCCACGAGCACAGC 
               
               
                 (type a) 
                 YCTR (SEQ ID NO: 162) 
                 CTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGG 
               
               
                   
                   
                 CCGTGTATTACTGTACAAGA (SEQ ID NO: 163) 
               
               
                   
                   
                 AGAGTGACCATCACCGCCGACAAGTCCACCTCCACCGC 
               
               
                   
                   
                 CTACATGGAACTGTCCTCCCTGAGATCCGAGGACACCG 
               
               
                   
                   
                 CCGTGTACTACTGCACCCGG (SEQ ID NO: 164) 
               
               
                   
                   
                 AGAGTGACTATCACCGCCGATAAGTCTACTAGCACCGC 
               
               
                   
                   
                 CTATATGGAACTGTCTAGCCTGAGATCAGAGGACACCG 
               
               
                   
                   
                 CCGTCTACTACTGCACTAGG (SEQ ID NO: 165) 
               
               
                   
               
               
                 VHFW3 
                 RFTISRDNSKNTLYLQMNSLRAEDTAVY 
                 AGATTCACCATCTCCAGAGACAATTCCAAGAACACGCT 
               
               
                 (type b) 
                 YCTR (SEQ ID NO: 166) 
                 GTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGG 
               
               
                   
                   
                 CCGTGTATTACTGTACAAGA (SEQ ID NO: 167) 
               
               
                   
                   
                 AGGTTCACCATCTCCCGGGACAACTCCAAGAACACCCT 
               
               
                   
                   
                 GTACCTGCAGATGAACTCCCTGCGGGCCGAGGACACCG 
               
               
                   
                   
                 CCGTGTACTACTGTACCAGA (SEQ ID NO: 168) 
               
               
                   
               
               
                 VHFW4 
                 WGQGTTVTVSS 
                 TGGGGCCAGGGCACCACCGTGACCGTGTCCTCC (SEQ 
               
               
                   
                 (SEQ ID NO: 169) 
                 ID NO: 170) 
               
               
                   
                   
                 TGGGGCCAGGGCACCACAGTGACCGTGTCCTCT (SEQ 
               
               
                   
                   
                 ID NO: 171) 
               
               
                   
                   
                 TGGGGTCAAGGCACTACCGTGACCGTGTCTAGC (SEQ 
               
               
                   
                   
                 ID NO: 172) 
               
               
                   
                   
                 TGGGGCCAGGGCACAACAGTGACCGTGTCCTCC (SEQ 
               
               
                   
                   
                 ID NO: 173) 
               
               
                   
               
               
                 VLFW1 
                 EIVLTQSPDFQSVTPKEKVTITC (SEQ 
                 GAAATTGTGCTGACTCAGTCTCCAGACTTTCAGTCTGT 
               
               
                 (type a) 
                 ID NO: 174) 
                 GACTCCAAAGGAGAAAGTCACCATCACCTGC (SEQ 
               
               
                   
                   
                 ID NO: 175) 
               
               
                   
                   
                 GAGATCGTGCTGACCCAGTCCCCCGACTTCCAGTCCGT 
               
               
                   
                   
                 GACCCCCAAAGAAAAAGTGACCATCACATGC (SEQ 
               
               
                   
                   
                 ID NO: 176) 
               
               
                   
               
               
                 VLFW1 
                 EIVLTQSPATLSLSPGERATLSC 
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTT 
               
               
                 (type b) 
                 (SEQ ID NO: 177) 
                 GTCTCCAGGGGAAAGAGCCACCCTCTCCTGC (SEQ 
               
               
                   
                   
                 ID NO: 178) 
               
               
                   
                   
                 GAGATCGTGCTGACCCAGTCCCCTGCCACCCTGTCACT 
               
               
                   
                   
                 GTCTCCAGGCGAGAGAGCTACCCTGTCCTGC (SEQ 
               
               
                   
                   
                 ID NO: 179) 
               
               
                   
                   
                 GAGATCGTCCTGACTCAGTCACCCGCTACCCTGAGCCT 
               
               
                   
                   
                 GAGCCCTGGCGAGCGGGCTACACTGAGCTGT (SEQ 
               
               
                   
                   
                 ID NO: 180) 
               
               
                   
               
               
                 VLFW1 
                 DIVMTQTPLSLPVTPGEPASISC (SEQ 
                 GATATTGTGATGACCCAGACTCCACTCTCCCTGCCCGT 
               
               
                 (type c) 
                 ID NO: 181) 
                 CACCCCTGGAGAGCCGGCCTCCATCTCCTGC (SEQ 
               
               
                   
                   
                 ID NO: 182) 
               
               
                   
               
               
                 VLFW1 
                 DVVMTQSPLSLPVTLGQPASISC (SEQ 
                 GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGT 
               
               
                 (type d) 
                 ID NO: 183) 
                 CACCCTTGGACAGCCGGCCTCCATCTCCTGC (SEQ 
               
               
                   
                   
                 ID NO: 184) 
               
               
                   
               
               
                 VLFW1 
                 DIQMTQSPSSLSASVGDRVTITC (SEQ 
                 GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGC 
               
               
                 (type e) 
                 ID NO: 185) 
                 ATCTGTAGGAGACAGAGTCACCATCACTTGC (SEQ 
               
               
                   
                   
                 ID NO: 186) 
               
               
                   
               
               
                 VLFW2 
                 WYQQKPGQAPRLLIY 
                 TGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCT 
               
               
                 (type a) 
                 (SEQ ID NO: 187) 
                 CATCTAT (SEQ ID NO: 188) 
               
               
                   
                   
                 TGGTATCAGCAGAAGCCCGGCCAGGCCCCCAGACTGCT 
               
               
                   
                   
                 GATCTAC (SEQ ID NO: 189) 
               
               
                   
                   
                 TGGTATCAGCAGAAGCCCGGTCAAGCCCCTAGACTGCT 
               
               
                   
                   
                 GATCTAC (SEQ ID NO: 190) 
               
               
                   
               
               
                 VLFW2 
                 WYQQKPGKAPKLLIY 
                 TGGTATCAGCAGAAACCAGGGAAAGCTCCTAAGCTCCT 
               
               
                 (type b) 
                 (SEQ ID NO: 191) 
                 GATCTAT (SEQ ID NO: 192) 
               
               
                   
                   
                 TGGTATCAGCAGAAGCCCGGTAAAGCCCCTAAGCTGCT 
               
               
                   
                   
                 GATCTAC (SEQ ID NO: 193) 
               
               
                   
               
               
                 VLFW2 
                 WYLQKPGQSPQLLIY 
                 TGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCT 
               
               
                 (type c) 
                 (SEQ ID NO: 194) 
                 GATCTAT (SEQ ID NO: 195) 
               
               
                   
               
               
                 VLFW3 
                 GVPSRFSGSGSGTDFTFTISSLEAEDAA 
                 GGGGTCCCCTCGAGGTTCAGTGGCAGTGGATCTGGGAC 
               
               
                 (type a) 
                 TYYC (SEQ ID NO: 196) 
                 AGATTTCACCTTTACCATCAGTAGCCTGGAAGCTGAAG 
               
               
                   
                   
                 ATGCTGCAACATATTACTGT (SEQ ID NO: 197) 
               
               
                   
                   
                 GGCGTGCCCTCTAGATTCTCCGGCTCCGGCTCTGGCAC 
               
               
                   
                   
                 CGACTTTACCTTCACCATCTCCAGCCTGGAAGCCGAGG 
               
               
                   
                   
                 ACGCCGCCACCTACTACTGC (SEQ ID NO: 198) 
               
               
                   
                   
                 GGCGTGCCCTCTAGGTTTAGCGGTAGCGGTAGTGGCAC 
               
               
                   
                   
                 CGACTTCACCTTCACTATCTCTAGCCTGGAAGCCGAGG 
               
               
                   
                   
                 ACGCCGCTACCTACTACTGT (SEQ ID NO: 199) 
               
               
                   
               
               
                 VLFW3 
                 GIPPRFSGSGYGTDFTLTINNIESEDAA 
                 GGGATCCCACCTCGATTCAGTGGCAGCGGGTATGGAAC 
               
               
                 (type b) 
                 YYFC (SEQ ID NO: 200) 
                 AGATTTTACCCTCACAATTAATAACATAGAATCTGAGG 
               
               
                   
                   
                 ATGCTGCATATTACTTCTGT (SEQ ID NO: 201) 
               
               
                   
               
               
                 VLFW3 
                 GVPSRFSGSGSGTEFTLTISSLQPDDFA 
                 GGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGAC 
               
               
                 (type c) 
                 TYYC (SEQ ID NO: 202) 
                 AGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATG 
               
               
                   
                   
                 ATTTTGCAACTTATTACTGT (SEQ ID NO: 203) 
               
               
                   
                   
                 GGCGTGCCCTCTAGATTCTCCGGCTCCGGCTCTGGCAC 
               
               
                   
                   
                 CGAGTTTACCCTGACCATCTCCAGCCTGCAGCCCGACG 
               
               
                   
                   
                 ACTTCGCCACCTACTACTGC (SEQ ID NO: 204) 
               
               
                   
               
               
                 VLFW3 
                 GVPSRFSGSGSGTDFTFTISSLQPEDIA 
                 GGGGTCCCATCAAGGTTCAGTGGAAGTGGATCTGGGAC 
               
               
                 (type d) 
                 TYYC (SEQ ID NO: 205) 
                 AGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAG 
               
               
                   
                   
                 ATATTGCAACATATTACTGT (SEQ ID NO: 206) 
               
               
                   
                   
                 GGCGTGCCCTCTAGGTTTAGCGGTAGCGGTAGTGGCAC 
               
               
                   
                   
                 CGACTTCACCTTCACTATCTCTAGCCTGCAGCCCGAGG 
               
               
                   
                   
                 ATATCGCTACCTACTACTGT (SEQ ID NO: 207) 
               
               
                   
               
               
                 VLFW4 
                 FGQGTKVEIK (SEQ ID NO: 208) 
                 TTCGGCCAAGGGACCAAGGTGGAAATCAAA (SEQ ID 
               
               
                   
                   
                 NO: 209) 
               
               
                   
                   
                 TTCGGCCAGGGCACCAAGGTGGAAATCAAG (SEQ ID 
               
               
                   
                   
                 NO: 210) 
               
               
                   
                   
                 TTCGGTCAAGGCACTAAGGTCGAGATTAAG (SEQ ID 
               
               
                   
                   
                 NO: 211) 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
               
                   
               
               
                 Constant region amino acid sequences of human IgG heavy chains 
               
               
                 and human kappa light chain 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 HC 
                 IgG4 (S228P) mutant constant region amino acid sequence 
               
               
                   
                 (EU Numbering) 
               
               
                   
                 ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV 
               
               
                   
                 HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES 
               
               
                   
                 KYGPPCPPCP APEFLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSQED 
               
               
                   
                 PEVQFNWYVD GVEVHNAKTK PREEQFNSTY RVVSVLTVLH QDWLNGKEYK 
               
               
                   
                 CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLTCLVK 
               
               
                   
                 GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG 
               
               
                   
                 NVFSCSVMHE ALHNHYTQKS LSLSLGK (SEQ ID NO: 212) 
               
               
                   
               
               
                 LC 
                 Human kappa constant region amino acid sequence 
               
               
                   
                 RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG 
               
               
                   
                 NSQESVTEQD SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK 
               
               
                   
                 SFNRGEC (SEQ ID NO: 213) 
               
               
                   
               
               
                 HC 
                 IgG4 (S228P) mutant constant region amino acid sequence 
               
               
                   
                 lacing C-terminal lysine (K) (EU Numbering) 
               
               
                   
                 ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV 
               
               
                   
                 HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES 
               
               
                   
                 KYGPPCPPCP APEFLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSQED 
               
               
                   
                 PEVQFNWYVD GVEVHNAKTK PREEQFNSTY RVVSVLTVLH QDWLNGKEYK 
               
               
                   
                 CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLTCLVK 
               
               
                   
                 GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG 
               
               
                   
                 NVFSCSVMHE ALHNHYTQKS LSLSLG (SEQ ID NO: 214) 
               
               
                   
               
               
                 HC 
                 IgG1 wild type 
               
               
                   
                 ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV 
               
               
                   
                 HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP 
               
               
                   
                 KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS 
               
               
                   
                 HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK 
               
               
                   
                 EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC 
               
               
                   
                 LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW 
               
               
                   
                 QQGNVFSCSV MHEALHNHYT QKSLSLSPGK (SEQ ID NO: 215) 
               
               
                   
               
               
                 HC 
                 IgG1 (N297A) mutant constant region amino acid sequence 
               
               
                   
                 (EU Numbering) 
               
               
                   
                 ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV 
               
               
                   
                 HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP 
               
               
                   
                 KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS 
               
               
                   
                 HEDPEVKFNW YVDGVEVHNA KTKPREEQYA STYRVVSVLT VLHQDWLNGK 
               
               
                   
                 EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC 
               
               
                   
                 LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW 
               
               
                   
                 QQGNVFSCSV MHEALHNHYT QKSLSLSPGK (SEQ ID NO: 216) 
               
               
                   
               
               
                 HC 
                 IgG1 (D265A, P329A) mutant constant region amino acid 
               
               
                   
                 sequence (EU Numbering) 
               
               
                   
                 ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV 
               
               
                   
                 HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP 
               
               
                   
                 KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVAVS 
               
               
                   
                 HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK 
               
               
                   
                 EYKCKVSNKA LAAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC 
               
               
                   
                 LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW 
               
               
                   
                 QQGNVFSCSV MHEALHNHYT QKSLSLSPGK (SEQ ID NO: 217) 
               
               
                   
               
               
                 HC 
                 IgG1 (L234A, L235A) mutant constant region amino acid 
               
               
                   
                 sequence (EU Numbering) 
               
               
                   
                 ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV 
               
               
                   
                 HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP 
               
               
                   
                 KSCDKTHTCP PCPAPEAAGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS 
               
               
                   
                 HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK 
               
               
                   
                 EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC 
               
               
                   
                 LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW 
               
               
                   
                 QQGNVFSCSV MHEALHNHYT QKSLSLSPGK (SEQ ID NO: 218) 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 4 
               
               
                   
               
               
                 Amino acid sequences of the heavy and light chain leader sequences 
               
               
                 for humanized mAbs BAP049-Clone-A to BAP049-Clone-E 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 BAP049-Clone-A 
                 HC 
                 MEWSWVFLFFLSVTTGVHS (SEQ ID NO: 219) 
               
               
                   
                 LC 
                 MSVPTQVLGLLLLWLTDARC (SEQ ID NO: 220) 
               
               
                   
               
               
                 BAP049-Clone-B 
                 HC 
                 MAWVWTLPFLMAAAQSVQA (SEQ ID NO: 221) 
               
               
                   
                 LC 
                 MSVLTQVLALLLLWLTGTRC (SEQ ID NO: 222) 
               
               
                   
               
               
                 BAP049-Clone-C 
                 HC 
                 MEWSWVFLFFLSVTTGVHS (SEQ ID NO: 219) 
               
               
                   
                 LC 
                 MSVPTQVLGLLLLWLTDARC (SEQ ID NO: 220) 
               
               
                   
               
               
                 BAP049-Clone-D 
                 HC 
                 MEWSWVFLFFLSVTTGVHS (SEQ ID NO: 219) 
               
               
                   
                 LC 
                 MSVPTQVLGLLLLWLTDARC (SEQ ID NO: 220) 
               
               
                   
               
               
                 BAP049-Clone-E 
                 HC 
                 MAWVWTLPFLMAAAQSVQA (SEQ ID NO: 221) 
               
               
                   
                 LC 
                 MSVLTQVLALLLLWLTGTRC (SEQ ID NO: 222) 
               
               
                   
               
            
           
         
       
     
     EXAMPLES 
     The Examples below are set forth to aid in the understanding of the inventions but are not intended to, and should not be construed to, limit its scope in any way. 
     Example 1: Pharmacokinetics Analysis of Flat Dosing Schedules 
     Based on pharmacokinetic (PK) modeling, utilizing flat dose is expected provide the exposure to patients at the appropriate Cmin concentrations. Over 99.5% of patients will be above EC50 and over 93% of patients will be above EC90. Predicted steady state mean Cmin for the exemplary anti-PD-1 antibody molecule utilizing either 300 mg once every three weeks (Q3W) or 400 mg once every four weeks (Q4W) is expected to be above 20 ug/mL (with highest weight, 150 kg) on average. 
     
       
         
           
               
             
               
                 TABLE 5 
               
               
                   
               
               
                 Exemplary PK parameters based on flat dosing schedules 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 Number of patients in PK dataset 
                 46 
               
               
                 CL (mL/h) 
                 10.9 [8.9, 13.2]; IIV: 62% 
               
               
                 Exponent of Weight on CL 
                 0.54 [0.021, 1.06] 
               
               
                 Volume of distribution at SS (L) 
                 7.2 [6.5, 7.9]; IIV: 22% 
               
               
                 Half-Life (days) 
                 20 [17, 23]; IIV: 64% 
               
               
                 Predicted Cmin (ug/mL) for 80 kg patient 
                 31 [22, 42] (400 mg q4w) 
               
               
                   
                 35 [26, 47] (300 mg q3w) 
               
               
                   
               
            
           
         
       
     
     The expected mean steady state Cmin concentrations for the exemplary anti-PD-1 antibody molecule observed with either doses/regimens (300 mg q3w or 400 mg q4w) will be at least 77 fold higher than the EC50 (0.42 ug/mL) and about 8.6 fold higher than the EC90. The ex vivo potentcy is based on IL-2 change in SEB ex-vivo assay. 
     Less than 10% of patients are expected to achieve Cmin concentrations below 3.6 ug/mL for either 300 mg Q3W or 400 mg Q4W. Less than 0.5% of patients are expected to achieve Cmin concentrations below 0.4 μg/mL for either 300 mg Q3W or 400 mg Q4W. 
     Predicted Ctrough (Cmin) concentrations across the different weights for patients while receiving the same dose of the exemplary anti-PD-1 antibody molecule are shown in  FIG. 12 . Body weight based dosing is compared to fixed dose (3.75 mg/kg Q3W vs. 300 mg Q3W and 5 mg/kg Q4W vs. 400 mg Q4W).  FIG. 12  supports flat dosing of the exemplary anti-PD-1 antibody molecule. 
     The PK model further is validated. As shown in  FIG. 13 , the observed versus model predicted concentrations lie on the line of unity.  FIG. 14  shows that the model captures accumulation, time course, and within subject variability. 
     Example 2: N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide 
     COMPOUND A (Compound A) is a morpholine-substituted biaryl compound of the following structure 
     
       
         
         
             
             
         
       
     
     Compound A is Example 1156 in published PCT application WO2014/151616, the contents of which are incorporated by reference. The preparation of Compound A, pharmaceutically acceptable salts of Compound A and pharmaceutical compositions comprising compound A are also disclosed in the PCT application, e.g., see pages 739-741. 
     COMPOUND A is a type II inhibitor of both b-Raf and c-Raf. 
     
       
         
           
               
               
               
               
             
               
                   
                   
               
               
                   
                 Compound 
                 b-Raf IC-50 (μM) 
                 c-Raf FL IC-50 (μM) 
               
               
                   
                   
               
             
            
               
                   
                 COMPOUND A 
                 0.00073 
                 0.00020 
               
               
                   
                   
               
            
           
         
       
     
     COMPOUND A is a potent and selective inhibitor targeting both BRAF and CRAF kinases with sub-nM IC50 values in biochemical assays. COMPOUND A has demonstrated efficacy in a wide range of MAPK pathway-driven human cancer cell lines and in vivo tumor xenografts including models harboring activating lesions in the KRAS, NRAS, and BRAF oncogenes. 
     Example 3: Anti-Tumor Activity of Compound a in KRAS-Mutant NSCLC Models 
     H358 Model: 
     SCID beige female tumor bearing NCI-H358 mice, n=8 per group, were randomized into 3 groups 14 days post tumor cell inoculation with an average tumor volume range of 259.44-262.47 mm 3 . 
     Animals were administered an oral dose of either vehicle, Compound A at 30 mg/kg or 200 mg/kg daily for 14 consecutive days at a dosing volume of 10 ml/kg of animal body weight during course of treatment. Tumor volumes were measured by digital caliper 3 times a week and body weights of all animals were recorded through the course of treatment. 
     Calu6 Model: 
     Female nude tumor bearing Calu6 mice, n=6 per group were randomized into treatment groups on day 17 following tumor implantation, when the average tumor volume was 180 mm3. Treatments with compound A were initiated on Day 17 and continued for 16 days. Dosing volume was 10 mL/kg. Tumor volumes were collected at the time of randomization and twice weekly thereafter for the study duration. 
     H727 Model: 
     Nude female mice tumor bearing NCI-H358, n=8 per group, were randomized into 2 groups with an average tumor volume range of 275.74 mm3. Animals were administered an oral dose of either vehicle or Compound A at 100 mg/kg daily for 14 consecutive days at a dosing volume of 10 ml/kg of animal body weight during course of treatment. Tumor volumes were measured by digital caliper 3 times a week and body weights of all animals were recorded through the course of treatment. As shown in  FIGS. 15A, 15B and 15C , Compound A showed single agent activity in KRASmt NSCLC models. 
     In cell-based assays, Compound A has demonstrated anti-proliferative activity in cell lines that contain a variety of mutations that activate MAPK signaling. For instance, Compound A inhibited the proliferation of the non-small cell lung cancer cell line Calu-6 (KRAS Q61K), colorectal cell line HCT116 (KRAS G13D) with IC50 values ranging from 0.2-1.2 μM. In vivo, treatment with Compound A generated tumor regressions in several human KRAS-mutant models including the NSCLC-derived Calu-6 (KRAS Q61K) and NCI-H358 (KRAS G12C) xenografts as well as the ovarian Hey-A8 (KRAS G12D, BRAF G464E) xenografts. In all cases, anti-tumor effects were dose-dependent and well tolerated as judged by lack of significant body weight loss. The Calu-6 model was sensitive to Compound A when implanted in both nude mice and nude rats with regressions observed at doses of 100, 200, and 300 mg/kg once daily (QD) in mice and 75 and 150 mg/kg QD in rats. Tumor stasis in this model was observed at 30 mg/kg QD and 35 mg/kg QD in mice and rats, respectively. Regressions were also achieved in a second human NSCLC model, NCI-H358, at the 200 mg/kg QD dose in mice and in the human ovarian Hey-A8 xenograft at doses as low as 30 mg/kg QD in mice. Furthermore, data from a dose fractionation efficacy study in Calu-6 xenografts demonstrated that across different dosing levels, Compound A dosed QD and fractioned twice a day (BID) showed similar levels of anti-tumor activity. These results support exploration of QD or BID dose regimen in the clinic. 
     Collectively the in vitro and in vivo MAPK-pathway suppression and anti-proliferative activity observed for Compound A at well-tolerated doses suggests that Compound A may have anti-tumor activity in patients with tumors harboring activating lesions in the MAPK pathway and in particular may therefore be useful as a single agent or in combination with anti-PD-1 antibody molecule for the treatment of NSCLC patients harboring KRAS mutations. 
     Example 4: Anti-Tumor Activity of Compound a in NRAS-Mutant Melanoma Model 
     The antitumor efficacy and tolerability of Compound A were determined in an NRAS-mutant melanoma xenograft nude mouse model. 5×10 6  SKMEL30 cells (NRAS Q61K  melanoma cells) in 50% Matrigel™ were implanted subcutaneously into the right flank of female nude mice. Mice were randomized into treatment groups on day 12 post implantation, when the average tumor volume was ˜200 mm 3 . Mice were grouped (n=9) and treated with vehicle or Compound A at 25 and 100 mg/kg bid (twice daily). Treatments began on day 12 and continued until day 21 post implantation. Tumor volume and body weights were collected at the time of randomization and twice per week for the study duration. Tumor volume was determined by measurement with calipers and calculated using a modified ellipsoid formula, where tumor volume (TV) (mm 3 )=[((1×w2)×3.14159))/6], where 1 is the longest axis of the tumor and w is perpendicular to 1. Mice were monitored for tumor growth, body weight and body condition. Animal well-being and behavior were monitored twice weekly. General health of mice was monitored daily. The anti-tumor activity was determined by assessing % T/C or % regression on day 21 post-implant (9 days of treatment). Treatment with Compound A with both doses, 25 mg/kg and 100 mg/kg bid, resulted in regression (48% and 59% regression respectively). All doses were well tolerated with no significant body weight loss and no signs of toxicity or mortalities were observed ( FIG. 16  which shows the efficacy and tolerability of Compound A in SKMEL30 xenograft in mice. Tumor volumes (A) or percent body weight change from initial (B) treatment groups were plotted vs. vehicle control). 
     Example 5: A Phase I Dose Finding Study of Compound a in Adult Patients with Solid Tumors (Including Solid Advanced Tumors) Harboring MAPK Pathway Alterations 
     Compound a Single Agent 
     The recommended starting dose and regimen of Compound A single agent in this study is 100 mg QD orally based on the preclinical safety, tolerability data, PK/PD data obtained in preclinical studies, as well as exploratory human efficacious dose range projection. Provisional doses for dose escalation can be found in the Table below. 
     
       
         
           
               
             
               
                 TABLE 6 
               
             
            
               
                   
               
               
                 Exemplary Dose levels for Compound A 
               
            
           
           
               
               
               
            
               
                 Dose level (DL) 
                 Proposed daily dose* 
                 Increment from previous dose 
               
               
                   
               
            
           
           
               
               
               
               
            
               
                  −1** 
                 50 
                 mg 
                 −50% 
               
               
                 1 
                 100 
                 mg 
                 (starting dose) 
               
               
                 (starting dose) 
               
               
                 2 
                 200 
                 mg 
                 100% 
               
               
                 3 
                 400 
                 mg 
                 100% 
               
               
                 4 
                 800 
                 mg 
                 100% 
               
               
                 5 
                 1200 
                 mg 
                  50% 
               
               
                   
               
               
                 *It is possible for additional and/or intermediate dose levels to be added during the course of the study, including doses outside the range of provisional doses shown in this table. 
               
               
                 **Dose level −1 represent treatment doses for patients requiring a dose reduction from the starting dose level. 
               
            
           
         
       
     
     To date, patients have been treated in the study at the dose levels of 100 mg QD, 200 mg QD, 300 mg QD, 400 mg QD, 800 mg QD and 200 mg BID. 
     In the dose expansion part, patients in Compound A single agent arm are treated with Compound A at the recommended dose and regimen selected based on the dose escalation data. This dose is expected to be safe and tolerated in adult patients in all indications included in the trial. The single agent arm consists of 3 distinct groups: KRAS- and/or BRAF-mutant NSCLC, KRAS- and/or BRAF-mutant ovarian cancer, and patients with other solid tumors (which may be advanced) harboring MAPK pathway alteration(s) such as relapsed/refractory melanoma after failure of BRAFi/MEKi combination therapy and NRAS-mutant melanoma patients. 
     Compound A single agent:
         Group 1: patients with confirmed KRAS and/or BRAF-mutated NSCLC.   Group 2: patients with confirmed KRAS and/or BRAF-mutated ovarian cancer   Group 3: patients with advanced solid tumors harboring documented MAPK pathway alteration(s) other than those defined in Group 1 and 2. These include but are not limited to:   patients with relapsed/refractory BRAF V600-mutated melanoma after failure of BRAFi/MEKi combination therapy   patients with NRAS-mutated melanoma.       

     The clinical regimen for this first-in-human trial is a continuous once daily dosing schedule for Compound A. The QD regimen has been demonstrated to be efficacious and tolerated in preclinical studies. In Calu6 xenografts, similar levels of efficacy were achieved with either QD or fractionated BID regimens, suggesting efficacy is related to overall exposure. The predicted human PK and the predicted half-life (˜9 h), also suggest efficacious exposure can be achieved with QD dosing. 
     This was further confirmed by preliminary results obtained from the clinical trial. A subject with non-small cell lung cancer (NSCLC) treated with 1200 mg QD of COMPOUND A was shown to result in partial response of −35% according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria. 
     BID dosing of Compound A (e.g. 200 mg twice daily or 400 mg twice daily) is also envisaged. 
     Example 6: A Phase I Dose Finding Study of Compound a in Adult Patients with Solid Tumors and Advanced Solid Tumors Harboring MAPK Pathway Alterations and of Compound a Combined with an Exemplary Antibody Molecule (Antibody B) in NSCLC Patients Harboring KRAS Mutations and in Patients Suffering from NRAS Mutant Melanoma 
     The exemplary antibody molecule (BAP049-Clone-E, also referred to as Antibody B) tested in this study is a humanized anti-programmed death-1 (PD-1) IgG4 monoclonal antibody (mAb) that blocks binding of programmed cell death ligand-1 (PD-L1) and programmed cell death ligand-2 (PD-L2) to PD-1. It binds to PD-1 with high affinity and inhibits its biological activity. The amino acid sequences of this antibody molecule are described in Table 1 herein (VH: SEQ ID NO: 38; VL: SEQ ID NO: 70). Results from pre-clinical toxicology studies have shown that it has a favorable safety profile. Its pharmacodynamic activity has also been demonstrated in vivo. 
     Compound a in Combination with Antibody B 
     The dose escalation of Compound A in combination with Antibody B will start once a recommended dose and regimen has been identified for Compound A single agent. The starting dose of Compound A will be a previously tested dose that is lower than the recommended single agent dose. The selection of this dose will be supported by the current available efficacy, safety, PK and/or PD data of Compound A single agent in order to minimize exposure to potentially toxic drug levels while limiting the number of patients that might receive inactive doses. 
     The regimen for Compound A will be the same as selected for single agent Compound A. In case both regimens for Compound A single agent will be explored during single agent expansion part, then one preferred regimen will be chosen for the combination based on all available data including safety and exposure. Switching Compound A dose regimen in the combination arm at a later stage may be decided based on emerging data. 
     Antibody B will be administered at a flat dose of 400 mg Q4W i.v. (intravenously) which is the single agent RDE (Recommended dose for expansion). Antibody B may also be administered 300 mg i.v. Q3W for combination treatment regimens for which this may be more convenient. 
     In the dose expansion part, patients in the combination arm will be treated at the recommended dose and regimen for the drug combination based on the dose escalation data. 
     KRAS-mutant NSCLC and NRAS-mutant melanoma patients will be enrolled in the combination arm of this study. It is also envisaged that in the treatment group of KRAS-mutated NSCLC patients who have received prior PD-1/PD-L1 inhibitor therapy and patients who are naïve to PD-1- or PD-L1-directed therapy will benefit from the combination therapy and that in the treatment group of NRAS-mutated melanoma patients previously treated with immunotherapy including e.g. ipilimumab or prior PD-1/PD-L1 inhibitor, and immunotherapy-naive patients will benefit from the combination therapy. 
     INCORPORATION BY REFERENCE 
     Other embodiments and examples including figures and tables are disclosed in International Patent Application Publication No. WO 2015/112900 and U.S. Patent Application Publication No. US 2015/0210769, entitled “Antibody Molecules to PD-1 and Uses Thereof,” which are incorporated by reference in its entirety. 
     All publications, patents, and Accession numbers mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. 
     EQUIVALENTS 
     While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.